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ABSTRACT
Selenocysteine (Sec), the 21st proteogenic amino acid, was first identified in 1976
by Thressa Stadtman. In proteins, Sec replaces the far more common sulfur-containing
amino acid cysteine (Cys). A key question since Stadtman’s discovery is: Why does Sec
replace Cys? This question is especially relevant since Cys-orthologs of Sec-enzymes
catalyze the identical reaction with only slightly reduced efficiency, and incorporation of
Sec into a protein is much more complicated and bioenergetically costly compared to Cys.
The study of selenoproteins is very difficult because Sec is incorporated into proteins by
recoding a UGA stop codon as a sense codon. Production of recombinant selenoproteins
involves reconstituting the recoding machinery. Alternatively, selenoproteins can be
produced using a combination of recombinant DNA technology and peptide synthesis.
While the development of solid phase peptide synthesis has provided a synthetic route for
studying Sec, the Sec side chain requires the use of sturdy protecting groups (PGs) during
synthesis.
Work herein first addresses complications associated with Sec and Cys PGs, which
until now have required harsh conditions for removal. My work has developed facile new
methods for the deprotection of Sec and Cys residues. For Sec, we found that the use of
DTNP to remove various PGs with subsequent ascorbolysis results in a Sec-selenol.
Likewise, we developed 2,2’-dipyridyl diselenide (PySeSePy) to deprotect Cys, which can
be used with subsequent ascorbolysis to provide a Cys-thiol. Notably, we found the
ascorbolysis step to be chemoselective; ascorbate can reduce a selenosulfide bond, but not
a formed disulfide bond. We harnessed this chemoselectivity for the synthesis of peptides
that contain multiple disulfide bonds, which we demonstrate by synthesizing guanylin and
tachyplesin-1 using PySeSePy as a chemical tool.
Another chemical tool that we utilize to explore selenoprotein chemistry is alphamethyl selenocysteine (αMe)Sec. This unique amino acid has a methyl group in place of
its α-H. We found that a peptide containing (αMe)Sec (compared to a Sec-peptide control),
showed enhanced stability when incubated in oxygenated buffer for prolonged periods of
time. We also utilized our (αMe)Sec-peptide as a glutathione peroxidase mimic to reduce
peroxides, and postulate that this peptide could serve as a therapeutic in times of high
oxidative stress.
Finally, it is now commonly accepted in the field that selenoproteins evolved to
resist oxidative stress. Herein, we expand this hypothesis: Sec replaces Cys in proteins to
resist all types of electrophilic stress. We found that when Sec residues are alkylated by
reactive biological electrophiles (such as acrolein), the formed adduct can be reversed.
There are many potential mechanisms of reversal, but we provide evidence supporting a
selenoxide elimination mechanism using a mutant form of thioredoxin reductase that
contains (αMe)Sec in place of the native Sec residue at the C-terminal active site. Taken
together, the works described in this dissertation expand the chemical toolbox for the study
of Se-containing biomolecules and provides new hypotheses for the chemical role of Se in
proteins.
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CHAPTER 1: INTRODUCTION TO SELENOCYSTEINE AND CYSTEINE IN
PEPTIDES AND PROTEINS

1.1 The chemistry of selenocysteine and cysteine
Cysteine (Cys) and selenocysteine (Sec) are proteogenic amino acids (AAs) whose
side chains contain sulfur and selenium, respectively. On the periodic table, sulfur (S) and
selenium (Se) are both group 16 elements and they have very similar physical and chemical
properties, but there are also significant differences. Therefore, Cys and Sec have very
similar physical and chemical properties as well. Despite this, the way in which the two
AAs are incorporated into proteins is significantly different, which is described in detail in
Section 1.2. As a consequence, there is a large difference in the frequency in which Cys
vs. Sec residues are found in the human proteome; there exists only 35 Sec residues
distributed among 25 proteins compared to ~214,000 Cys residues which are widely
distributed among proteins1, 2. Below is a discussion of the chemical ways in which Cys
and Sec are similar and different, and how these properties might explain what biochemical
advantages Sec has over Cys.

1.1.1 Similarities between sulfur and selenium
Perhaps the most important similarity that allows Sec to replace Cys in some
proteins is that the AAs have nearly identical structures, as displayed in Figure 1.1.
Additionally, both the sulfur and selenium atoms in the side chains of Cys and Sec can
adopt a large range of oxidation states (-2 to +6) which allows both AAs to adopt a plethora
of chemically unique forms and functional group types3. In proteins, Cys and Sec are
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subjected to alkylation by electrophiles and oxidation by reactive oxygen and nitrogen
species, leading to post translationally modified forms of these unique AAs that can exhibit
significantly altered biochemical functions4.
Figure 1.1: Structures of Cys and Sec
AAs. The pKa of the side chain thiol
and selenol moieties are displayed. For
Cys and Sec, and many sulfur and
selenium compounds, the substantially
lower basicity of the selenolate versus
thiolate results in a difference of 3−4
pKa units5.

1.1.2 Differences between sulfur and selenium
As displayed in Figure 1.1, Sec has a much lower pKa than Cys and is deprotonated
(in the reactive selenolate form) at physiological pH while Cys is largely protonated (in the
thiol form). Additionally, Sec has a much lower redox potential than Cys. When they form
hypervalent compounds, S-X bonds are weaker than Se-X bonds, and this ability to tolerate
hypervalency contributes to Sec being a better electrophile than Cys5. For example, when
nucleophiles attack the Se or S atom in an SN2 reaction, a hypervalent intermediate forms
before reaching the desired product. The hypervalent Se transition state would be more
stable than the hypervalent S transition state5. Similarly, the Se radical is more stable than
the S radical6. In 2014, Koppenol and co-workers showed that when a thiyl radical is
formed in a peptide, Cα−H abstraction is greatly favored, while the same reaction of a
selanyl radical is slow5, 6. This has very important implications in protein chemistry as the
ability to catalyze one electron reactions might be an advantage of Sec-proteins over their
Cys-ortholog7.
2

Perhaps the most important difference between Sec and Cys is the larger size of the
side chain Se atom of Sec (115 ppm) compared to the side chain S atom of Cys (100 ppm)5.
As a result of their size difference, selenium is much “softer” and more polarizable than
sulfur. The increased polarizability of the Se atom makes it both a better nucleophile and a
better electrophile than sulfur. The larger size of Se also means that the Se-X bond (where
X is carbon, oxygen, or hydrogen) is longer and therefore, weaker than the S-X bond. The
increased lability of the Se-X bond is very important for much of the work in this
dissertation; it might explain the ability of Sec-proteins to reverse oxidative and
electrophilic modifications while Cys-proteins cannot. The ability of Sec-proteins to
reverse post-translational modifications, and the biological consequences of this, are
discussed in greater detail in Chapter 4.

1.2 The role of selenium in proteins
Selenium, a rare chemical element, was discovered in 1817 by Jöns Jacob Berzelius
and received its name based on: Σεληνή, “moon” (goddess)5. Like the moon, selenium (Se)
has two faces since it is both toxic to all organisms and essential to many bacteria and
animal species5. Se is also two-faced in its chemical reactivity since it is both a strong
nucleophile and potent electrophile. In the past ~80 years, scientists have discovered that
Se has replaced S in several biological molecules.
Selenium was first discovered as a nutritional factor in prokaryotes in 1954, then
eukaryotes in 1957, and selenocysteine was ultimately identified as the organoselenium
moiety present in proteins in 1976 by Stadtman and coworkers8, 9. 10 years later, it was
reported that genes to express Sec-proteins contain in-frame TGA termination codons,
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which allowed researchers to name Sec the 21st proteogenic amino acid9. Since this
discovery, the role of Sec in proteins has been debated.
At the foundation of this debate lies the costly process for incorporating Sec into
proteins, which is described in detail in previous publications9, 10. Briefly, Sec is encoded
by UGA, which is typically a stop codon. UGA must be recoded as a sense codon for Sec
incorporation into proteins, and this recoding process requires numerous accessory proteins
and a special structural element in the 3′-untranslated region of the mRNA. For the cell to
provide the complicated apparatus for UGA recoding, one can assume it would require
considerably more energy to insert Sec into a protein compared to Cys, which requires ~25
mol ATP per residue5. Further complicating Sec incorporation is the geological distribution
of selenium in the Earth’s crust which is largely uneven; there are selenium deficient areas
in China, New Zealand, and Finland, meaning mammals there would have poor access to
the essential nutrient. Additionally, sulfur is much more abundant relative to selenium. This
ratio is estimated to be as low as 6000:1175 and as high as 55,500:15.
Considering the complications involved with Sec incorporation into proteins, the
question of “why did nature chose selenium?” frequently arises when studying
selenoproteins5. Often, there are Cys-orthologs of Sec-proteins that can catalyze the same
reactions. Therefore, there must be a critical reason for Sec to replace Cys in some cases;
Sec must confer a significant advantage to proteins to justify its incorporation.
It was previously thought that Sec replaced Cys in selenoenzymes as a chemical
necessity; that is, the reaction catalyzed by these enzymes would be much faster with
selenium at the C-terminus active site than sulfur11. However, this was found to be incorrect
when Kanzok and coworkers determined that the rate of E. coli Trx reduction by human
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(Sec-containing) TrxR was only about ~3 fold higher than the rate of E. coli Trx reduction
by Drosophila melanogaster (Cys-containing) TrxR12 (DmTrxR). The authors determined
that “these data speak against the proposition that selenocysteine in the COOH-terminal
Cys-X sequence of high Mr TrxRs is a chemical necessity.”12 Thus, it can be concluded
that the presence of Sec in mTrxR is not confined to a purely catalytic role.

1.2.1 Selenoproteins resist oxidative inactivation
One hypothesis, first proposed by Chaudiere in 199213 and strongly revived by the
Hondal lab, is that Sec replaces Cys to resist oxidative stress14, 15. The ability of mammalian
thioredoxin reductase (mTrxR) to resist oxidative stress was strongly demonstrated by
Snider and coworkers in 2013 who showed a direct comparison of the abilities of mTrxR
and a Cys-ortholog (DmTrxR) to resist inactivation by oxidation from a variety of oxidants
including H2O2, hydroxyl radical, peroxynitrite, hypochlorous acid, hypobromous acid,
and hypothiocyanous acid. Their in vitro results showed that Sec-containing TrxR enzymes
are far superior to Cys-orthologs in resisting inactivation by oxidation14.
Additionally, in vivo evidence from Conrad and Coworkers provides strong support
for Chaudiere’s hypothesis. Using mouse embryonic fibroblast cells, they found that cell
lines that only expressed Cys-contaning GPX underwent peroxide induced ferroptosis,
while wild type cells expressing Sec-GPX did not16. Conrad and coworkers also provided
mechanistic support via mass spectrometric (MS) analysis; MS analysis showed that for
the Cys-mutant GPX, the active site Cys residue was overoxidized to both the Cys-sulfinic
and Cys-sulfonic acid forms16. In contrast, previous works showed that Sec-containing
GPX avoids inactivation because the selenenic acid is protected from further oxidation by
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rapid attack by a backbone amide nitrogen to form a cyclic selenenylamide17. The
selenenylamide is then reduced by GSH to restore the active selenol form of Sec-GPX17.
Further evidence supporting the hypothesis that Sec in proteins confers resistance
to permanent oxidation is provided from numerous studies conducted using [NiFeSe]hydrogenases and selenosubtilisin. A thorough review of these important studies, which
undoubtably advance and refine this hypothesis, is provided by Hondal and Maroney15.

1.2.2 Selenoproteins resist electrophilic inactivation
A new hypothesis that we explore in Chapter 4 expands upon the idea that Sec has
evolved in enzymes to resist oxidative stress. Ground-state oxygen atoms, which are
diradicals, behave as distinctly electrophilic reagents18. However, oxygen is not the only
biological electrophile that Sec-enzymes encounter in vivo. Indeed, there are many small
molecule, biological electrophiles that have previously been shown to interact with Secenzymes, including Sec-TrxRs. Due to their high reactivity, they can be considered
biological reactive electrophilic species (RES), which in cells, react with intracellular
nucleophilic substrates including DNA, lipids, and proteins. In proteins, Cys and Sec
residues are the most nucleophilic, followed by His and Lys, and the N-terminal amine,
making these sites targets for RES alkylation.
It has been proven that selenoproteins can be alkylated by RES at the highly
nucleophilic Sec residue, which causes a loss of enzyme function19-21. For example, in the
case of mTrxR, the enzyme would no longer be able to reduce Trx, which would be
detrimental to numerous cellular functions. However, there are many mechanisms, both
enzymatic and chemical, by which the formed Sec-adduct could be reversed, which would
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restore protein function. Though reversal of a formed Cys-RES adduct could also be
possible, we predict Cys-RES reversal would be very slow by chemical mechanisms.
Currently, we can find only two examples in the literature that suggest Cys-alkylation could
be chemically reversible, though neither study uses proteins; both studies are completed
using peptide models22 or polymer-supported thiols23. These studies are examined in
greater detail in Chapter 4.
Thus, Sec-enzymes would have an advantage over their Cys-orthologs in that they
could readily restore activity after RES-alkylation by non-enzymatic mechanisms. In
recent years, fragments of in vivo evidence in support of this hypothesis have emerged2426

, however none tell the full story. Perhaps the strongest example comes from Randall and

coworkers who showed that acrolein rapidly inactivates Sec-TrxR in human bronchiolar
epithelial cells, but this activity can be recovered after 4-8 h by a mechanism depending on
the presence of cellular glutathione and Trx. Their reported loss and subsequent recovery
of Sec-TrxR activity corresponds with reversal of the formed protein–acrolein adduct.27
However, there is no mechanistic or in vitro evidence provided in this study, and
mechanisms for such reversal remain elusive. In this dissertation, we provide evidence of
a selenoxide elimination mechanism for which Sec-RES Michael adducts can be reversed
and propose that this one reason why nature chose selenium.

1.3 Human selenoproteins
There are currently 25 known human proteins, summarized in Table 1.1. Each
selenoprotein contains one Sec residue except for iodothyronine deodinase 2 (which has
two Sec residues), and selenoprotein P (which has 10 Sec residues).
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Table 1.1: Human selenoproteome with abbreviations, Sec-location, size, and reported
functions specified. Adapted from Labunskyy et al., 2014.28 Nomenclature for the TrxR
family follows recommendations from Arnér, 2009.29
Selenoprotein

Abbrv.

Sec location
(AA residue #)

Size
(# AA)

15 kDa selenoprotein

Sep15

93

162

Putative role in quality control of
protein folding in the ER

Glutathione peroxidase 1

GPX-1

47

201

Cytosolic glutathione
peroxidase

Glutathione peroxidase 2

GPX-2

40

190

Gastrointestinal glutathione
peroxidase

Glutathione peroxidase 3

GPX-3

73

226

Plasma glutathione peroxidase

Glutathione peroxidase 4

GPX-4

73

197

Phospholipid hydroperoxide
glutathione peroxidase

Glutathione peroxidase 6

GPX-6

73

221

Olfactory glutathione
peroxidase

Iodothyronine deodinase 1

DIO1

126

249

Thyroid hormone-activating DIO

Iodothyronine deodinase 2

DIO2

133, 266

273

Tissue-specific thyroid
hormone-activating DIO

Iodothyronine deodinase 3

DIO3

144

278

Tissue-specific thyroid
hormone-deactivating DIO

Methionine-R-sulfoxide
reductase

MsrB1

95

116

Reduction of oxidized
methionine residues

Selenophosphate
synthetase 2

SPS2

60

448

Involved in the synthesis of
selenoproteins

Selenoprotein H

SelH

38

116

Unknown

Selenoprotein I

SelI

387

397

Unknown

Selenoprotein K

SelK

92

94

Putative role in quality control of
protein folding in the ER

Selenoprotein M

SelM

48

145

Unknown

Selenoprotein N

SelN

428

556

Putative role in quality control of
protein folding in the ER

Selenoprotein O

SelO

667

669

Unknown

Selenoprotein P

SelP

59, 300, 318, 330,
345, 352, 367,
369, 376, 378

381

Se transport

8

Function

Selenoprotein S

SelS

188

189

Putative role in quality control of
protein folding in the ER

Selenoprotein T

SelT

36

182

Unknown

Selenoprotein V

SelV

273

346

Unknown

Selenoprotein W

SelW

13

87

Unknown

Thioredoxin reductase 1

TrxR-1

498

499

Reduction of cytosolic
thioredoxin

Thioredoxin reductase 2

TrxR-2

522

523

Mitochondrial-specific reduction
of thioredoxin

Thioredoxin reductase 3

TrxR-3,
TGR

655

656

Testis-specific reduction of
thioredoxin and glutaredoxin

The most well studied selenoproteins are the glutathione peroxidase (GPX) and
TrxR families of enzymes. In this dissertation, the primary focus is TrxR-2, mitochondrial
TrxR. Examination of each human selenoprotein is beyond the scope of this dissertation.
However, Sections 1.3.1-1.3.2 discuss two popular selenoproteins that are the key to works
described herein.

1.3.1 Glutathione peroxidase
Glutathione peroxidase (GPX) is a widespread protein superfamily of eight
enzymes found in many organisms throughout all kingdoms of life30. Vertebrate GPX is an
enzyme that catalyzes the reduction of H2O2, organohydroperoxides, and lipid
hydroperoxides13, 31. Multiple forms of the enzyme contain the rare AA Sec30, 32. The GPX
catalytic cycle proceeds by nucleophilic attack of the selenolate on to the peroxyl oxygen
of the substrate resulting in a selenenic acid intermediate, that is subsequently reduced
back to the selenolate by two equivalents of glutathione (Figure 1.2). 32
When concentrations of H2O2 are elevated, such as during reoxygenation after a
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period of ischemia, GPX can become overwhelmed and does not reduce H2O2 fast enough
to prevent reperfusion injury.33 Additionally, since it plays a major role in antioxidant
defense, deficiencies in GPX have been linked to the pathogenesis of many diseases
including diabetes, cancer, obesity, Alzheimer disease and Parkinson’s disease. Thus, it is
desirable to design a small molecule GPX mimic that can serve a therapeutic function for
situations of high oxidative stress, or for long term antioxidant defense.34 In Chapter 3,
work regarding the design of novel GPX mimics is presented and discussed.

Figure 1.2: Catalytic cycle of GPX. The selenol of Sec first reduces oxidants resulting in
a selenenic acid intermediate, which is then reduced by one equivalent of GSH forming the
GPX-Sec-glutathione adduct. A second equivalent of GSH regenerates the enzyme by
restoring the reduced selenol, forming oxidized glutathione (GSSG) as a byproduct. GSSG
is then reduced by glutathione reductase (GR) in the presence of NADPH.

1.3.2 Thioredoxin reductase
Thioredoxin reductase (TrxR) is a NADPH dependent pyridine nucleotidedisulphide oxidoreductase whose canonical function is to reduce the small protein,
thioredoxin (Trx)29. TrxR, NADPH, and Trx comprise the thioredoxin system which is a
vital antioxidant system responsible for maintaining redox homeostasis in the cell by
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providing essential reducing equivalents to a number of important cellular targets, as
illustrated in Figure 1.335.

Figure 1.3: Thioredoxin system. Once Trx is reduced by TrxR, it goes on to provide
reducing equivalents to numerous cellular substrates including (but not limited to): (i.)
peroxiredoxins (Prx), a ubiquitous family of antioxidants that controls cytokine-induced
peroxide levels and mediates signal transduction; (ii.) tumor protein 53 (p53), which
regulates the cell cycle and hence functions as a tumor suppressor; (iii.) ribonucleotide
reductase (RNR), which catalyzes the formation of deoxyribonucleotides from
ribonucleotides, a process vital for DNA synthesis; and (iv.) methionine-sulfoxide
reductase 1 (MsrB1), which reduces methionine (R)-sulfoxide back to methionine,
ultimately repairing oxidized Met residues.35, 36
After the discovery of TrxR in 1964 by Laurent and coworkers37, much work has
been done to study this vital enzyme. There are two classes of TrxRs that differ by size and
the number of redox centers present in the enzyme38. The lower molecular weight (Mr)
TrxRs have two redox centers: a flavin adenine dinucleotide (FAD) and an N-terminal
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disulfide redox center. Bacteria, plants, archaea, and most unicellular eukaryotes utilize
this low Mr form of TrxR38.
In contrast, higher Mr TrxRs have three redox centers: a flavin adenine dinucleotide
(FAD), an N-terminal disulfide redox center, and an additional C-terminal redox center38.
This C-terminal redox center is highly conserved among species and contains one of three
motifs, depending on the organism for which it is found. The three possible motifs are as
follows: (i.) a disulfide redox center with sequence: Xaa-Cys1-Cys2-Xaa, or (ii.) a
selenosulfide redox center with sequence: Xaa-Cys-Sec-Xaa (Sec-TrxRs) or, (iii.) a disulfide
redox center with the sequence: Gly-Cys1-Gly-Gly-Gly-Lys-Cys2-Gly38.
There are three isoforms of mammalian TrxR (mTrxR, EC 1.8.1.9): (i.) mTrxR-1,
the most common form of the enzyme, mainly cytosolic and found in most tissues; (ii.)
mTrxR-2, a predominantly mitochondrial protein that is commonly expressed at lower
levels than TrxR-1 in most tissues; and (iii.) mTrxR-3, also frequently known as TGR, is
mainly expressed in testis (male germ cells)29. TGR is a TrxR-glutathione reductase hybrid
enzyme that possesses an N-terminal glutaredoxin-domain in addition to a C-terminal Seccontaining redox center39.
Mammalian TrxRs are highly homologous to glutathione reductases (GRs) and
lipoamide dehydrogenase (LipDH), and the overall fold of mTrxR resembles other
homodimeric pyridine nucleotide disulphide oxidoreductases39. Human TrxR1 and
glutathione reductase (GR) share a high active site residue similarity at the cofactor and
substrate binding sites, as well as a similar reaction mechanism39. In Sec-mTrxRs, the 8
membered selenosulfide ring acts as an internal substrate that receives electrons from the
N-terminal disulfide once it is reduced by NADPH. In contrast, GR is essentially a
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truncated form of mTrxR that do not contain the flexible C-terminal tail. Instead, GR
reduces an external substrate, oxidized glutathione (GSSG)38.
All higher Mr TrxRs function as head to tail homodimers, and each subunit contains
a binding domain for FAD and NADPH, an interface domain, and a discrete active center38.
Both subunits are absolutely required for normal catalysis during a single catalytic cycle
due to the interactions between the C-term of one subunit with the N-term of the other29.
The full catalytic mechanism of TrxR is given in Figure 1.4.
The mTrxRs have a wide substrate scope that arises from the fact that substrates
may be reduced both by the easily accessible C-terminal selenolthiol motif of the NADPHreduced enzyme, and some low-molecular weight substrates can also be reduced directly
by the N-terminal redox center of the enzyme29. Lipoic acid, selenocystine, and Ellman’s
reagent are examples of small molecule substrates that can be reduced directly by the Nterminal redox active disulfide of mTrxRs40, 41. Trx contain two vicinal cysteines in a
CXXC motif that are key to the ability of Trx to reduce other proteins. Upon reduction of
other proteins, the vicinal Cys resdues of Trx are left in a disulfide that is subsequently
reduced by mTrxR, returing Trx to its active form (Figure 1.4)29.
Several Pfam domains (described by The European Bioinformatics Institute
(EMBL-EBI)) present in mTrxR1 include: a pyridine nucleotide-disulphide oxidoreductase
domain, pyridine nucleotide-disulphide oxidoreductase dimerisation domain, and
nucleotide phosphate-binding region. Its substrate, thioredoxin, contains a glutaredoxin
domain42,

43

. CATH database classifies mTrxR1 as an “Alpha Beta” protein, with 3-

Layer(ββα) Sandwich architecture, and a FAD/NAD(P)-binding domain. It also contains
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an enolase-like domain and is considered a member of the glutaredoxin homologous
superfamily44, 45.

Figure 1.4: Catalytic mechanism of high Mr Sec-TrxRs. (Top): First, exogenous
NADPH donates a hydride to reduce a bound flavin. The reduced flavin next reduces the
conserved N-terminal disulfide redox center. Once reduced, one of the Cys-thiols forms
a charge transfer complex with the flavin, and the other Cys-thiol goes on to reduce the
8-membered selenosulfide ring of the Cys-Sec dyad that is attached to the enzyme
through a flexible peptide linker on the opposite subunit. (Bottom): Once the C-terminal
selenosulfide is reduced, the Sec-selenol reduces the disulfide bond of Trx, forming a
senosulfide bonded intermediate. This intermediate is then “resolved” by the C-term
Cys, which is adjacent to Sec. This results in the formation of a rare 8-membered
selenosulfide ring, which is often thought to be the resting state.

Currently, there are no crystal structures of the flexible C-terminal redox center of
mTrxR without substrate present. However, crystal structures of mTrxR1 bound to Trx
have been solved (PDB: 3QFA and 3QFB). The first crystal structure of Type 1 mTrxR in
14

complex with its Trx substrate was solved by Karin Fritz-Wolf, et al. in 2011 and gave
much information into structural details of the enzyme39. The N-terminally located redox
active disulfide (Cys59-Cys64) is buried in the protein, whereas the second, C-terminally
located redox active selenosulfide (Cys497-Sec498) is positioned on a flexible, highly
accessible C-terminal tail of the other subunit39. Complex formation of mTrxR-1 with Trx
involves the generation of an intermolecular disulfide bond between the catalytic residues
Cys32 of Trx and Sec498 of mTrxR-1, which is stabilized by several other interactions,
including hydrogen bonding, hydrophobic packing, and electrostatic interactions. All
residues involved in forming the intermediate are highly conserved in mammals39. It is
important to note in this crystal structure the penultimate Sec residues (one on each
monomer) were mutated to Cys residues and the resolving Cys residue was mutated to
alanine to keep Trx bound.
Like other selenoproteins, the role of Sec in high Mr TrxRs is not fully understood.
The hypotheses that selenoproteins can resist oxidative and electrophilic stress better than
their Cys orthologs apply to Sec-TrxRs. In fact, Sec and Cys TrxRs have served as model
enzymes for many of these studies7, 14, 15, 38. One hypothesis that is somewhat unique to
Sec-TrxRs is that Sec accelerates thiol disulfide exchange reactions in enzymes, thus
conferring a kinetic advantage38. This hypothesis is particularly well suited for Sec-TrxRs,
which undergo three thiol disulfide exchange reactions involving selenium in a single
catalytic cycle. Sec can accelerate thiol disulfide exchange reactions in three different
ways. First, Sec can enhance the rate of the enzyme by being a better nucleophile than Cys
(see Figure 1.5)38. This is a reasonable hypothesis considering the lower pKa of Sec (pKa
~ 5.3) compared to Cys (pKa ~ 8.3); Sec would be deprotonated at a much lower pH
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(especially at physiological pH), making it a reactive nucleophile5, 38, 46. Second, Sec is a
better leaving group than Cys, and this accelerates the exchange reaction (see Figure 1.5).
Because the acidity of a selenol is ~1000 times greater than a thiol, the selenol that results
after the X-Se bond is broken will be significantly more stable than the corresponding thiol
when an X-S bond is broken, which makes selenols superior leaving groups38. Third, Sec
is a better electrophile than Cys and this greater electrophilicity accelerates the reaction
(see Figure 1.5)38. The Hondal research group has provided much evidence supporting the
idea that mTrxR uses Sec as a superior electrophile47.
A

B

C

Figure 1.5: Selenium replaces sulfur in enzymes that utilize thiol/disulfide exchange
reactions. Adapted from Hondal, et al., 201138. This reaction can be accelerated by
selenium in three different ways. (A) Since Se is a better nucleophile than S, nucleophilic
attack is faster. (B) Thiol/disulfide exchange can also be accelerated by the center atom
(Xc) being a good electrophile. (C) Last, the reaction is also sensitive to leaving group
ability, which is largely determined by the pKa of XLg. While Se accelerates
thiol/disulfide exchange reactions by all of the ways shown above, it accelerates the
reaction up 104-fold faster by being a better electrophile.

Because mTrxRs depend heavily on Sec to reduce Trx, disorders arise when the
Sec residue is compromised. Sec can be bound by naturally or chemically occurring
compounds rendering Sec-TrxRs inactive, leading to inactive Trx, and multiple diseases.
Some natural compounds that inhibit mTrxR include: curcumin and curcumin analogs,
quinones, flavonoids, 4-HNE (4-hydroxy-2-nonenal) and other endogenous lipid
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electrophiles, and mercury, gold, and other metal ions29. This topic is discussed in further
detail in Chapter 4.

1.4 Methods to obtain selenoproteins for study
Currently, there are several unanswered questions surrounding many aspects of
selenoproteins. The largest barrier in studying mammalian selenoproteins is that it is very
difficult to obtain them in high yield and purity using traditional recombinant protein
expression techniques. We currently have only snapshots of individual players that are
involved in determining the mRNA stability and translational efficiency of each
selenoprotein mRNA. We also have only vague notions about how they assemble on each
mRNA inside the cell to allow regulated selenoprotein mRNA maturation and
selenoprotein synthesis48. The lack of knowledge in this area makes it nearly impossible to
replicate the necessary cellular machinery. Further complicating the matter, it is evident
that selenoproteins have evolved their own unique mRNA features that fine-tune
expression in various in vivo conditions, making it hard to express selenoproteins
originating from one species in a separate vector48. Recombinant protein expression and
purification in E. coli is the most common method used by biochemists to obtain usable
quantities of proteins of interest since E. coli is relatively inexpensive, robust, and
reproduces quickly. However, as eluded to above, there are many challenges associated
with recombinant eukaryotic selenoprotein expression in E.coli.
One challenge lies in the fact that the SECIS binding mRNA structural loop of E.
coli is significantly different in both sequence and location compared to the archaeal or
eukaryotic elements48, 49. SECIS elements are critical as Sec incorporation depends on
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RNA-binding proteins that bind to them. These variations between species’ SECIS
elements, and their associated RNA-binding proteins are problematic and typically result
in unwanted AA changes when archaeal or eukaryotic selenoproteins are expressed in E.
coli.49 Therefore, the natural Sec incorporation machinery of E. coli cannot be exploited
without manipulation to produce selenoproteins. This is described in detail in a recent
review by Fu and coworkers49.
To circumvent the above described problems, efforts have been made towards
engineering components of the insertion machinery to be more suitable in E. coli systems49.
For example, a few studies have engineered the E. coli tRNASec or tRNASec and elongation
factor Tu (ET-Tu) together, allowing the resultant tRNASec to be recognized by EF-Tu
directly50-52. While this approach is mostly successful, it still relies on conversion of Ser to
Sec on the engineered tRNASec. Since the tRNASec is a mutant engineered component, the
conversion efficiency is decreased, ultimately resulting in misincorporation of Ser instead
of the desired Sec50-52.
Another method that has been explored, which involves expansion of the genetic
code using an orthogonal tRNA/synthetase pair, has the potential to site-specifically
incorporate Sec while completely avoiding Sec-dedicated incorporation components52-55.
One example from Rakauskaite and coworkers utilizes an orthogonal tRNALeu/CmnRS pair
to incorporate a photocaged Sec analog into a protein in yeast.55 The photocaged Sec analog
was then converted into Sec through photolysis. However, photolysis to generate Sec
resulted in an unwanted >15% conversion of Sec to dehydroalanine (DHA)56. To date,
there have been no native selenoproteins prepared with the photocaged analog approach52.
A second example in which genetic code expansion was exploited comes from Liu and
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coworkers who evolved an orthogonal tRNAPyl/ASecRS pair to genetically incorporate a
Sec analog with a small allyl protecting group in E. coli, which reportedly does not rely on
any Sec-dedicated incorporation components. Following incorporation, the allyl protected
Sec was deprotected using a facile palladium-mediated cleavage under mild biocompatible
conditions52. The authors speculate that this method would be also suitable for use in live
tissues.

Figure
1.6
(adapted
from
Eckenroth et al.57): Cleavage of
mTrxR-intein fusion construct by
addition of tripeptide and thiol.
Previous work from our group
constructed a fusion protein that
consists of mouse thioredoxin
reductase-2 (mTrxR-2, pink sphere),
intein, and a chitin binding domain
peptide (CBD). The CBD binds
tightly to chitin-agarose resin (grey
sphere), and this affinity is used for
purification of the fusion protein.
The fusion protein was made such
that glycine 487 of mTrxR-2 is the
AA at the junction between mTrxR2 and the intein (blue sphere)
through a thioester linkage. Addition
of a cleavage buffer containing thiol
and H-CUG-OH (which are the final
three AAs in the protein sequence)
initiates an N → S acyl transfer, with
subsequent cleavage of full length
mTrxR-CUG from the column.

One general problem with this type of method is that the Sec analogs
utilized are noticeably bulkier than native Sec, and may not fit well in buried Sec sites in
native selenoproteins, which may interfere with protein folding52. Additionally, genetic
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code expansion is complicated; it involves sophisticated microbiology and biological
engineering techniques which are simply not accessible for many laboratories.
Protein semi-synthesis, championed by the Raines group in 2002, has allowed
biochemists to obtain eukaryotic selenoproteins in high yields and purity58. Protein semisynthesis, defined as the assembly of a protein from a combination of synthetic and
recombinant fragments—is an expanding field of chemical biology that has impacted many
areas in the life sciences59. Using synthesis as the primary method works particularly well
for relatively small selenoproteins (up to 200 AAs) and can yield homogenous product in
milligram quantities49. Recently, Dery and coworkers reported the first total chemical
synthesis of human selenoproteins M and W60.
Expressed protein ligation works particularly well for Sec-containing mTrxRs. In
mTrxR, Sec is the penultimate residue of the AA sequence and it is adjacent to a Cys
residue, which can undergo native chemical ligation with the expressed portion of the
enzyme, as depicted in Figure 1.6. Here, only the short peptide H-Cys-Sec-Gly-OH, which
corresponds to the C-terminus of the enzyme, needs to be synthesized using solid phase
peptide synthesis (SPPS) while a majority of the protein (487 residues) can be expressed
and purified in E. coli. Our research group has used this method to make mTrxR-CUG
(wild type), along with a myriad of mTrxR mutants where the C-terminal synthetic peptide
is mutated with both natural and non-natural AAs to enable detailed mechanistic studies7,
14, 38, 41, 47, 57, 61, 62

.
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1.5 Solid phase peptide synthesis
Solid phase peptide synthesis (SPPS), which is crucial for producing semi-synthetic
enzymes (including selenoproteins), is a method for synthesizing peptides in high yield and
purity that was first developed by Merrifield in 196363. Utilizing a solid support for
synthesis enables high yield because unreacted reagents are easily washed away after each
synthetic step without a need for column purification. Furthermore, introduction of
coupling reagents and optimization of each synthetic step during SPPS has allowed nearly
100% yield for each step which allows for peptides to be made in very high final yield
despite the many steps required for synthesis.
Briefly, the process for SPPS goes as follows. The C-terminus AA of the desired
sequence is coupled directly to a solid support using Nα-protected AAs. Protecting group
chemistry is explained in more detail in Section 1.5.1. Next, any unreacted AA or coupling
reagent is washed away from the solid support, followed by a deprotection step where the
Nα-protecting group is removed. The next AA in the desired sequence is then activated at
the carboxylic acid using a coupling reagent, and the Nα acts as a nucleophile to form an
amide bond, resulting in a dipeptide on the resin. Any unreacted AA is washed away, and
deprotection and coupling steps are repeated until the desired sequence has been achieved.
The peptide is then cleaved from the resin using either acid (typically trifluoroacetic acid
(TFA)), or saponification, depending on the resin/ Nα-protecting group strategy utilized.
Thorough descriptions of the various resins, Nα-protecting groups, and coupling reagents
available to peptide chemists have previously been reviewed64-67.
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1.5.1 Amino acid protecting groups
SPPS relies heavily on AA protecting groups. As discussed in Section 1.2, a Nαprotecting group is imperative to prevent self-coupling of an AA during coupling steps.
Common Nα-protecting groups are acid-labile tert-Butyloxycarbonyl (Boc), and base-labile
fluorenylmethoxycarbonyl (Fmoc).
Additionally, AAs with reactive side chains must be protected during synthesis to
avoid unwanted side reactions. A suitable protecting group should have the following
characteristics: (i) it is easily introduced into the functional group; (ii) it is stable to a broad
range of reaction conditions; and (iii) it is safely removed at the end of a synthetic process
when the functional group requires manipulation. A fourth characteristic that is desirable
but not always attainable is orthogonality.
Cys and Sec chemistry is diverse and versatile due to the highly reactive thiol and
selenol functional groups their respective side chains. Thus, Cys and Sec residues must
remain protected during SPPS to prevent numerous side reactions. Common Cys protecting
groups include trityl (Trt)68, acetamidomethyl (Acm)69, tert-butyl (But)70, benzyl (Bzl)71,
and p-methoxybenzyl (Mob)72, 73. These PGs are displayed in Table 1.2. These same
protecting groups exist for Sec, except for Trt which is too labile to be a suitable Sec
protecting group.
During Fmoc-SPPS, trifluoroacetic acid (TFA) is commonly used to cleave the
peptide from resin, and Trt is removed from Cys residues during this step. Thus, peptides
synthesized using Fmoc-Cys(Trt)-OH are left with reactive thiol functionality upon resin
cleavage and Cys residues are not protected for future applications. In contrast, the Acm,
But, Mob, and Bzl groups are difficult to remove and require harsh conditions. Mob, Bzl,
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and But are typically removed by hydrofluoric acid and scavengers, or by mercuric
trifluoroacetate74. Acm is typically removed by oxidative treatment with iodine, which
often results in mixed disulfide bonds75. All the above-mentioned methods for protecting
group removal are challenging and require use of toxic reagents. Thus, gentler methods of
Sec and Cys protecting group removal is desirable.

Table 1.2: Common Cys protecting groups and their reported conditions for removal.
All the same protecting groups also exist for Sec and require similar deprotection condition.
Protecting group

p-Methoxybenzyl

Acetamidomethyl

Tert-butyl

Abbreviation

Mob

Acm

But

HF at 0 °C &
scavengers; or
triflic acid; or Hg (II)
acetate in TFA.

Iodine oxidation; or
Hg (II) & silver
triflate.

HF at 20 °C; or
triflic acid &
scavengers; or Hg
(II) acetate in TFA.

Cys-S-PG
structure

Removal
conditions

We have developed new deprotection schemes for Cys and Sec residues using mild
reagents such as triisopropylsilane (TIS), pyridyl diselenide, and ascorbate. Among other
applications, this work has allowed us to synthesize the fully deprotected H-Cys-Sec-GlyOH tripeptide for use in protein semi-synthesis using biocompatible reagents. These works
are described in detail in Chapter 2.
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1.5.2 Applications of Sec- and Cys- containing peptides
Cys and Sec chemistry is intriguing and versatile due to the high reactivity of their
side chains. The thiol (SH) of Cys and selenol (SeH) functionality of Sec are very
susceptible to oxidation and can readily form stable dimers (disulfide or diselenide bonds),
which play important roles in protein tertiary structure. Cys and Sec are also quite
nucleophilic and react readily with electrophilic molecules to form a variety of thiol-linked
derivatives (e.g. thioethers, thioesters, and thioacetals)76. Thus, Cys and Sec side chains are
common sites for various biological coupling and conjugation reactions, including
palmitoylation, isoprenylation, and thiol-disulfide exchange76.
The modification of AA residues in proteins are called post-translational
modifications, which are essential for a myriad of essential processes including cell growth,
repair and death, as well as modulation of macromolecular functions. The ability to mimic
these processes outside of an in vivo environment allows researchers to mimic nature,
explore biosynthetic pathways, manipulate and decipher natural protein function, and to
attach affinity or fluorescent tags for imaging77. Cys and Sec provide reactive handles for
chemical modifications in peptides that have the potential to advance the understanding of
PTMs and their biological consequences.
Additionally, peptide chemists have exploited Cys chemistry for a variety of
applications and biotechnologies. For example, Cys is also the site of “peptide stapling”
which allows peptide chemists to make peptides of desired, cyclic structures bound by a
staple. Stapled peptides have enhanced biophysical properties such as conformational and
proteolytic stability, cellular uptake and elevated binding affinity, varying topology, and
specificity for their biological targets78. Currently, there are limited methods available to
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achieve stapled peptides, but promising Cys-based strategies have been recently developed
thanks to facile access from Cys functionalized peptide precursors78.
Importantly, many peptide therapeutics contain multiple disulfide bonds79.
Disulfide bonds in peptides and proteins provide enhanced stability. There are many
examples of bioactive, disulfide rich peptides and proteins such as the insulin
superfamily80, 81, conotoxins82, 83, guanylin84, 85, designed peptide therapeutics79, apamin
and analogs8,9, sarafatoxin10, cyclotides11,12, defensins13, elafin14, and atracotoxins15, 16,
whose biological activity relies heavily on proper disulfide connectivity. Synthesis of these
bioactive peptides and therapeutics relies upon methods for oxidative refolding or
regioselective disulfide bond formation.17,18 Though many methods have been developed
for regioselective disulfide bond formation, many of these methods suffer from a lack of
orthogonality between pairs of protected cysteine (Cys) residues, efficiency, and high
yields.19, 20
The multiple disulfide bonds present in these peptides confer enhanced chemical,
biophysical, and metabolic stability83, 86. Chemical synthesis of these peptides is essential
as it provides a source of the peptide/protein that could not otherwise be obtained by other
methods, and allows for investigation of their structure−activity relationships 86, 87. Though
there are several established Cys protection and activation strategies, applying these in a
chemoselective and orthogonal fashion to peptides containing multiple disulfide bonds
remains a challenge86-88. Chapter 2 of this dissertation focuses on improving these
strategies by developing highly specific methods for regioselective disulfide bond
formation and chemoselective disulfide bond reduction.
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1.6 Conclusions and Introductory Remarks
The biological role of selenium is intriguing. Selenoproteins, while energetically
costly to synthesize, play very important physiological roles. One such example is
thioredoxin reductase (TrxR), which is directly responsible for maintaining redox
homeostasis in the cell. Though it is now widely accepted that higher molecular weight
TrxRs have evolved to use selenium to resist oxidative inactivation, it is highly possible
that the chemical role of Sec is much more expansive than currently realized.
One aim of this work was to explore the role of selenium in mammalian TrxR
(mTrxR), which we propose has evolved to resist inactivation from reactive electrophilic
species such as acrolein. Along the way, we developed chemical tools to make the study
of this selenoprotein, and others, more accessible. Specifically, we focused on improving
methods for the chemical synthesis of peptides that contain Cys and Sec residues. One
large barrier in working with Cys and Sec-containing peptides is that the chemical
reactivity of their sidechains must be masked with sturdy protecting groups during
synthesis. However, subsequent removal of these protecting groups has required use of
harsh conditions that are not biocompatible for protein semi-synthesis without purification.
Thus, we saw a great need to develop methods for Cys and Sec deprotection that
are facile, non-toxic, and chemoselective. Herein, we describe three deprotection schemes
that provide either free Sec-selenols/Cys-thiols, or peptide disulfide bonds when more than
one Cys-residue is deprotected at the same time. We also describe a new chemoselective
tool, 2,2’-dipyridyl diselenide, that works as a disulfide bond forming reagent in the
synthesis of peptides that already have one disulfide bond formed.
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Another tool to explore the role of selenium in proteins is alpha-methyl
selenocysteine ((αMe)Sec) since this unique AA is resistant to β-syn elimination that
results from either over-oxidation or RES alkylation of Sec. By incorporating (αMe)Sec
into TrxR, we were able to conduct in vitro mechanistic studies in which interpretation of
the data was unambiguous as a result. Additionally, we found that incorporation of
(αMe)Sec into a peptide allowed the peptide to redox cycle and convert hydrogen peroxide
to water. These redox properties make our (αMe)Sec-peptide a GPX mimic that has
therapeutic potential.
Finally, we envision that the chemical tools, methods, and concepts that we have
developed herein will have applications and implications reaching far beyond protein
chemistry, and the potential of this work is described.
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CHAPTER 2: STRATEGIES FOR CYS AND SEC DEPROTECTION AND
CHEMOSELECTIVE DISULFIDE BOND FORMATION

2.0 OVERVIEW
To overcome the challenges associated with Cys and Sec protecting group
chemistry described in Section 1.5.1, the Hondal lab previously reported on a method for
the facile removal of 4-methoxybenzyl (Mob) and acetamidomethyl (Acm) protecting
groups from Cys and Sec using 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved in
trifluoroacetic acid (TFA) (DTNP/TFA), with or without thioanisole. The use of this
reaction mixture removes the protecting group and replaces it with a 2-thio(5-nitropyridyl)
(5-Npys) group. This results in either a mixed selenosulfide bond or disulfide bond
(depending on the use of Sec or Cys), which can subsequently be reduced by thiolysis. A
major disadvantage of thiolysis is that excess thiol must be used to drive the reaction to
completion and then removed before using the Cys- or Sec-containing peptide in further
applications. Here, we report a further advancement of this method as we have found that
ascorbate at pH 4.5 and 22 °C will reduce the Sec-selenosulfide to the selenol. Ascorbolysis
of the mixed disulfide between Cys and 5-Npys is much less efficient but can be
accomplished at higher concentrations of ascorbate at pH 7 and 37 °C with extended
reaction times.
To improve upon the methods for Cys deprotection, we decided to switch the
position of sulfur and selenium in the selenosulfide bond to be reduced by ascorbolysis.
This was accomplished by using 2,2´-dipyridyl diselenide (PySeSePy) in place of DTNP
in the deprotection scheme for Cys peptides. Here, we show the utilization of PySeSePy as
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a chemical tool for the removal of Cys-protecting groups and regioselective formation of
disulfide bonds in peptides. We found that peptides containing either Cys(Mob) or
Cys(Acm) groups treated with PySeSePy in TFA (with or without triisopropylsilane (TIS))
were converted to Cys-S–SePy adducts at 37 °C and various incubation times. This novel
Cys-S–SePy adduct is able to be chemoselectively reduced by five-fold excess ascorbate
at pH 4.5, a condition which should spare already installed peptide disulfide bonds from
reduction.
We applied our new chemistry to the iodine-free synthesis of the human intestinal
hormone guanylin, which contains two disulfide bonds. While we originally envisioned
using ascorbate to chemoselectively reduce one of the formed Cys-S–SePy adducts to
catalyze disulfide bond formation, we found that when pairs of Cys(Acm) residues were
treated with PySeSePy in TFA, the second disulfide bond formed spontaneously.
Spontaneous formation of the second disulfide is most likely driven by the formation of
the thermodynamically favored diselenide (PySeSePy) from the two Cys-S–SePy adducts.
Notably, TIS was needed for complete deprotection of Cys(Acm) by PySeSePy.
TIS, a hindered hydrosilane, has long been utilized as a cation scavenger for the removal
of AA protecting groups during peptide synthesis. However, its ability to actively remove
Cys-S-protecting groups by serving as a reductant has largely been mischaracterized by the
peptide community. Here, we provide strong evidence that TIS can act as a reducing agent
to facilitate the removal of acetamidomethyl (Acm), 4-methoxybenzyl (Mob), and tertbutyl (But) protecting groups from cysteine (Cys) residues in the presence of trifluoroacetic
acid (TFA) at 37 °C.
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Unexpectedly, we found that TIS promoted disulfide formation in addition to aiding
in the removal of the protecting group. We also tested other common scavengers under
these reaction conditions and found that thioanisole and triethylsilane were similarly
effective as TIS in enhancing deprotection and catalyzing disulfide formation. Our findings
show that careful consideration should be given to the type of scavenger used when it is
desirable to preserve the Cys-protecting group.
In all, we present three new Sec and Cys deprotection schemes in this chapter: (i.)
the ascorbolysis of Sec(5-Npys) adducts, (ii.) the conversion of Cys(Mob) or Cys(Acm) to
Cys-S–SePy adducts with subsequent ascorbolysis, and (iii.) the reduction of Cys-Sprotecting groups by TIS. These schemes can be used to produce free Cys-thiols and Secselenols in situ, or can be used for chemoselective disulfide bond formation.
We envision that our improved deprotection methods will allow for in situ reactions
with alkylating agents and electrophiles without the need for further purification, as well
as a number of other applications. We have also developed a one-pot method for
concomitant deprotection and disulfide bond formation of Cys(Acm) pairs in the presence
of an existing disulfide bond. This chemoselective reduction by ascorbate will undoubtedly
find utility in numerous biotechnological applications. Finally, our results raise the
possibility of using TIS in orthogonal deprotection strategies of Cys-protecting groups
following peptide synthesis as TIS can be viewed as a potential deprotection agent instead
of merely a scavenger in deprotection cocktails based on our results.
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2.1 Removal of the 5-Npys protecting group from Sec and Cys by ascorbolysis
The Hondal research group recently reported a method for the facile removal of 4methoxybenzyl (Mob) and acetamidomethyl (Acm) protecting groups from cysteine (Cys)
and selenocysteine (Sec) using 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved in TFA
(DTNP/TFA), with or without thioanisole as shown in Figure 2.189,

90

. Prior to the

development of this method, removal of these protecting groups required harsh conditions,
as described in Chapter 165, 91. DTNP can be added to all standard cleavage cocktails that
are used to cleave the peptide from the solid support in Fmoc solid-phase peptide synthesis
(SPPS) with simultaneous removal of the protecting group from Cys or Sec.

Figure 2.1: Deprotection of Sec-Se(protecting group) using DTNP in a
TFA/thioanisole/H2O cleavage cocktail, followed by thiolysis. Deprotection of Cys(Mob)
works similarly. Figure is adapted from Harris et al.89

However, one limitation of this method is that it requires the use of excess thiol in
a subsequent step to remove the 5-Npys group from Sec or Cys. In both cases, but
especially for Sec, a very large excess of thiol must be added in order to ensure that thiolysis
results in production of a free Cys-thiol or free Sec-selenol. In many cases a mixture of free
thiol/selenol and mixed disulfide/selenosulfide peptide results90. Another drawback of
thiolysis is that purification must be performed if the peptide is to be used in a subsequent
application.
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We hypothesized that a modification to our earlier method could replace thiolysis
of the mixed disulfide/selenosulfide bond in Figure 2.1 with ascorbolysis as shown in
Figure 2.2. It is known that ascorbate will reduce reactive disulfide bonds such as DTNP
and 5,5'-dithio-bis(2-nitrobenzoic acid (better known as DTNB), with a lesser ability to
reduce cystine and disulfide bonds with similar reactivity92, 93. Ascorbate has also been
used for the specific reduction of S-nitrosothiols in the biotin switch assay94, 95.

Figure 2.2: Deprotection of Sec-Se(protecting group) using DTNP in a
TFA/thioanisole/H2O cleavage cocktail, followed by ascorbolysis.

We envision that ascorbolysis will allow for in situ reactions with alkylating agents
and electrophiles without the need for further purification, as well as a number of other
applications. Another advantage of using ascorbate to reduce the selenosulfide in Figure
2.2 is that excess ascorbate in solution helps quench dissolved oxygen in the sample,
thereby keeping the selenol in a reduced form. Another area where we envision this
ascorbate chemistry to be useful is in the synthesis of peptides or small proteins that have
multiple disulfide bonds.
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2.1.2 Results of Asc reduction
We first set out to test the ability of ascorbate to reduce Sec(5-Npys) and Cys(5Npys) by visual inspection since ascorbolysis of the peptides should liberate 5-Npys, which
has an absorbance maximum at 412 nm, similar to thio-nitrobenzoic acid, and a yellow
color produced is visible to the naked eye at sufficiently high concentration. We found that
the reaction between ascorbate and Sec(5-Npys) at 22 °C is fast upon addition of ascorbate
to Sec(5-Npys) at a pH of 4.5 as a color change from clear to bright yellow was observed
almost immediately (within minutes of addition), as displayed in Figure 2.3. In contrast,
we observed that the reaction between ascorbate and Cys(5-Npys) is slow, as a color
change could only be observed after hours of reaction and most prominently when heated
to 37 °C.
Initially, we tried to add ascorbic acid directly to the solution of peptide dissolved
in the cleavage cocktail containing DTNP and TFA (plus scavengers), after allowing for
sufficient reaction time for Sec(Mob) to be converted to Sec(5-Npys). Such a procedure
would be advantageous because such “one-pot” procedures are highly desirable in peptide
chemistry96-98. However, the results of this reaction showed that ascorbate could not
deprotect the Sec(5-Npys) in TFA (pH ~2) and thus, ascorbolysis was performed in
aqueous solution.
Next, we explored various reaction conditions for both Sec(5-Npys) and Cys(5Npys) in order to maximize the extent of deprotection. We chose a pH of 4.5 as a lower
bound because it is just slightly above the pKa of ascorbic acid, 4.299. At this pH ascorbic
acid will be 67% ionized and in the active enolate form. Our chosen reaction pH of 4.5 fits
well with the findings of Dutton and coworkers who showed that the use of DTNP to
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catalyze heterodisulfide formation was fastest at pH values between 3.5 and 6.5100. Pyridyl
disulfides are more reactive at acidic pH101 due to protonation of the pyridine nitrogen
atom, which in the case of both Sec(5-Npys) and Cys(5-Npys) greatly polarizes the mixed
disulfide bond. This polarization of the mixed disulfide bond activates the disulfide bond
towards thiol/disulfide exchange as well as reduction by ascorbate101. Thus, our chosen
reaction pH of 4.5 is a balance between conversion of ascorbic acid to the reactive ascorbate
(enolate) form, and the maximum effective range of DTNP reactivity.
In order to determine whether ascorbate could convert Sec(5-Npys) to Sec-SeH, we
incubated a Sec-containing test peptide (crude product without HPLC purification) with 5fold excess ascorbate at either pH 4.5 or pH 7.0 under various reaction conditions as
summarized in Table 2.1. Ascorbolysis was monitored by HPLC and ESI-MS. We found
that near complete deprotection occurred at pH 4.5 and 25 ºC after 4 hrs of reaction time
(reaction Se1, Table 2.1). Our results show that pH 4.5 was slightly better than pH 7.0 for
achieving deprotection, but deprotection was very similar under all of the conditions listed
in Table 2.1.
The percentage of deprotection was estimated by measuring the area under the peak
in the HPLC chromatogram compared to the control. In Figure 2.4A we show the HPLC
chromatogram of the Sec-peptide without addition of ascorbate (control), while the effect
of addition of 5-fold excess ascorbate to the Sec-peptide is shown in Figure 2.4B. The
identity of each peak was determined by ESI-MS analysis before and after treatment with
ascorbate. The MS data is shown in Figure 2.4C and Figure 2.4D. We note that some of
the 5-Npys group was removed during work up of the peptide by an undetermined
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mechanism before the addition of ascorbate. These results show that ascorbate successfully
removes the 5-Npys group from Sec under relatively mild conditions.
Our initial experiments with the Cys-containing peptide using a ratio of ascorbate
to peptide that ranged from 2:1 to 20:1 for 4 hrs at pH 4.5 and 25 °C (conditions analogous
to those used for complete conversion of Sec(5-Npys) to Sec-SeH) did not result in
conversion of Cys(5-Npys) to Cys-SH as determined by HPLC analysis (data not shown).
In order to see if we could deprotect Cys(5-Npys) with ascorbate, we increased the ratio of
ascorbate to Cys-peptide to 100:1. At this ratio of ascorbate to peptide we found that ~50%
deprotection was achieved at pH 4.5 and 25 °C with a reaction time of 24 hrs (reaction S2,
Table 2.1). We next tried to push the reaction to completion by raising the pH from 4.5 to
7 (potassium phosphate buffer, reaction S6, Table 2.1), but the result was nearly an
identical level of deprotection as determined by HPLC analysis. We then explored the
effect of elevated temperature on the reaction and found that increasing the temperature
from 25 °C to 37 °C at pH 7 with a reaction time of 24 hrs improved deprotection (reaction
S8, Table 1). One difference at pH 7 compared to pH 4.5 was the appearance of the
disulfide form of the peptide in the HPLC chromatogram (Figure 2.5A). Using these
reaction conditions conversion of Cys(5-Npys) to Cys-SH increased to 70-75%, but the
reaction is still slow as is evidenced by the extended reaction time, high concentration of
ascorbate, elevated temperature, and incomplete removal of the 5-Npys group. Both HPLC
and mass analysis show incomplete removal of the 5-Npys group from Cys under these
conditions (Figures 2.5A and B).
Our results do indeed show that ascorbate was very efficient in converting Sec(5Npys) to Sec-SeH at acidic pH (Table 2.1). Increasing the reaction pH to 7 slightly
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decreases the extent of conversion for Sec as might be expected based on our discussion
above. However, the opposite pH reaction profile is observed for the conversion of Cys(5Npys) to Cys-SH. At pH 4.5, only about 50% conversion can be achieved, even when the
temperature is increased from 22 °C to 37 °C (compare S2 to S4 in Table 2.1). Increasing
the reaction pH to 7 did increase the extent of conversion of Cys(5-Npys) to Cys-SH, but
only after extended reaction time (24 hrs) and elevated temperature (37 °C). Thus the ideal
deprotection of Cys(5-Npys) occurs with 100 molar excess ascorbate at pH 7, 37 °C, and
after 24 hours of incubation (reaction S8 in Table 2.1). These conditions are significantly
different than that for Sec(5-Npys) and this difference might be exploited for orthogonal
deprotection conditions in the future.

Scheme 2.1: Strategy for creating an interstrand selenosulfide bond between two
peptide chains. Directed disulfide bond formation could occur (1), followed by
conversion of Sec(Mob) to Sec(5-Npys) (2). Treatment with Asc would liberate the
selenol, which could then be coupled to a Cys residue on a second peptide strand.

While we do not report further on the utility of this deprotection reaction here, we
envision multiple applications of this chemistry, which are discussed in Section 2.5. One
such application we explore in Section 2.2 is the creation of interchain disulfide,
diselenide, or selenosulfide bonds as depicted in Scheme 2.1. Such a strategy would be
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identical to the biotin-switch assay where a mild reductant is needed so as to avoid
reduction of the intact disulfide bond94, 95, 102.
In conclusion, we have developed a gentle and highly effective method for
conversion of Sec(5-Npys) to Sec-SeH. This chemistry also works for deprotection of
Cys(5-Npys), but higher concentrations of ascorbate and longer reaction times are required.
However, we wanted to further explore the adaption of these deprotection method for Cys
peptides, and this work is discussed below.
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2.2. PySeSePy: A chemoselective tool for cysteine deprotection and disulfide
formation
As discussed in Chapter 1, disulfide bonds in peptides are very important for
structure, function, and bioactivity. Synthesis of these bioactive peptides and therapeutics
relies upon methods for oxidative refolding or regioselective disulfide bond formation.17,18
Though many methods have been developed for regioselective disulfide bond formation,
many of these methods suffer from a lack of orthogonality between pairs of protected
cysteine (Cys) residues, efficiency, and high yields.19, 20
As has been reviewed extensively by Moroder using the Fmoc/But strategy of solidphase peptide synthesis (SPPS), pairs of S-trityl (S-Trt), S-methoxytrityl (S-Mmt), S-tertbutylmercapto (S-SBut), or S-2,4,6-trimethoxyphenylthio (S-Tmp) must be used to install
the first disulfide bond in regioselective strategies involving orthogonal pairs of Cysprotecting groups103-105. In the case of Cys(Trt) or Cys(Mmt) pairs, both protecting groups
can be removed by trifluoroacetic acid (TFA) used in the cleavage step from the solid
support68, 106-108. In the case of Cys(SBut) or Cys(Tmp) pairs, thiol or phosphine reducing
agents can be used for deprotection107, 108. In both cases, air-oxidation can then be used to
install the first disulfide bond.
Common reducing agents lack chemoselectivity and must be avoided after
formation of the first disulfide bond. For example, if a Cys(SBut) pair is used to install the
first disulfide bond, then a Cys(Tmp) pair cannot be used later because reducing agents are
required to remove the Tmp protecting group and these reducing agents would also disrupt
the pre-existing disulfide bond.
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We realized that this limitation might be overcome using chemistry described in
Section 2.1. We previously showed that the 5-Npys protecting group could be removed
chemoselectively from Sec, but not Cys using ascorbate (Asc) in aqueous buffer at pH 4.5
as shown in Figure 2.6109. Thus, reduction of a mixed aryl-selenosulfide bond by Asc is
very facile, while the same reduction of a mixed aryl-disulfide bond by Asc is slow.

Figure 2.6: Removal of the 5-Npys group from Cys or Sec by ascorbolysis. We
previously found that Asc can reduce the Se–S bond of Sec(5-Npys) very easily, while
the same reduction of the S–S bond of Cys(5-Npys) is very slow.27

This finding gave rise to the idea of developing a new selenium-containing
deprotection reagent. Since 2,2'-dithiobis(5-nitropyridine) (DTNP) was used by our group
previously for simultaneous deprotection/disulfide bond formation with a wide variety of
Cys-protecting groups89, 90, 110, we reasoned that we may be able to use 2,2´-dipyridyl
diselenide (PySeSePy) or a substituted derivative, as a deprotection reagent. Use of
PySeSePy to remove Cys-protecting groups would result in a mixed aryl-selenosulfide
bond that could subsequently be removed by Asc as shown in Figure 2.7.
Asc is a chemoselective reductant because it has been reported that it does not
reduce peptide/protein disulfide bonds, or does so very slowly at neutral pH (and more
slowly at acidic pH)93, 111. As such it has been widely used in the so-called “biotin switch
assay” to detect S-nitrosothiols in proteins94, 102, 111.
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Figure 2.7: Proposed reduction of the S–Se bond of Cys(PySe) by Asc. We found
that reduction of Sec-Se–SPy with Asc was fast.27 In order to gain the same
chemoselective advantage with Cys residues, we “switched” the position of sulfur and
selenium through the use of PySeSePy and derivatives so as to create a Cys-S–SePy
adduct.
We are aware of only two other reports of chemoselective reduction of disulfides
in the literature. Both reports involve borohydride derivatives that can chemoselectively
reduce aromatic disulfides preferentially over alkyl disulfides and are only compatible with
organic solvents112,

113

. Asc is gentle, highly soluble in aqueous buffer, and can

chemoselectively reduce mixed aryl-selenosulfide bonds over typical disulfide bonds as
illustrated in Figure 2.8. This is especially true at acidic pH (pH 4 to 5) where Asc is very
effective at only reducing the Cys(PySe) adduct and not peptide disulfide bonds. At acidic
pH, the pyridyl ring is protonated, activating the selenosulfide for attack. In addition, when
pH = pKa = 4.21, half of the ascorbic acid in solution is present as the active enolate109.
Thus, we sought out to develop a method to deprotect Cys residues using
PySeSePy, with concomitant conversion to the Cys(PySe) adduct. We reasoned that the
resulting S–Se bond of the Cys(PySe) adduct should be easy to reduce using Asc
(especially at low pH), giving a chemoselective advantage to regioselective disulfide bond
forming strategies that would also be free of the use of iodine as discussed below.
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Figure 2.8: Advantage of chemoselective reduction of Cys(PySe) adducts by Asc
compared to conventional reducing agents. A) Conventional reducing agents such as
thiols will reduce each S–S or S–Se bond as shown. B) Asc chemoseletively reduces the
S–Se bond of Cys(PySe) adducts. Note that R represents a covalent modification of Cys
that can be removed by typical reducing agents.

2.2.1. Results and Discussion of PySeSePy deprotection scheme
Synthesis of PySeSePy: PySeSePy is not commercially available. Thus, we began with the
synthesis of PySeSePy by first reducing elemental selenium with sodium borohydride, then
introducing 2-bromopyridine for a nucleophilic displacement reaction, using reported
methodologies114. The synthesis was completed giving 49% yield. Mass spectral (MS)
analysis, 77Se-NMR, and 1H-NMR spectrograms of PySeSePy are given as Figure 2.9 and
Figure 2.10.

Use of PySeSePy and ascorbate as a cysteine deprotection strategy. With PySeSePy in
hand, we went on to test its effectiveness as a deprotection reagent to convert Cys(Mob) to
Cys(PySe). While we tested a variety of deprotection conditions, we found that quantitative
deprotection of Cys(Mob) occurs using 5-fold excess PySeSePy after 4 h at 37 °C in
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TFA/water (98:2) as judged by the HPLC and MS analyses shown in Figure 2.11. A
deprotection cocktail of TFA/TIS/water (96:2:2) for 4 h at 37 °C gave very similar results
(data not shown). We note that in order for full deprotection of the Cys(Mob) peptide to be
achieved, a reaction temperature at 37 °C is required. If the reaction is done at rt, 30% of
the peptide remained protected as Cys(Mob) (data not shown).
We then reduced the formed Cys(PySe) adduct with Asc. We found that the adduct
could be reduced using 5-fold excess Asc in 100 mM ammonium acetate buffer, pH 4.5,
after 4 h incubation at rt. The reduction of the Cys(PySe) adduct with Asc resulted in
quantitative conversion to Cys-SH as shown in Figure 2.11C and 2.11F. Ascorbolysis of
the S–Se bond may be achieved in a shorter time, but we did not test a shorter reaction
condition.
We next turned our attention to the deprotection of Cys(Acm), which is
significantly more difficult to deprotect than Cys(Mob). Deprotection of Cys(Acm) is
commonly achieved by the use of iodine under acidic conditions with measures taken to
suppress disulfide rearrangement69,

115, 116

. Our group showed that deprotection of

Cys(Acm) could be achieved by using the gentle, electrophilic disulfide DTNP. However,
the drawback to this method is that at least 20-fold excess DTNP and 2% thioanisole in
TFA is required and deprotection was only achieved in 68% yield90.
We hypothesized that the deprotection of Cys(Acm) using PySeSePy could be
achieved using similar conditions that were used above for the deprotection of Cys(Mob).
We tested many conditions and found partial deprotection (~55%) using 5-fold excess
PySeSePy in neat TFA at 37 °C for 12 h as judged by HPLC (Figure 2.12A). Interestingly
we found that ~95% deprotection occurs under the same conditions, but with the addition
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of 2% TIS (Figure 2.12B)117. The MS analysis corresponding to Figure 2.12 is given as
Figure 2.13. Our observation that TIS is required for deprotection is discussed in further
detail in Section 2.3.
These findings agree very well with our prior results in which we showed that
addition of TIS to deprotection cocktails greatly enhances the removal of Mob and Acm
groups from Cys118. We found that TIS can directly reduce Cys(Acm) to Cys-SH in TFA
at 37 °C for 12 h,118 and this finding proved to be important in developing the deprotection
of Cys(Acm) by PySeSePy. TIS likely facilitates the deprotection of Cys(Acm) by
PySeSePy by two different pathways. First, Cys(Acm) is partially deprotected by TIS to
the free thiol which can then act as a nucleophile attacking the diselenide. Second, the
protected S-atom of Cys(Acm) attacks the soft diselenide of PySeSePy in similar way as
S-protected derivatives attack the soft disulfide bond of DTNP, resulting in deprotection89.
As before, we found that addition of Asc resulted in removal of the PySe-adduct
(Figure 2.12D). The ability of the Cys(PySe) to be easily reduced by ascorbate, resulting
in a free thiol, will undoubtedly find utility in numerous applications including
regioselective disulfide bond formation.
Because PySeSePy required slight heat (37 °C versus rt) in order for deprotection
of both Cys(Mob) and Cys(Acm) to be complete, we decided to revisit the use of DTNP
for the deprotection of Cys(Acm), as full deprotection was not achieved at ambient
temperatures90. We found that we were able to effect full deprotection of Cys(Acm) with a
cocktail of 5 equivalents of DTNP dissolved in TFA/thioanisole (98:2) at 37 °C with a 12
h incubation time as shown by the HPLC analysis in Figure 2.14A and 2.14B, and the MS
analysis in Figure 2.15. While the addition of TIS to the deprotection cocktail containing
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PySeSePy greatly enhanced the removal of Acm as shown by the results in Figure 2.12,
addition of TIS to the cocktail containing DTNP resulted in breakdown of the Cys(5-Npys)
adduct and the appearance of other unidentified products as shown by the HPLC
chromatogram in Figure 2.14C. The breakdown of the Cys(5-Npys) adduct is most likely
caused by reduction of this reactive disulfide bond by TIS. The identity of one of the sideproducts could be a TIS-(5-Npys) adduct. We note that we attempted to deprotect Cys(But),
another popular S-protecting group, with PySeSePy, but we found the reaction to be
ineffective. In our hands, we could only achieve less than 30% deprotection under the same
conditions used to deprotect Cys(Acm).

Comparison of PySeSePy with DTNP as a deprotection reagent. Compared to DTNP,
PySeSePy was not as effective as converting Cys(Mob) or Cys(Acm) to the corresponding
pyridyl-adduct. For example, when our Cys(Mob)-containing peptide was treated with 5fold excess PySeSePy for 4 h at rt in (96:2:2) TFA:TIS:water, about 45% of Cys(Mob)
remained (Figure 2.16). In contrast, nearly quantitative conversion of Cys(Mob) to Cys(5Npys) was achieved when using 5-fold excess DTNP under the same conditions (Figure
2.17). Similarly, PySeSePy was less effective at deprotecting Cys(Acm), which can be
realized by directly comparing Figure 2.14B and 2.16B. Using similar conditions, 5%10% of Cys(Acm) remained when using PySeSePy compared to when using DTNP in the
deprotection cocktail.
There are two reasons for PySeSePy being less effective as a deprotection reagent
compared to DTNP. First, the disulfide bond of DTNP is more electrophilic (“softer”) due
to the presence of the p-nitro group on the aromatic ring. The p-nitro group polarizes the
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disulfide bond making it more reactive. Though we attempted synthesizing the p-nitro
derivative of PySeSePy to increase its reactivity, attempts to obtain the compound in high
yield and purity were unsuccessful. The second reason is that the redox potential of
PySeSePy is much lower compared to DTNP, which means that diselenide bond formation
is more favored compared to mixed disulfide bond formation119. However, the advantage
that PySeSePy has is that the mixed Cys-S–SePy adduct that is formed as a result of the
deprotection reaction can be reduced by ascorbate in a chemoselective fashion, whereas
the mixed Cys-S–S(5-Npys) adduct cannot.

Synthesis of guanylin using the PySeSePy/ascorbate strategy. Having showed that
PySeSePy in combination with reduction by Asc was an effective method for removal of
S-Mob and S-Acm protecting groups and resulting PySe-adduct, we next set out to
demonstrate that this method could be used as part of an overall strategy for regioselective
disulfide bond formation in a bioactive peptide containing multiple disulfide bonds. We
chose the human intestinal peptide guanylin as our target.
Guanylin is a human hormone that regulates electrolyte and water transport in
intestinal and renal epithelia84, 85. Guanylin is a 15-AA polypeptide that has two disulfide
bonds. One between Cys4 and Cys12, and the second disulfide is between Cys7 and Cys15.
Previously reported syntheses of guanylin utilized the Trt-group to protect Cys4 and Cys12,
and Acm to protect Cys7 and Cys1585, 120 The first step of the synthesis utilized TFA to
remove S-Trt groups, followed by air oxidation to form the first disulfide bond. Next,
iodine oxidation was used to remove S-Acm from the second set of Cys residues, forming
the second disulfide85, 120. However, iodine oxidation is cumbersome; the peptide must be
45

dissolved in deoxygenated acetic acid/hydrochloric acid (4:1), resulting in a solution of pH
2, then incubated with 10-20 equivalents of iodine85. Excess iodine is then reduced with
sodium thiosulfate (or other quenching reagents such as activated charcoal or powdered
zinc dust), and the peptide must be purified via HPLC85, 116. Such purification is necessary
as iodine oxidation can result in disulfide bond scrambling116, 121, which leads to low yields
of the desired peptide with correct disulfide pairing. Iodine oxidation can also modify
oxidation-sensitive residues, such as methionine, tryptophan, and tyrosine75, 122-124. Rapid
quenching of excess iodine after completion of the desired oxidation reaction can help to
minimize the unwanted modification of Met, Trp, and Tyr116,

125

. However, these

quenching reactions can result in undesired side products such as the formation of a
peptide-thiosulfate adduct when sodium thiosulfate is used as the quenching reagent126.
Zhang and coworkers provide a detailed account of the cumbersome nature of working
with iodine, and provide an alternative purification using ether precipitation116.
To improve the synthesis of guanylin without using iodine, we also synthesized
guanylin with Cys4 and Cys12 with S-Trt protecting groups, and Cys7 and Cys15 with SAcm protecting groups. During cleavage from the resin, both Trt protected Cys residues
were converted to Cys-SH, and subsequent air oxidation provided the first disulfide bond
(Figure 2.18A and 2.18B).
Our next step replaces the use of iodine with PySeSePy. We envisioned that we
would form the second disulfide bond by first forming the Cys-S–Se-Py adduct, followed
by addition of Asc to catalyze formation of the second disulfide without reduction of the
first formed disulfide. However, we found that ascorbate reduction of the Cys-S–Se-Py
adduct was not necessary.
46

Figure 2.20: Possible mechanisms for 2,2´-dipyridyl diselenide-mediated disulfide
formation. (A) Cys(PySe) adducts results after Acm removal with PySeSePy. Asc is a
one-electron reducing agent53 that can reduce the Cys-S–SePy adduct, resulting in a Cysthiolate and a PySe• radical. The ejected PySe• radical can then combine with another
PySe• radical, reforming PySeSePy. The Cys-thiolate then undergoes SN2 attack onto
the remaining Cys-S–SePy adduct to install the second disulfide bond. (B) An alternate
mechanism has the PySe• radical formed after the reaction with Asc undergoing a S RN2
reaction54 with the remaining Cys-S–SePy adduct forming PySeSePy and a Cys-S•
radical. The Cys-S• radical then can undergo a rapid radical recombination to form the
second disulfide bond. (C) Experimentally, we found that disulfide bond formation was
independent of the addition of Asc. In the partially folded intermediate, the two
Cys(PySe) adducts are close together in 3D-space. We postulate that PySeSePy
spontaneously forms as shown due to the low redox potential of the resulting
diselenide.45 This thermodynamic driving force pushes disulfide bond formation to
completion.
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Instead, we found that when incubating guanylin with 1 equivalent of PySeSePy in
98:2 TFA:TIS for 8 h at 37 °C, the second disulfide bond formed spontaneously (Figure
2.18C). The MS analysis confirms the correct mass for each step of the synthesis (Figure
2.19). In this case, the propensity of PySeSePy to exist as the diselenide works in favor of
disulfide bond formation. One can imagine that the two Cys-S–SePy adducts are close
together in 3D-space in the partially folded peptide and that the two Se atoms
spontaneously form a diselenide bridge with concomitant formation of the disulfide. This
point is illustrated in Figure 2.20.
We confirmed the correct disulfide connectivity by HPLC (Figure 2.18C and
2.18D) by comparing our HPLC trace to that of commercially available guanylin. The
peaks labelled in Figure 2.18 are confirmed by MS analysis (Figure 2.19). Notably, there
is a one-minute change in retention time between guanylin with only one disulfide bond
formed (Figure 2.18B), and native guanylin with two disulfide bonds (Figure 2.18C and
2.18D). Thus, synthesis of guanylin was completed using orthogonal S-Trt and S-Acm
groups, and PySeSePy to catalyze the formation of the second disulfide bond.

Synthesis of Tachyplesin-1 using the PySeSePy/ascorbate strategy.
Tachyplesin-1 is a 17-AA antimicrobial peptide (AMP) extracted from the
hemocytes of the horseshoe crab, Tachypleus tridentatus127, 128. Tachyplesin-1 is a broadspectrum AMP as it has exhibited potent activity against Gram-positive and Gram-negative
bacteria, as well as fungi129. It works as an AMP via a membranolytic mechanism of action
that did not induce resistance in short-term studies. However, tachyplesin-1 did show signs
of decreased susceptibility under long-term continuous selection conditions and has been
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shown to compromise the integrity of both the outer and cytoplasmic cell membranes of E.
coli130. Tachyplesin-1 was also found to be unsuitable for therapeutic development when
it displayed high levels of toxicity toward mammalian cells. This, unfortunately, is a
common detrimental characteristic of many AMPs128.
For therapeutic development, there is a great desire to obtain tachyplesin-1, and
other AMPs synthetically. A facile synthetic route to obtain AMPs would allow for studies
where AA replacements could be used to analyze and optimize antimicrobial activity,
cytotoxicity, membrane binding affinity, hemolytic activity, and other important AMP
properties128. Currently, one major hurdle in synthesizing tachyplesin-1, and other AMPs,
is the presence of multiple disulfide bonds79. We predicted that our PySeSePy deprotection
scheme would allow for facile synthesis of tachyplesin-1, as it did for guanylin.
First, tachyplesin-1 was synthesized using Fmoc-based SPPS63, 66 and orthogonal
Cys protection103-105. Notably, the carboxyl-terminal end of Tachyplesin-1 contains an
arginine α-amide127. To achieve this C-term amide functionality, Rink Amide AM resin
(100-200 mesh, Novabiochem®) was used for SPPS. Tachyplesin also contains two
disulfide bonds: one between Cys3 & Cys16, and one between Cys7 & Cys12127. To ensure
correct disulfide connectivity, we utilized the same stepwise disulfide bond formation
scheme that was used to successfully fold guanylin.
Briefly, the first disulfide bond was formed between Cys7 & Cys12, which were STrt protected during SPPS. Upon cleavage from the resin using (96:2:2) TFA:TIS:H2O, the
Trt protecting groups were removed via acidolysis. The resulting Cys-thiols were air
oxidized in ammonium bicarbonate buffer (pH 8.12), forming the first disulfide bond. The
peptide was then frozen and lyophilized to remove water and volatile buffer salts. Next,
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the second disulfide bond was formed between Cys3 & Cys16, which were S-Acm
protected during SPPS. Lyophilized peptide powder was re-dissolved in (96:2:2)
TFA:TIS:H2O containing 5-fold excess PySeSePy, and allowed to react for 8 h at 37 °C.
After incubation with PySeSePy, the peptide was precipitated with cold ether and
lyophilized to powder. Excess PySeSePy was subsequently removed via preparative highpressure liquid chromatography (HPLC) purification using a water/acetonitrile gradient.
The correct mass was confirmed for each step of the synthesis using MS analysis, and the
spectra are given as Figures 2.21-2.23.
As expected, the use of PySeSePy to install a disulfide bond in the presence of an
already formed disulfide bond was successful, even when using the larger peptide,
tachyplesin-1. We predict that our new scheme will allow for facile synthesis of other
AMPs in the future.

Test of Asc as a chemoselective reductant of selenosulfide bonds. To show that Asc does
not reduce disulfide bonds in the context of a folded peptide/protein under the acidic
conditions used here to reduce a mixed Cys-S–SePy adduct, we tested whether 5-fold
excess Asc would reduce guanylin at pH 4.5. Figure 2.24A-C shows the mass spectra of
guanylin in buffer with or without 5-fold excess Asc at pH 4.5. Reduction should result in
a gain of mass of either 2 or 4 daltons if Asc reduced one or both disulfide bonds of
guanylin. The MS data in Figure 2.24 shows that 5-fold excess Asc does not reduce either
disulfide bond at pH 4.5 after 4 h of incubation. Thus, Asc is a chemoselective reductant
of Cys-S–SePy adducts.
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While PySeSePy has some significant advantages for regioselective disulfide bond
formation as discovered here such as the use of Asc to chemoselectively reduce a
selenosulfide bond and spontaneous disulfide bond formation from pairs of Cys-S–SePy
adducts thermodynamically driven by formation of PySeSePy, we must note two
disadvantages. First, PySeSePy is not commercially available and this will undoubtedly
preclude its use for some users. We hope that PySeSePy will soon become commercially
available, so as not to be a limiting factor. Second, like DTNP, PySeSePy remains as a
contaminant in the peptide solution even after many washes with diethyl ether.
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2.3. Reduction of cysteine-S-protecting groups by triisopropylsilane
In Section 2.2, we showed that addition of TIS to deprotection cocktails greatly
enhances the removal of Mob and Acm groups from Cys118. We found that TIS can directly
reduce Cys(Acm) to Cys-SH in TFA at 37 °C for 12 h,118 and this finding proved to be
important in developing the deprotection of Cys(Acm) by PySeSePy. TIS likely facilitates
the deprotection of Cys(Acm) by PySeSePy by two different pathways. First, Cys(Acm) is
partially deprotected by TIS to the free thiol which can then act as a nucleophile attacking
the diselenide. Second, the protected S-atom of Cys(Acm) attacks the soft diselenide of
PySeSePy in similar way as S-protected derivatives attack the soft disulfide bond of DTNP,
resulting in deprotection89.

2.3.1 Background and Introduction
Hindered hydrosilanes such as TIS are commonly used as cation scavengers in the
deprotection of AA side-chains following SPPS65, 131. Protecting groups such as trityl (Trt)
and tert-butyl (But) form stable cations upon acidolysis and are easily removed from N-,
O-, and S-containing AA side-chains (for cysteine (Cys) But is not easily removed). In
acid, TIS drives the equilibrium towards cleavage of the protecting group from the AA
side-chain by donating a hydride to the resulting cation in an irreversible manner

131

. In

these cases the addition of TIS to the peptide cleavage cocktail is almost an afterthought
because TIS need not directly participate in breaking of a carbon-heteroatom bond.
Though TIS and other hindered hydrosilanes are exclusively thought of as
protecting group scavengers in SPPS 65, 107, they are actually mild reducing agents and can
reduce a carbon-heteroatom bond and can therefore directly participate in the removal of a
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protecting group from an AA side-chain. This fact has largely been misunderstood in the
peptide chemistry literature. Silicon is metallic in nature, and has low electronegativity
relative to hydrogen resulting in polarization of the Si-H bond

132, 133

. This polarization

causes hydrogen to be hydridic, and results in a milder reducing agent than the usual
aluminum-, boron-, and other metal-based hydrides

132, 133

. Thus, hydrosilanes have long

been commonly employed to provide the hydride in reductions of various carbenium ion
precursors and it should not be surprising that TIS can function as a deprotection reagent,
such as iodine or mercuric acetate, in SPPS as we now report.
An earlier investigation into the use of various scavengers in the synthesis of a
target Cys-containing peptide protected with the Acm group demonstrated that TIS
afforded the highest yield of Cys(Acm)-protected peptide compared to other commonly
used scavengers such as water, phenol, anisole, and ethanedithiol (EDT)

134

. All of the

tested scavengers including TIS also yielded a mixture of other products including the fully
deprotected peptide and the peptide disulfide. The use of TIS in the deprotection cocktail
yielded 4% fully deprotected peptide and 20% peptide disulfide 134.
The results of Singh and coworkers were later misinterpreted in several reviews to
mean that TIS helped to suppress removal of S-protecting groups

65, 107

. In contrast, we

have tested TIS and other commonly used scavengers used in Fmoc peptide cleavage
cocktails, and provide evidence that TIS serves as a reducing agent to actively aid in the
removal of S-protecting groups including Acm, 4-methoxybenzyl (Mob), and But in the
presence of trifluoracetic acid (TFA) and mild heat. In addition, we find that TIS actually
helps to promote disulfide formation as initially reported by Singh and coworkers 134.
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2.3.2 Results and Discussion of TIS deprotection scheme
TIS is a hindered hydrosilane that is used in organic synthesis as a mild reducing
reagent131-133. While working on methods to overcome the limitations of using DTNP to
deprotect Cys(Acm) residues (described previously), we unexpectedly discovered that
Acm was partially removed (70%) from a test peptide of sequence H-PTVTGGC(Acm)GOH in TFA:TIS (98:2), when incubated for 12 h at 37 ºC (Figure 2.25B). In contrast, the
same test peptide incubated in 100% TFA showed almost no conversion of Cys-Acm to
Cys-SH when incubated under the same conditions (Figure 2.25A). We found that the
deprotected peptide existed as both the Cys-SH (35%) and disulfide forms (35%). The
peptide disulfide was unambiguously identified by adding 5-fold excess TCEP to the
peptide reaction mixture containing 2% TIS. Under these acidic conditions, reduction of
the disulfide using TCEP is slow and the reaction was incomplete, but the amount of
peptide disulfide dramatically decreased with a concomitant rise in the Cys-SH form as
revealed by HPLC analysis (Figure 2.25C).
Our identification of each of the peaks in Figure 2.25 is further supported by mass
spectrometric (MS) analyses. Mass chromatograms of the reactions are shown in Figure
2.26. The deprotection reactions in Figure 2.25 were carried out at 37 ºC and extended
reaction time. However, use of elevated temperature allowed us to “discover” side
reactions that may be absent under standard deprotection conditions. To test whether the
inclusion of TIS would drive deprotection of our Cys(Acm)-containing peptide under
typical deprotection conditions, we incubated the peptide in TFA/TIS (98/2) for 2 h at rt.
HPLC analysis of this reaction shows that little or no deprotection occurred (Figure 2.27).
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As demonstrated in Figures 2.25A and 2.27, the S-Acm protecting group is stable
to incubation with neat TFA in agreement with earlier reports69, 107. However, others, both
at elevated temperature and at rt, have questioned the stability of S-Acm. The reason for
this disparity is most likely due to sequence specific effects. For example, Muttenthaler
and coworkers report that S-Acm is stable to TFA at 25 ºC, but loss of ~10% of the Acm
group occurs at 40 ºC of a bis-Acm protected oxytocin peptide135. We posit that one reason
for the higher loss of the Acm group reported by Muttenthaler may be due to the peptide
containing two Cys(Acm) residues whereas our peptide only contains one. Engebretsen
and coworkers speculate that sequence specific effects may also play a role in the loss of
the Acm group as they reported loss (11%) of both Acm groups of a fragment of human
coagulation factor VII after incubation in TFA/H2O (95/5) at rt124.
We next tested water, anisole, phenol, thioanisole, and triethylsilane (TES) to see
if these commonly used scavengers would also aid in the removal of the Acm group using
our reaction conditions (2% scavenger, 37 ºC, and extended reaction time). The results of
our HPLC analyses for these scavengers are shown in Figure 2.28. Peak assignments in
Figure 2.28 are based upon retention times and MS analyses of the reactions (Figure 2.29).
Of the scavengers tested, water was very ineffective at aiding in the removal of the Acm
group, while anisole and phenol were comparable to TIS in ability to remove the Acm
group. Thioanisole under these reaction conditions removed 80-90% of the Acm group and
thus was significantly better than anisol or phenol in this respect, and like TIS promoted
disulfide formation. This data is consistent with previous reports which showed that
anisole136 and thioanisole137 act to enhance the lability of S-Acm. TES was slightly better
than all other scavengers tested (including TIS) in promoting the removal of the Acm
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group. This should not be surprising since TES is much less hindered than TIS and thus it
is a better hydride donor131. However, one drawback of using TES is that it can reduce the
indole ring of tryptophan, whereas this is much less of a problem with TIS131. One
interesting thing to note is that like TIS, both thioanisole and TES promote disulfide bond
formation whereas the other scavengers tested do not.
We also wondered about the lability of other commonly used Cys-protecting groups
in the presence of TIS. We synthesized peptides H-PTVTGGC(Mob)G-OH and HPTVTGGC(But)G-OH, isolated each peptide by ether precipitation and lyophilization, and
then incubated each in TFA:TIS (98:2) at 37 ºC for 12 h as before. HPLC analyses of both
of these reactions are shown in Figures 2.30 and 2.31.
As is evident in Figure 2.30, S-Mob is mostly stable to TFA in the absence of TIS.
In contrast, S-Mob is very labile in the presence of TIS at slightly elevated temperature and
extended reaction time as shown by the complete conversion of Cys(Mob)-protected
peptide to the Cys-SH and disulfide forms as shown by the HPLC trace in Figure 2.30C.
We did not test shorter reaction times and it is likely that removal of Mob can be achieved
using much shorter reaction times at 37 ºC.
In the case of the Cys(But)-protected peptide, ~20% of the But-protecting group is
removed when incubated in neat TFA in the absence of TIS (Figure 2.31), which indicates
that Cys(But) is more acid labile than Cys(Mob). The addition of TIS to the reaction results
in only slightly more deprotection of Cys(But), but also results in more disulfide formation
(Figure 2.31C).
Our HPLC analyses of the products of deprotection for Cys(Mob)- and Cys(But)containing peptides is further supported by the MS data shown in Figure 2.32. As shown
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in Figure 2.32B, the amount of Cys(Mob) protected peptide is almost completely
diminished, while the amount of disulfide and deprotected peptide are in abundance, in
agreement with the HPLC trace shown in Figure 2.30C. The MS data shown in Figures
2.32C and 2.32D show that the Cys(But)-containing peptide remains largely intact in the
presence of 2% TIS, with a relatively small amount of peptide in the Cys-SH and disulfide
forms, in agreement with the HPLC trace shown in Figure 2.31C.
As is evident from the deprotection reactions with Cys(Mob) and Cys(Bu t), one
effect of using TIS in the deprotection cocktail is to help catalyze disulfide formation as
originally observed by Singh and coworkers134. While we can only speculate on the
mechanism by which TIS promotes disulfide formation, it most likely involves transient
bonding of silicon to sulfur. A possible mechanism by which TIS helps to deprotect
Cys(Acm) and other Cys-protecting groups is shown in Figure 2.33.
The lability of the Cys protecting groups in TFA/TIS in this study are Cys(Mob) >
Cys(Acm) > Cys(But). We suggest the reason for the higher lability of Cys(Mob) relative
to Cys(Acm) is due to the higher stability of the resulting cation upon cleavage of the S–C
bond of the protecting group. Cleavage of the S–C bond in the case of the Mob protecting
group results in the formation of a 1º benzylic cation that can be stabilized by resonance
from the electron donating methoxyphenyl substituent. Cleavage of the S–C bond in the
case of the Acm protecting group also results in the formation of a 1º carbocation that can
be stabilized by resonance from the adjacent lone pair of electrons on nitrogen, but the Acm
carbocation should be less stable due to the competing resonance of the adjacent amide
group.
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Figure 2.33: Potential mechanism of reduction of Cys(Acm) containing test peptide
to Cys-SH by TIS. See text for explanation.

A potential reason for the unexpected lability of Cys(Acm) compared to other alkyl
protecting groups is the formation of an iminium nitrogen in the transition state as shown
in Figure 2.33. The iminium nitrogen would result from protonation of the sulfur atom in
TFA, weakening the S–C bond. As a result, a partially empty p-orbital on carbon could be
stabilized by donation of the lone pair of electrons on the neighboring nitrogen, resulting
in an electrophilic iminium carbon that can more easily accept a hydride from TIS in
comparison to the 3º carbon of S-But for example.
If stability of the protecting group carbocation was the dominant factor in lability
of the protecting group in a solution of TIS, it should be expected that But would be the
most labile since it results in a 3º carbocation, but this is not observed. A likely explanation
for the stability of S-But towards TIS is that steric hindrance prevents the tertiary carbon of
But from accepting the hydride from TIS in agreement with our proposed mechanism in
Figure 2.33. Thus, lability of the protecting group is a combination of factors including
carbocation stability and lack of steric hindrance. These factors explain the lability of
Cys(Mob) towards TIS.
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The role of TIS as a reductant undoubtedly explains the results of Singh and
coworkers who showed that a TFA:TIS (95:5) cleavage cocktail did in fact result in
moderate conversion of a Cys(Acm)-containing peptide to the Cys-SH form (4%) and 20%
to the disulfide form134. Therefore, the addition of TIS results in 24% removal of the Acm
protecting group under their reported conditions. Our examination of their data shows that
a cocktail of TFA:anisole (95:5) resulted in an even higher percentage of Acm removal
(32%). On this basis in part, Singh and coworkers concluded that TIS gave the best yields
of the fully protected peptide in comparison to phenol, EDT, and anisole134. However their
study lacked an important control since they did not report the extent of removal of the
Acm group when using only neat TFA. Based on our results, we believe they would have
found minimal removal of the Acm group with neat TFA.
The conclusion of Singh and coworkers is the source of subsequent incorrect
statements about the role of TIS in deprotection of Cys(Acm) in TFA. For example,
Houben-Weyl’s “Synthesis of Peptides and Peptidomimetics” cites the results reported by
Singh, stating that:
“The type of scavenger used, e.g. anisole or thioanisole as additive to HF, or thiols
added to TFA, apparently plays an important role; for example, use of TIS as a scavenger
prevents partial cleavage of S-(acetamidomethyl) by TFA.”107
The key word in the quote above is “prevents” (bolded for our emphasis) as TIS
does not prevent cleavage of the carbon-sulfur bond, but rather facilitates it. This
mischaracterization was further propagated in the review of Isidro-Llobet and coworkers
on AA protecting groups who also state that:
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“Nevertheless, it (Acm) is partially removed with HF or even TFA depending on
the scavengers used. In the latter case, absence of water and use of TIS minimizes the
removal.”65
We have again bolded a key phrase from the sentence above since our results
contradict this statement. Our results are supported by the original work by Singh and
coworkers who clearly showed that the presence of TIS in the deprotection cocktail resulted
in the removal of Acm. Other examples of the misunderstanding regarding the abilities of
TIS to act as reducing agents are present in the literature135, 138.
Since its introduction as a scavenger for protecting group cations in 1989, the role
of TIS as a reductant has been overlooked, even though the original report cites the known
role of trialkylsilanes as mild reductants in TFA131. For example, it has been shown that
TIS can reduce the indole ring of tryptophan residues to indoline131. Interestingly, indoles
are commonly reduced via iodine oxidation, using similar techniques to those typically
used to reduce the S-Acm bond139, 140.
Our results present a cautionary tale for those attempting regioselective disulfide
bond forming strategies using orthogonal pairs of Cys-protecting groups when using TIS
as a scavenger. Using “standard” deprotection conditions, Cys(Mob) and Cys(Acm) will
be more stable than reported here, but sequence specific effects as discussed above could
result in a small percentage of deprotection that would result in low yields of the target
disulfide as disulfide scrambling would inevitably occur.
If peptide disulfide bonds are stable to TIS, then our results suggest that TIS itself
could be used in orthogonal deprotection strategies of Cys-protecting groups. In a
hypothetical peptide with two-disulfide bonds, the first disulfide bond could be installed
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using a pair of Cys(Trt) residues. The Trt group could be removed in TFA with mild
scavenger at rt, and then the peptide could be subjected to air oxidation. The second
disulfide bond could then be installed using a pair of Cys(Mob) residues. The peptide could
then be incubated in TFA/TIS or TFA/thioanisole at 37 ºC to remove the Mob groups, and
help catalyze disulfide formation. If disulfide formation was incomplete, appropriate
catalyst could be added to aid in formation of the second disulfide.
In conclusion, we hope our results provide strong evidence that TIS can reduce Sprotecting group bonds under acidic conditions and draws attention to this observation to
researchers in the peptide community.
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2.4 Materials and methods
2.4.1 Materials.
Solvents including DCM, dimethylformamide (DMF), and TFA for peptide synthesis were
purchased from Fisher Scientific (Pittsburgh, PA). Tetrahydrofuran for PySeSePy
synthesis was also purchased from Fisher Scientific (Pittsburgh, PA). Fmoc-Cys(But)-OH
and Fmoc-Cys(Mob)-OH were purchased from NovaBiochem (Burlington, MA). FmocCys(Acm)-OH,

2-Chlorotrityl

chloride

resin

SS

(100-200

[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium

mesh),

and

1-

3-oxid

hexafluorophosphate (HATU) for solid-phase synthesis were purchased from Advanced
ChemTech (Louisville, KY). All other Fmoc-amino acids were purchased from
RSsynthesis (Louisville, KY). Peptide synthesis scavengers: triisopropylsilane (98%),
triethylsilane (99%), thioanisole (99%), and anisole (99%) were purchased from Acros
Organics (Pittsburgh, PA). L-Ascorbic acid sodium salt (99%) for deprotection
experiments, as well as selenium powder (200 mesh), 2-bromopyridyine (99%), and
sodium borohydride for the synthesis of PySeSePy, were purchased from Acros Organics
(Pittsburgh, PA). Guanylin was purchased from CPC Scientific (Sunnyvale, CA). Tris(2carboxyethyl)phosphine hydrochloride (TCEP) was purchased from ThermoFischer
Scientific. All other chemicals were purchased from either Sigma-Aldrich (Milwaukee,
WI) or Fisher Scientific (Pittsburgh, PA). The HPLC system is from Shimadzu with a
Symmetry® C18 -5 mm column from Waters Corp. (Milford, MA) (4.6 x 150 mm). Mass
spectral analysis was performed on an Applied Biosystems QTrap 4000 hybrid triplequadrupole/linear ion trap liquid chromatograph-mass spectrometer (SciEx, Framingham,
MA).
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2.4.2 Peptide Synthesis.
For this chapter, test peptide sequence was chosen based on the C-terminal
sequence of high Mr TrxR. Either Fmoc-Cys(Acm)-OH, Fmoc-Cys(Mob)-OH, or FmocCys(But), were used to synthesize test peptides of sequence H-Pro-Thr-Val-Thr-Gly-GlyCys-Gly-OH (H-PTVTGGCG-OH). Fmoc-Sec(Mob)-OH was synthesized as reported
previously58 and used to construct test peptides of sequece H-Pro-Thr-Val-Thr-Gly-GlySec-Gly-OH (PTVTGGUG). All peptides were synthesized on a 0.05 or 0.1 mmol scale
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. For each
batch, 300 mg or 600 mg (for 0.05 or 0.1 mmol scale, respectively) of 2-chlorotrityl
chloride resin SS (100-200 mesh), was swelled in dichloromethane (DCM) for 30 min. The
first amino acid was directly coupled to the resin using 2% N-methylmorpholine (NMM)
in DCM, shaking for 1 h. The resin was then capped using 8:1:1 DCM:methanol:NMM.
Subsequent amino acids were coupled using 0.2 mmol of Fmoc-protected amino acid, 0.2
mmol of HATU coupling agent, and 2% NMM in dimethylformamide (DMF), shaking for
1 h. To couple Sec, and any AA residue after Sec, slightly different coupling conditions
were used; 0.2 mmol HOAt and 1% DIC were used in place of HATU/NMM. Preactivation
of any amino acid was not performed prior to coupling. These coupling conditions are
essentially the same as those of Barany and co-workers, which were used to minimize
racemization of cysteine141. Between amino acid couplings, the Fmoc protecting group was
removed via two 10 min agitations with 20% piperdine in DMF. Success of Fmoc removal
steps and amino acid couplings were monitored qualitatively using a ninhydrin test

142

.

Removal of the final Fmoc protecting group completed the peptide synthesis. Peptides were
next cleaved from the resin as described below.
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2.4.3 Cleavage of peptides from resin.
Peptides were cleaved from the resin (via 1.5 h reaction at 22 °C) using a cleavage
cocktail consisting of various scavengers in TFA. Our standard cleavage cocktail consists
of TFA:TIS:H2O (96:2:2). Simultaneous cleavage of peptide from the resin and
deprotection of Cys or Sec protecting groups, was achieved via a 2 hr reaction using a
cleavage cocktail consisting of 2-excess 2,2′-dithiobis-5-nitropyridine (DTNP) dissolved
in TFA:TIS:H2O:thioanisole (94:2:2:2). This reaction mixture removes the Mob, Acm, and
But protecting group from Cys, replacing it with 5-Npys90, 110. Note: this reaction does not
go to completion for all protecting group/peptide sequence combinations. This is a topic of
study in this chapter. The same DTNP reaction can be used for the concomitant cleavage
and deprotection of the Sec-containing peptide, but without the addition of thioanisole89, 90,
110

. Following cleavage and side chain deprotection, the resin was washed with minimal

amounts of TFA and DCM and the volume of the cleavage solution was reduced by
evaporation with nitrogen gas. The peptide solution was then transferred by pipette into
cold, anhydrous diethyl ether, where the peptides were observed to precipitate.
Centrifugation at 3000 rpm on a clinical centrifuge (International Equipment Co., Boston,
MA) for 10 min pelleted the peptide. Peptides were dried, then dissolved in a minimal
amount of water with 20% acetonitrile, lyophilized, and used without further purification.

2.4.4 Deprotection of Cys(5-Npys) and Sec(5-Npys) by ascorbate.
Lyophilized Cys(5-Npys) and Sec(5-Npys) peptides were then dissolved in
distilled/deionized water and divided into eight aliquots of 0.5 mL before treatment with
ascorbate. Two ascorbate-containing buffers were prepared either at pH 4.5 and pH 7.0.
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Buffer A consisted of 40 mM ascorbate dissolved in 500 mM potassium phosphate buffer,
pH = 7.0 ± 0.1, and buffer B consisted of 40 mM ascorbate dissolved in 500 mM
ammonium acetate buffer pH = 4.5 ± 0.1. Deprotection of the Cys-containing peptide was
initiated by adding 0.5 mL of either buffer A or buffer B to the sample so that the total
reaction volume was 1.0 mL, and the final concentration of ascorbate was 20 mM. At this
concentration of ascorbate, the ratio of ascorbate to peptide was 100:1. Deprotection of the
Sec-containing peptide was initiated by adding 0.1 mL of either buffer A or buffer B to 0.5
mL of the sample and then the reaction volume was adjusted to 1.0 mL by addition of either
0.4 mL of 500 mM potassium phosphate buffer (pH 7.0), or 500 mM ammonium acetate
buffer (pH 4.5). At this concentration of ascorbate, the ratio of ascorbate to peptide was
5:1. The reactions were then allowed to proceed at either rt or 37 °C for either 4 hours or
24 hours according to Table 2.1.

2.4.5. Synthesis of 2,2´-dipyridyl diselenide.
PySeSePy was synthesized following previously reported methods.39 Water (20
mL), in a round bottom flask containing 0.596 g (15.75 mmol) of sodium borohydride, was
cooled on ice to 0 °C. To this, 92 mg (7.5 mmol) of elemental selenium was added with
vigorous stirring. The reaction was warmed to rt and stirred for ~10 min. Another 92 mg
(7.5 mmol) of elemental selenium was then added, the reaction warmed to 40 °C, and
stirred until all selenium had dissolved (~35 min). A brown/red solution of disodium
diselenide resulted, which was sealed with a rubber septum and purged under nitrogen gas.
To the aqueous solution of disodium diselenide, 1.43 mL (15 mmol) of 2-bromopyridine
in 40 mL of anhydrous THF was added under a flow of nitrogen gas, and refluxed for ~36
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h. After reflux, a clear, dark yellow/green solution resulted. This solution was diluted with
~400 mL brine, extracted 8X with ethyl acetate, dried with magnesium sulfate, then
concentrated via rotary evaporation to a thick orange oil. The resulting oil was column
purified using 35 g silica and 80:20 hexane:ethyl acetate as the solvent. Yellow product
was collected, concentrated, then dried, resulting in 952 mg of an orange solid (~49%
yield). The correct product was verified via 1H- and 77Se- NMR and mass spectrometry.

2.4.6 Deprotection of Cys(Acm) and Cys(Mob) by PySeSePy.
Lyophilized test peptide H-PTVTGGCG-OH, with either S-Acm or S-Mob
protection on the Cys residue, was dissolved in cleavage cocktail consisting of either neat
TFA, or TFA with addition of 2% TIS and/or 2% water, and the solution was divided into
two aliquots. To one aliquot, 5-fold excess PySeSePy was added. Both aliquots were
incubated either at rt, or in a 37 ºC water bath for either 4 or 12 h. For all reactions, the
final reaction volume was 1.0 – 1.5 mL and contained 1.7 – 2.5 mM peptide. After
incubation, peptides were precipitated with cold diethyl either, pelleted via centrifugation
(as described above), and dried using nitrogen gas. For purification; dried pellets were redissolved in minimal amounts of neat TFA, precipitated with cold ether, pelleted via
centrifugation, and dried using nitrogen gas. Dried peptide pellets were then dissolved in
water:acetonitrile (80:20), lyophilized, and analyzed without further purification.
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2.4.7 Reduction of Cys(PySe) by ascorbate.
Lyophilized H-PTVTGGC(PySe)G-OH peptide (3 mg, 0.0035 mmol) was
dissolved in 100 mM ammonium acetate buffer pH = 4.5, and divided into two aliquots.
To one aliquot, 5-fold excess (0.0177 mmol) L–ascorbic acid sodium salt was added, while
buffer missing ascorbate was added to the control aliquot. Both aliquots were covered in
foil, incubated for 4 h at 22 °C, then flash frozen and lyophilized. For purification; dried
pellets were re-dissolved in minimal amounts of neat TFA, precipitated with cold ether,
pelleted via centrifugation, and dried (all as described previously). Dried peptide pellets
were then dissolved in water:acetonitrile (80:20), lyophilized, and analyzed without further
purification.

2.4.8 Synthesis of guanylin.
Guanylin peptide of sequence H-Pro-Gly-Thr-Cys(Trt)-Glu-Ile-Cys(Acm)-AlaTyr-Ala-Ala-Cys(Trt)-Thr-Gly-Cys(Acm)-OH was synthesized on a 0.1mmol scale using
standard solid phase peptide synthesis, as described above. The peptide was cleaved from
the resin via a 1.5 h reaction with a cleavage cocktail consisting of 96:2:2 TFA:TIS:water.
Following cleavage, the resin was washed with TFA and DCM and the volume of the
cleavage solution was reduced by evaporation with nitrogen gas. The peptide solution was
then transferred by pipette into cold, anhydrous diethyl ether, where the peptides were
observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge for 10 min
pelleted the peptide. Guanylin peptide was dried, then dissolved in a minimal amount of
water:acetonitrile (80:20), lyophilized, and used without further purification. The first
disulfide bond between Cys4 & Cys12 was formed by dissolving 24 mg (0.015 mmol) of
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lyophilized peptide in 50 mL of 0.1 M ammonium bicarbonate buffer pH = 8.2, and stirred
vigorously in a large round bottom flask for 40 h. Complete formation of the first disulfide
bond was monitored qualitatively using Ellman’s regent. The reaction was frozen and
lyophilized to remove water. The second disulfide bond (between Cys7 & Cys15) was
formed by dissolving 5.6 mg (0.0035 mmol) lyophilized peptide in neat TFA, then divided
into two aliquots. To one aliquot, 2.75 mg (0.00873 mmol) of PySeSePy, 20 L of TIS,
and 20 L of water was added, then the reaction was filled to 1 mL with TFA. The second
aliquot (control) was filled to 1 mL with neat TFA, then both aliquots were incubated for
4 h at 37 °C. After incubation, excess TFA was blown off using nitrogen gas, and peptides
were precipitated with cold diethyl ether, pelleted via centrifugation, and dried (all as
described previously). Dried peptide pellets were then dissolved in water:acetonitrile
(80:20), lyophilized, and analyzed without further purification.

2.4.9 Solid phase peptide synthesis of tachyplesin-1
Either Fmoc-Cys(Acm)-OH or Fmoc-Cys(Trt)-OH were used to synthesize
tachyplesin-1 of sequence: H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-TyrArg-Arg-Cys-Arg-CONH2 (H-KWCFRVCYRGICYRRCR-CONH2), on a 0.2 mmol scale
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. To begin,
0.136 g of Rink Amide AM resin (200-400 mesh, Novabiochem®), was swelled in 1:1
dimethylformamide (DMF):dichloromethane (DCM) for 1 h. Fmoc was removed from the
resin via two, 10 min agitations using 20% piperidine in DMF (10 mL total). Success of
Fmoc removal steps (from resin and amino acids) and subsequent amino acid couplings
were monitored qualitatively using a ninhydrin test142. The first amino acid was directly
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coupled to the resin using 0.8 mmol Fmoc-Arg(Pbf)-OH, 0.8 mmol HATU, and 1.6 mmol
N,N-diisopropylethylamine (DIPEA) in ~5mL DMF, shaking for 2 h at 22 °C. Subsequent
amino acids were coupled using 0.8 mmol of Fmoc-protected amino acid, 0.8 mmol of
HATU coupling agent, and 1.6 mmol, shaking for 2 h. Between amino acid couplings, the
Fmoc protecting group was removed via two, 10 min agitations with 20% piperdine in
DMF. Removal of the final Fmoc protecting group completed the peptide synthesis.
Tachyplesin was cleaved from the resin via 2 h reaction with a cleavage cocktail consisting
of 96:2:2 TFA:TIS:water at 22 °C. Following cleavage, the resin was washed with TFA
and DCM and the volume of the cleavage solution was reduced by evaporation with
nitrogen gas. The peptide solution was then transferred by pipette into cold, anhydrous
diethyl ether, where the peptide was observed to precipitate. Centrifugation at 3000 rpm
on a clinical centrifuge (International Equipment Co., Boston, MA) for 10 min pelleted the
peptide. The pellet was dried, then dissolved in a minimal amount of 80:20 water:
acetonitrile (ACN), frozen and lyophilized to powder form.
2.4.10 Tachyplesin stepwise disulfide bond formation
The first disulfide bond between Cys7 & Cys12 was formed by dissolving 62 mg
(0.026 mmol) of lyophilized peptide in 150 mL of 0.1 M ammonium bicarbonate buffer
pH = 8.12, and stirred vigorously in a large round bottom flask for 50 h. Complete
formation of the first disulfide bond was monitored qualitatively using Ellman’s regent.
The reaction was frozen and lyophilized to remove water and volatile buffer salts. The
second disulfide bond (between Cys3 & Cys16) was formed by dissolving 48 mg (0.020
mmol) lyophilized peptide in neat TFA. To this, 32 mg (0.10 mmol) of PySeSePy was
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added. The reaction was incubated for 8 h at 37 °C. After incubation, excess TFA was
blown off using nitrogen gas, and peptides were precipitated with cold diethyl ether,
pelleted via centrifugation, and dried. Dried peptide pellets were then dissolved in
water:acetonitrile (80:20), lyophilized, then purified via preparative, reverse-phase high
pressure liquid chromatography (HPLC). HPLC purification was completed using a
Shimadzu instrument with a Symmetry® C18 5 µm column. Aqueous and organic phases
were 0.1% TFA in distilled, deionized water (buffer A) and 0.1% TFA in HPLC‐grade
acetonitrile (buffer B), respectively. Beginning with 100% buffer A, buffer B was increased
by 1% up to 50% over 50 min by gradient elution. Buffer B was then increased by 10% up
to 100% over 5 min. Peptide elution was monitored via absorbance at both 214 and 254 nm,
and fractions were collected of major peaks.
2.4.11 Testing ability of ascorbate to reduce peptide disulfide bonds.
Guanylin, synthesized as described previously, (lyophilized powder, (1.6 mol)
was dissolved in 2 mL of 100 mM ammonium acetate buffer, pH 4.5. The sample was split
into two aliquots, and five-fold excess ascorbate was added to one of the samples. To the
other (control), no ascorbate was added. In addition, the guanylin standard (0.5 mol, from
CPC scientific) was dissolved in 1 mL of 100 mM ammonium acetate buffer, pH 4.5, and
five-fold excess ascorbate was added. All samples were incubated at rt for 4 h, then flash
frozen and lyophilized.
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2.4.12 Reduction of Cys(Acm), Cys(Mob), and Cys(But) by triisopropylsilane.
Lyophilized test peptide H-PTVTGGCG-OH with either S-Acm, S-But, or S-Mob
protection on the Cys residue were dissolved in neat TFA and the solution was divided into
two aliquots. To one aliquot, 2% TIS was added. Both aliquots were incubated in a 37 ºC
water bath for 12 h. To test TIS reduction under standard cleavage conditions, S-Acm
protected peptide was dissolved in neat TFA, divided into two aliquots, 2% TIS was added
to one aliquot, and both aliquots were incubated at rt for 2 h. For all reactions, the final
reaction volume was 1.0 – 1.5 mL and contained 1.7 – 2.5 mM peptide. After incubation,
peptides were precipitated with cold diethyl either, pelleted via centrifugation (as described
above), and dried using nitrogen gas. For purification; dried pellets were re-dissolved in
minimal amounts of neat TFA, precipitated with cold ether, pelleted via centrifugation, and
dried (all as described previously). Dried peptide pellets were then dissolved in water,
lyophilized, and analyzed without further purification.

2.4.13 Reduction of Cys(Acm) with water, phenol, anisole, thioanisole, and
triethylsilane.
Test peptide H-PTVTGGC(Acm)G-OH was dissolved in neat TFA and the solution
divided into two aliquots. To one aliquot, 2% scavenger (either water, phenol, anisole,
thioanisole or triethylsilane) was added. Both aliquots were incubated in a 37 °C water bath
for 12 h. For all reactions, the final reaction volume was 1.0 mL with 2.0 mM peptide.
After incubation, peptides were precipitated with cold diethyl ether, pelleted via
centrifugation (as described above), and dried using nitrogen gas. For purification, dried
pellets were re-dissolved in minimal amounts of neat TFA, precipitated with cold ether,
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pelleted via centrifugation, and dried (as described previously). Peptide pellets were then
dissolved in a minimal amount of water, lyophilized, and analyzed without further
purification.

2.4.14 Reduction of peptide disulfide by TCEP.
Cys(Acm) protected test peptide (3.45 mol) that was previously incubated with
TFA:TIS (98:2) for 12 h at 37 °C was precipitated and lyophilized as described above. The
peptide was next re-dissolved in 4:1 water: acetonitrile. To this solution, 4.95 mg (17.3
mol) of TCEP was added and allowed to react for 12 h at rt. HPLC analysis was then
performed without further purification.

2.4.15 High Pressure Liquid Chromatography.
HPLC analysis of all samples was completed using a Shimadzu with a Symmetry®
C18 5 µm column from Waters (4.6 × 150 mm). Aqueous and organic phases were 0.1%
TFA in distilled, deionized water (buffer A) and 0.1% TFA in HPLC‐grade acetonitrile
(buffer B), respectively. Beginning with 100% buffer A, buffer B was increased by 1% up
to 50% over 50 min with a 1.4 mL/min gradient elution. Buffer B was then increased by
10% up to 100% over 5 min. This method was used for analysis of each sample. Peptide
elution was monitored via absorbance at both 214 and 254 nm.

2.4.16 Mass spectrometry
Peptides were using an Applied Biosystems QTrap 4000 hybrid triplequadrupole/linear ion trap liquid chromatograph-mass spectrometer operating in positive
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ESI mode. Aliquots of peptide were injected into the sample loop with a guard column at
10 μL/min into a 100 μL/min mobile phase flow consisting of 50/50 water/acetonitrile with
0.1% formic acid. Mass spectra were collected in linear ion trap mode, scanning from m/z
200–2000.
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2.5 Conclusions and future work
Herein, we have developed a gentle and highly effective method for conversion of
Sec(5-Npys) to Sec-she using Asc, and this deprotection has multiple applications as
described above. This chemistry also works for deprotection of Cys(5-Npys), but higher
concentrations of ascorbate and longer reaction times are required. Based on this, we
concluded that the reduction of a S-Se is chemoselective; that is, ascorbate will not reduce
a S-S bond. These concepts are illustrated in Figure 2.34.

Figure 2.34: Summary of ascorbolysis S-X bond reduction at pH 4.5 and 22 °C.
Notably, the reduction of an S-S bond is slow, while the reduction of an S-Se bond is
fast by ascorbate, regardless of the position of the S or Se atom in the bond to be reduced.
To better adapt ascorbolysis of a S-Se bond for Cys deprotection, we developed the
use of PySeSePy as a new deprotection reagent for Cys(Acm) and Cys(Mob) residues after
SPPS. We found that incubation of these protected Cys residues with PySeSePy in TFA
with scavengers for various lengths of time at 37 °C resulted in a stable Cys(PySe) adduct.
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This Cys(PySe) adduct was noticeably stable in TFA with TIS, while the Cys(5-Npys) that
results from using DTNP is not. In addition, the Cys(PySe) adduct can be chemoselectively
reduced by Asc in buffer, as Asc is very slow to reduce unactivated disulfide bonds at pH
4.5. In addition, we show the utility of this new deprotection reagent for the regioselective
formation of disulfide bonds in the synthesis of the human intestinal hormone guanylin,
and anti-microbial peptide tachyplesin-1.
During the course of this investigation, we also found that in the case of Cys(Acm),
TIS scavenger is essential for deprotection using PySeSePy. This is due to the ability of
TIS to reduce the S–C bond between Cys and the Acm protecting group. This reduction by
TIS had previously been mischaracterized in the literature.
Our new deprotection chemistry, especially the chemoselective reduction of S-Se
by Asc, has numerous potential applications that should be explored in the future. First,
our ascorbate chemistry is still limited to aqueous conditions, so ascorbate ester derivatives
should be explored for utilization of this chemistry in organic/lipid environments. An
example includes commercially available, 6-O-palmitoyl-L-ascorbic acid, which is a lipid
soluble ester of ascorbic acid. The use of lipid or organic soluble ascorbate would allow
for generation of a free-selenol in situ, which can be used for nucleophilic alkylation
reactions in organic synthesis. This could be highly effective for installing selenium into
molecules, a task that is otherwise challenging143.
Another application of this chemistry may be in the use of N-terminal Cys(PySe)
or Sec(5-Npys) residues in peptide fragments that also contain a C-terminal thioester where
three or more peptides segments are to be ligated together in native chemical ligation
(NCL) reactions144, 145. NCL is a method of joining together two or more peptides via
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reaction between an N-terminal Cys residue of one peptide and a C-terminal thioester of
another peptide to yield a product with a native amide bond at the ligation site146, 147. The
use of PySe protected Cys for this application is depicted in Figure 2.35. Protection of the
N-terminal Cys is needed in such cases to avoid cyclization and polymerization of the
peptide containing both a N-terminal Cys residue and a C-terminal thioester148, 149. Cys
protecting groups currently used for this application are methylsulfonylethyloxy-carbonyl
amine (Msc), acetamidomethyl (Acm), and the thiazolidine protecting group (Thz)148, 150,
151

. Both Acm and Msc require harsh conditions for their removal146, 150, 152, 153. While the

Thz group has found wide use for this application151, 154, removal of the Thz group requires
a large excess of methoxylamine, which can result in hydrolysis/solvolysis of the
thioester147, 155, 156. The use of ascorbate to deprotect Sec(5-Npys) or Cys(PySe) would be
extremely mild and should not require further purification due to the absence of exogenous
thiol to affect deprotection.

Figure 2.35: NCL of three peptide segments utilizing a C-terminal thioester and a
N-terminal Cys(PySe) protected residue. Ascorbate can be used to gently liberate the
nucleophilic N-terminal Cys to facilitate amide bond formation.

Another application could be the generation of C-terminal thioesters from Cterminal Cys or Sec residues. In NCL, the most difficult step is typically the generation of
a C-terminal thioester. Because resin-bound thioesters are unstable to repeated piperidine
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exposure, these derivatives are largely incompatible with standard (Fmoc)-based SPPS
approaches157,

158

. Many strategies have been used to address these problems such as

development of a thioester-compatible Fmoc cleavage cocktails, and use of “safety-catch”
linker resins158, 159. Another widely used method of thioester generation that avoids the
need for “safety-catch” linker resins is via an N → S acyl shift157, 160-162. In an N → S acyl
shift, the nucleophilic sulfur atom attacks the peptide backbone initiating an acyl shift that
results in a thioester. However, while nature has evolved ways to catalyze this step, in a
regular peptide sequence such migration is not favorable163. Macmillan and coworkers
proposed using Sec instead of Cys to facilitate this acyl shift due to higher acidity, lower
redox potential and consequentially increased nucleophilicity of selenium to sulfur157.
However, when Macmillan and coworkers attempted such an approach, they
reported that generation of the free selenol was difficult157. A cyclic peptide was
synthesized from a linear precursor by generating a C-terminal thioester that originated
from a C-terminal Sec(5-Npys) residue. The reported reaction conditions used for the
synthesis of this cyclic peptide were 10% w/v MESNA, in 0.1 M sodium phosphate buffer
pH 5.8, with 5% w/v sodium ascorbate and 0.5% w/v TCEP157. Macmillan reported that
the use of ascorbate helped to prevent deselenization of the peptide, which has also been
reported by others164, 165. We hypothesize that TCEP could be eliminated from this reaction
because ascorbate will directly reduce the Sec(5-Npys) group to the desired selenol, thus
initiating the formation of the desired selenoester. Though we have not tested this
hypothesis experimentally, it seems to be an attractive route for generating stable thioesters
for use in NCL reactions.
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2.6 Figures and tables
Table 2.1: Summary of deprotection conditions for Cys- and Sec-peptides.
Reaction
number

pH

Temp
(°C)

Time
(hrs)

Asc:Peptide
ratio

% Deprotected

Se1
Se2
Se3
Se4
Se5
Se6
Se7
Se8
S1
S2
S3
S4
S5
S6
S7
S8

4.5
4.5
4.5
4.5
7
7
7
7
4.5
4.5
4.5
4.5
7
7
7
7

22
22
37
37
22
22
37
37
22
22
37
37
22
22
37
37

4
24
4
24
4
24
4
24
4
24
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Figure 2.3: Observed color change when a Sec(5-Npys) containing peptide is treated
with ascorbate in pH 4.5 buffer at 22 °C. The clear solution on the left is the no ascorbate
control, and the right is the ascorbate treated peptide. A yellow color appears almost
immediately after the reaction is initiated.
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Figure 2.4: HPLC chromatograms and mass spectrometry of the Sec-containing
test peptide treated with ascorbate under various conditions for 24 hrs with a 5:1
ascorbate: peptide ratio. (A) HPLC chromatogram of the Sec-containing peptide
without ascorbate treatment (control). (B) HPLC chromatogram of the Sec-containing
peptide treated with ascorbate at 22 °C and pH = 4.5. (C) Mass spectrum of the Seccontaining peptide without ascorbate treatment (control). (D) Mass spectrum of the Seccontaining peptide treated with ascorbate at 22 °C and pH = 4.5.
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Figure 2.5: HPLC and mass spectroscopic analysis of the Cys-containing test
peptide treated with 100-fold excess ascorbate. (A) HPLC chromatogram of the
Cys(5-Npys)-containing peptide treated with ascorbate at 37 °C, pH = 7 for 24 hrs. (B)
Mass spectrum of the Cys-containing peptide treated with ascorbate at 37 °C and pH =
7.0 for 24 hrs.
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Figure 2.9: Mass spectrum of PySeSePy. The double-Se isotope pattern is present
using this high-resolution analysis. The arrow points to the observed m/z whereas the
number inside the parentheses denotes the theoretical m/z value.
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Figure 2.10: NMR spectra of PySeSePy. (A) 77Se-NMR of pyridyl diselenide
compound. The diselenide gives a single peak at 450 ppm in deuterated chloroform. (B)
1
H-NMR of pyridyl diselenide compound in deuterated chloroform. Both spectra were
taken with a Bruker 500 mHz NMR spectrometer.
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Figure 2.11 (A, B, C): Deprotection of the
Cys(Mob)-containing
peptide
using
PySeSePy and Asc determined by HPLC
and MS analyses. A) HPLC chromatogram
of the Cys(Mob)-containing peptide
incubated in neat TFA for 4 h at 37 °C
(control). B) HPLC chromatogram of the
Cys(Mob)-containing peptide incubated in
TFA:water (98:2) with 5-fold excess
PySeSePy for 4 h at 37 °C. Quantitative
conversion to the PySe-adduct is apparent.
C) HPLC chromatogram of the peptide
containing the Cys(PySe) adduct treated
with 5-fold excess ascorbate in 100 mM
ammonium acetate pH 4.5, for 4 h at rt.
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Figure 2.11 (D, E, F): Deprotection of the
Cys(Mob)-containing
peptide
using
PySeSePy and Asc determined by HPLC
and MS analyses. Panels D, E, and F are the
mass spectra that correspond with panels A,
B, and C, respectively. The arrow points to
the observed m/z whereas the number inside
the parentheses denotes the theoretical m/z
value.
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Figure 2.12: Deprotection of the Cys(Acm)-containing peptide using PySeSePy and
Asc determined by HPLC analysis. A) HPLC chromatogram of the Cys(Acm)containing peptide incubated in neat TFA with 5-fold excess PySeSePy for 12 h at 37
°C. B) HPLC chromatogram of the Cys(Acm)-containing peptide incubated in TFA:TIS
(98:2) with 5-fold excess PySeSePy for 12 h at 37 °C. C) HPLC chromatogram of the
Cys(Acm)-containing peptide incubated in neat TFA for 12 h at 37 °C (control). D)
HPLC chromatogram of the peptide containing the Cys(PySe) adduct treated with 5-fold
excess ascorbate in 100 mM ammonium acetate pH 4.5, for 4 h at rt. The MS analysis
that corresponds to each panel of Figure 2.12 is given as Figure 2.13.
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Figure 2.13. Deprotection of the Cys(Acm)-containing peptide using PySeSePy and
Asc determined by mass spectrometry. A) Mass spectrum of the Cys(Acm)-containing
peptide incubated in neat TFA with 5-fold excess PySeSePy for 12 h at 37 °C. B) Mass
spectrum of the Cys(Acm)-containing peptide incubated in TFA:TIS (98:2) with 5-fold
excess PySeSePy for 12 h at 37 °C. C) Mass spectrum of the Cys(Acm)-containing
peptide incubated in neat TFA for 12 h at 37 °C (control). D) Mass spectrum of the
peptide containing the Cys(PySe) adduct treated with 5-fold excess ascorbate in 100 mM
ammonium acetate pH 4.5, for 4 h at rt.
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Figure 2.14: Deprotection of the
Cys(Acm)-containing peptide using
DTNP in the presence or absence of TIS
determined by HPLC analysis. A) HPLC
chromatogram
of
the
Cys(Acm)containing peptide incubated in neat TFA
for 12 h at 37 °C (control). B) HPLC
chromatogram
of
the
Cys(Acm)containing
peptide
incubated
in
TFA:thioanisole (98:2) with 5-fold excess
DTNP for 12 h at 37 °C. C) HPLC
chromatogram
of
the
Cys(Acm)containing
peptide
incubated
in
TFA:thioanisole:TIS (96:2:2) with 5-fold
excess DTNP for 12 h at 37 °C. The MS
analysis that corresponds to panels 2.14A
and 2.14B are given as Figure 2.15.
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Figure 2.15. Deprotection of the Cys(Acm)-containing peptide using DTNP in the
absence of TIS determined by mass spectrometry. A) Mass spectrum of the
Cys(Acm)-containing peptide incubated in neat TFA for 12 h at 37 °C. B) Mass spectrum
of the Cys(Acm)- peptide incubated in TFA:thioanisole (98:2) with 5-fold excess DTNP
for 12 h at 37 °C.
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Figure 2.16: Deprotection of the Cys(Mob)-containing peptide using PySeSePy
determined by HPLC analysis. HPLC chromatogram of the Cys(Mob)-containing
peptide incubated in TFA:TIS:water (96:2:2) with 5-fold excess PySeSePy for 4 h at rt.
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Figure 2.17: Deprotection of the Cys(Mob)-containing peptide using DTNP
determined by HPLC and MS analysis. A) HPLC chromatogram of the Cys(Mob)containing peptide incubated in TFA:TIS:H2O (96:2:2) with 5-fold excess DTNP for 4
h at 22°C. B) Mass spectrum corresponding to the HPLC trace in part A.
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Figure 2.18: HPLC chromatograms of guanylin peptide at various stages of
synthesis. A) Crude guanylin peptide after cleavage from the resin with concomitant
removal of S-Trt protecting groups. Cys4 and Cys12 are in the free thiol form, while
Cys7 and Cys15 remain S-Acm protected. B) HPLC trace of the guanylin intermediate
after the formation of the first disulfide bond between Cys4 and Cys12 using air
oxidation. C) HPLC trace of the mature guanylin peptide after the formation of the
second disulfide bond between Cys7 and Cys15 using 1 eq. of PySeSePy, incubated for
8 h at 37 °C. D) HPLC trace of the guanylin standard purchased from CPC Scientific.
MS analysis that corresponds to Figure 2.18 can be found as Figure 2.19.
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Figure 2.19: Mass spectra of guanylin
peptide at various stages of synthesis. A)
Crude guanylin peptide after cleavage from
the resin with concomitant removal of STrt protecting groups. Cys4 and Cys12 are
in the free thiol form, while Cys7 and
Cys15 remain S-Acm protected. B) The
guanylin intermediate after the formation
of the first disulfide bond between Cys4
and Cys12 using air oxidation. C) The
mature guanylin peptide after the
formation of the second disulfide bond
between Cys7 and Cys15 using 1 eq. of
PySeSePy, incubated for 8 h at 37 °C.
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Figure 2.21: Mass spectrum of tachyplesin-1 after cleavage from the resin. Cys7 &
Cys12 are in Cys-thiol form, while Cys3 & Cys16 are S-Acm protected. Due to the high
Arg and Lys content of this peptide, which pick up positive charges readily, the peptide
is detected as a mixture of multiply charged species. Species “A” is the m/z+6 product
(theoretical m/z+6 = 402.76); species “B” is the m/z+5 product (theoretical m/z+5 =
482.63); species “C” is the m/z+4 product (theoretical m/z+4 = 603.04); species “C +Na”
is the sodium adduct of the m/z+4 product (theoretical m/z+4 + Na+ = 626.60); and species
“D” is the m/z+3 product (theoretical m/z+3 = 803.92). The major peaks are labeled in the
spectrum with the observed m/z value.
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Figure 2.22: Mass spectrum of tachyplesin-1 with first disulfide bond formed.
Tachyplesin after formation of first disulfide bond between Cys7 & Cys12 by air
oxidation. Cys3 & Cys16 remain S-Acm protected. Species “C” is the m/z+4 product
(theoretical m/z+4 = 602.54); and species “D” is the m/z+3 product (theoretical m/z+3 =
803.06). The major peaks are labeled in the spectrum with the observed m/z value.
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Figure 2.23: Mass spectrum of tachyplesin-1 with both disulfide bonds formed.
Tachyplesin after formation of second disulfide bond between Cys3 & Cys16 using
PySeSePy, and after HPLC purification using a gradient of water/acetonitrile (ACN).
Species “C” is the m/z+4 product (theoretical m/z+4 = 566.50); species “C +Na+” is the
sodium adduct of the m/z+4 product (theoretical m/z+4 + Na+ = 588.5); species “C +H2O”
is the monohydrate of the m/z+4 product (theoretical m/z+4 + H2O = 584.50); species “C
+K+” is the potassium adduct of the m/z+4 product (theoretical m/z+4 + K+ = 505.60);
species “C +ACN” is the acetonitrile/NH3+ adduct of the m/z+4 product (theoretical m/z+4
+ ACN/NH3+ = 622.6); species “D” is the m/z+3 product (theoretical m/z+3 = 755.00);
species “D +Na+” is the sodium adduct of the m/z+3 product (theoretical m/z+3 + Na+ =
778.00); and species “D +ACN” is the acetonitrile/NH3+ adduct of the m/z+3 product
(theoretical m/z+3 + ACN/NH3+ = 811.10). Note: the ACN adduct is prevalent in our
final product due to the HPLC purification step where ACN is the solvent. The major
peaks are labeled in the spectrum with the observed m/z value.
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Figure 2.24. Mass spectra of guanylin
with and without Asc treatment at pH
4.5 for 4 h at rt. A) Mass spectrum of the
synthesized guanylin peptide incubated in
100 mM ammonium acetate at pH 4.5
without Asc (control). B) Mass spectrum of
the synthesized guanylin peptide incubated
in 100 mM ammonium acetate at pH 4.5
with 5-fold excess Asc. C) Mass spectrum
of the commercially available guanylin
peptide incubated in 100 mM ammonium
acetate at pH 4.5 with 5-fold excess Asc.
As is evident, there is no change in mass
upon reduction with Asc under these
conditions. For all samples, the arrow
points to the observed m/z whereas the
number inside the parentheses denotes the
theoretical m/z value.
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Figure 2.25 (A, B, C): Extent of
deprotection of Cys(Acm) by TIS at 37
ºC as measured by HPLC. (A) No
reduction of the S-Acm bond in the
Cys(Acm) test peptide was observed by
HPLC after incubation in neat TFA for 12
h at 37 ºC. (B) In contrast, incubation of
the test peptide with TFA:TIS (98:2) for 12
h at 37 ºC resulted in conversion of S-Acm
to S-H (35%) and peptide disulfide (35%)
as evidenced by the HPLC trace. (C)
Addition of 5-fold excess TCEP to the
reaction in (B) for 12 h resulted in nearly
complete reduction of the disulfide to the
reduced form.
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Figure 2.25 (D, E, F): Extent of
deprotection of Cys(Acm) by TIS at 37
ºC as measured by HPLC. Traces D, E,
and F are zoomed in views of traces A, B,
and C, respectively.
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Figure 2.26: Mass chromatograms of the Cys(Acm) protected peptide under
various conditions. The arrow points to the observed m/z whereas the number inside
the parentheses denotes the theoretical m/z value. (A) Mass chromatogram of the Acmtest peptide after 12 h incubation in neat TFA at 37 ºC. The MS data show that nearly all
of the peptide exists in the Cys(Acm) form, in agreement with HPLC analysis. (B) Mass
chromatogram of the Acm-test peptide after 12 h incubation in TFA:TIS (98:2) at 37 ºC.
The MS data show that inclusion of 2% TIS in the reaction mixture drives deprotection
to the Cys-SH (m/z = 691.4) and disulfide (m/z = 690.46) forms in support of our HPLC
analysis. Please note that the value m/z = 690.46 for the peptide disulfide correspond to
the doubly charged ion (z = 2).
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Figure 2.27: Extent of deprotection of
Cys(Acm) by TIS under standard
deprotection conditions as measured by
HPLC. (A) HPLC chromatogram of the
Acm-test peptide after cleavage from the
solid support using a cleavage cocktail
containing TFA:TIS:H2O (96:2:2) for 2 h
at rt. (B) HPLC chromatogram of the Acmtest peptide after further incubation of the
isolated peptide in neat TFA for 2 h at rt.
(C) HPLC chromatogram of the Acm-test
peptide after further incubation of the
isolated peptide in TFA:TIS (98:2) for 2 h
at rt. Little or no deprotection is observed
as evidence by the absence of change in the
HPLC chromatogram.
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Figure 2.28: Extent of deprotection of
Cys(Acm) by commonly used SPPS
scavengers at 37 ºC in TFA as measured
by HPLC. (A) 2% H2O. (B) 2% anisole.
(C) 2% phenol. (D) 2% thioanisole. (E) 2%
TES.
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Figure 2.29: Mass chromatograms of the Cys(Acm) protected test peptide using
various scavengers in TFA at 37 ºC. The arrow points to the observed m/z whereas the
number inside the parentheses denotes the theoretical m/z value. (A) 2% H2O. (B) 2%
anisole. (C) 2% phenol. (D) 2% thioanisole.
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Figure 2.30: Extent of deprotection of
Cys(Mob) by TIS at 37 ºC as measured
by HPLC. (A) HPLC chromatogram of the
Cys(Mob) test peptide after cleavage from
the solid support using a cleavage cocktail
containing TFA:TIS:H2O (96:2:2) for 2 h
at rt. (B) HPLC chromatogram of the
Cys(Mob) test peptide after incubation in
neat TFA for 12 h at 37 ºC. (C) HPLC
chromatogram of the Cys(Mob) test
peptide after incubation in TFA:TIS (98:2)
for 12 h at 37 ºC.
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Figure 2.31: Extent of deprotection of
Cys(But) by TIS at 37 ºC as measured by
HPLC. (A) HPLC chromatogram of the
Cys(But) test peptide after cleavage from
the solid support using a cleavage cocktail
containing TFA:TIS:H2O (96:2:2) for 2 h
at rt. (B) HPLC chromatogram of the
Cys(But) test peptide incubation in neat
TFA for 12 h at 37 ºC. (C) HPLC
chromatogram of the Cys(But) test peptide
after incubation in TFA:TIS (98:2) for 12 h
at 37 ºC.

105

A

B

C

D

Figure 2.32: Mass chromatograms of the Cys(Mob)- and Cys(But) protected test
peptides under various conditions. The arrow points to the observed m/z whereas the
number inside the parentheses denotes the theoretical m/z value. (A) Mass spectrum of
the Cys(Mob) test peptide incubated in TFA for 12 h at 37 ºC. The peak at m/z = 827
corresponds to the oxidized Cys(Mob) peptide and the peak at m/z 793 corresponds to a
dehydrated form of the Cys(Mob) peptide, (B) Mass spectrum of the Cys(Mob) test
peptide after incubation in TFA:TIS (98:2) for 12 h at 37 ºC. The inset shows a close up
of the region between m/z 685 and m/z 695. The m/z values in the inset show the
presence of the deprotected peptide and the peptide disulfide. (C) Mass spectrum of the
Cys(But) test peptide incubated in TFA for 12 h at 37 ºC. (D) Mass spectrum of the
Cys(But) test peptide incubated in TFA:TIS (98:2) for 12 h at 37 ºC.
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CHAPTER 3: SYNTHESIS OF ALPHA-METHYL SELENOCYSTEINE AND ITS
UTILIZATION AS A GLUTATHIONE PEROXIDASE MIMIC.

3.0 ABSTRACT
Selenocysteine (Sec) is the 21st AA in the genetic code where this AA is primarily
involved in redox reactions in enzymes due to its high reactivity towards oxygen and
related reactive oxygen species. Sec has found wide utility in synthetic peptides, especially
as a replacement for cysteine. One limitation of using Sec in synthetic peptides is that it
can undergo β-syn elimination reactions after oxidation, rendering the peptide inactive due
to loss of selenium. This limitation can be overcome by substituting Cα-H with a methyl
group. The resulting Sec-derivative is α-methylselenocysteine ((αMe)Sec). In
collaboration with Dr. Masterson and coworkers from University of Southern Mississippi,
we previously reported a novel strategy for the synthesis of (αMe)Sec166. We then
synthesized two peptides, one containing Sec, and the other containing (αMe)Sec, based
on the sequence of glutathione peroxidase (GPX). We made these two peptides with the
goal of designing a GPX mimic therapeutic that could be administered in times of high
oxidative stress.
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3.1 Introduction
As described in Section 1.3.1, Sec-containing glutathione peroxidases are enzymes
whose canonical function is to reduce lipid hydroperoxides to their corresponding alcohols
and H2O2 to water. When concentrations of H2O2 are elevated, such as during
reoxygenation after a period of ischemia, GPX can become overwhelmed and does not
reduce H2O2 fast enough to prevent reperfusion injury.33 Thus, it is desirable to design a
small molecule GPX mimic therapeutic to assist GPX in times of high oxidative stress.
One example of a small molecule GPX mimic is ebselen (2-phenyl-1,2benzisoselenazol-3(2H)-one). Ebselen, first reported in 1924,167 became a widely studied
GPX mimic after its antioxidant properties were recognized in 1984
by Müller and coworkers.168 Like GPX, ebselen relies on the redox
properties of selenium to reduce harmful oxidants and proceeds
through a similar catalytic mechanism. Ebselen previously made it to clinical trials as a
neuro- and cardioprotective agent,169 and is currently in clinical trials for treatment of
hearing loss that is related to oxidative stress.170, 171 However, ebselen is not water soluble,
making rapid intravenous administration impossible and has shown cellular toxicity in
some studies.172-174 Other selenium containing GPX mimics have been synthesized and
some have potent GPX-like activity including cyclic seleninate and selenenate esters,175180

spirodioxyselenuranes,181-183 pincer selenuranes,181 and spirodiazaselenuranes.184,

185

However, many of these compounds are expected to be toxic, are not water soluble, are
unstable, or quickly lose catalytic activity in the presence of thiols.34
Peptide therapeutics are growing in popularity due to their high efficacy, high
selectivity for their desired targets, and relatively low toxicity79, 186. Peptides would also be
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water soluble, which would overcome many of the issues presented with other small
molecule GPX mimics.
One possible reason that the GPX enzyme itself cannot respond optimally to very
high concentrations of H2O2, as occurs during reperfusion injury, is that GPX can be
inactivated by conversion of the Sec residue to dehydroalanine (DHA).187 DHA results
when the Sec residue becomes overoxidized to the seleninic acid (Sec-SeO2–) state
followed by rapid β-syn elimination.
Ebselen is not as efficient of a catalyst as GPX, but it can be overoxidized without
undergoing β-syn elimination because it contains an aromatic selenol. Sec-containing
peptides however can undergo β-syn elimination,188 so the design of any successful peptide
based GPX mimic needs to avoid this problem. One useful derivative of Sec is (αMe)Sec
in which the α-hydrogen has been replaced with a methyl group, removing the possibility
of β-syn elimination (Figure 3.1).

Figure 3.1: Avoidance of -syn elimination in (Me)Sec. Sec and Sec-containing
peptides can undergo deselenization due to oxidation of the selenol followed by rapid syn elimination. The (Me)Sec analog avoids this complication as it lacks hydrogen on
C.
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Thus, (αMe)Sec can resist inactivation by overoxidation while Sec cannot. These
unique properties are suitable for many potential applications. In the work described in this
chapter, we used a peptide containing (αMe)Sec to function as a GPX mimic; our (αMe)Sec
-peptide can rapidly convert H2O2 to water without undergoing self-inactivation, even with
prolonged exposure to oxidative conditions.
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3.2 Materials and methods
3.2.1 Materials.
Solvents for peptide synthesis were purchased from Fisher Scientific (Waltham,
MA).

Solvents for synthesis including N,N-dimethylformamide (DMF) and

dichloromethane (DCM) were purchased from Fisher Scientific (Fair lawn, NJ) or Acros
Organics (Morris Plains, New Jersey). N-Fmoc amino acids were purchased from
RSsynthesis (Louisville, KY). 2-Chlorotrityl chloride resin SS (100-200 mesh) and 1[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium

3-oxid

hexafluorophosphate (HATU) for solid-phase synthesis were purchased from Advanced
ChemTech (Louisville, KY). Triisopropylsilane (98%) was purchased from ACROS
Organics (Pittsburgh, PA). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and
hydrogen peroxide for enzyme assays were purchased from ThermoFischer Scientific
(Waltham, MA). NADPH was purchased from AppliChem (Darmstadt, Germany).
Diphenylphosphoryl azide (DPPA) was purchased from TCI America (Portland, OR). 9fluorenemethanol was purchased from Chempep Inc. (Miami, Fl). Titanium (IV) tertbutoxide was purchased from EMD Millipore. Silica gel (230-400 mesh) for purifications
was purchased from Silicycle (Quebec City, QC, Canada). Deuterated solvents were
purchased from Cambridge Isotope Laboratories (Andover, MA). All other chemicals were
purchased from Sigma-Aldrich (Milwaukee, WI), Fisher Scientific (Waltham, MA), or
ACROS Organics (Pittsburgh, PA). Mass spectral analysis for synthetic peptides was
performed on an Applied Biosystems QTrap 4000 hybrid triple-quadrupole/linear ion trap
liquid chromatograph-mass spectrometer (SciEx, Framingham, MA). Enzyme kinetic
assays were performed on a Cary50 UV-Vis spectrophotometer (Walnut Creek, CA) at rt.
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3.2.2 Peptide Synthesis.
Either Fmoc-(Me)Sec(But)-OH, or Fmoc-Sec(Mob)-OH were used to synthesize
peptides of sequence H-(Me)Sec-Gly-Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH (H(Me)UGTTVRDYTQ-OH), or H- Sec-Gly-Thr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH (HUGTTVRDYTQ-OH). We note that we followed the recommendations of Jones for all of
the abbreviations of amino acids and reagents for peptide synthesis in this thesis.189 All
peptides were synthesized on a 0.1 mmol scale using a glass vessel that was shaken with a
model 75 Burrell wrist action shaker. For each batch, 300 mg of 2-chlorotrityl chloride
resin SS (100-200 mesh), was swelled in DCM for 30 min. The first amino acid was directly
coupled to the resin using 2% N-methylmorpholine (NMM) in DCM, shaking for 1 h. The
resin was then capped using 10 mL of 8:1:1 DCM:methanol:NMM. Subsequent amino
acids were coupled using 0.2 mmol of Fmoc-protected amino acid, 0.2 mmol HATU, and
2% NMM in dimethylformamide (DMF), shaking for 1 h, rt. Fmoc-Sec(Mob)-OH or
Fmoc-(Me)Sec(But)-OH were coupled using a solution of 0.2 mmol amino acid, 1% N,N′Diisopropylcarbodiimide (DIC), and 0.2 mmol 1-hydroxy-7-azabenzotriazole (HOAt) in
DMF, shaking for 2 h, rt. Preactivation of any amino acid was not performed prior to
coupling. Between amino acid couplings, the Fmoc protecting group was removed via two
10 min agitations with 10 mL of 20% piperidine in DMF. Success of Fmoc removal steps
and amino acid couplings were monitored qualitatively using a ninhydrin test 142. Removal
of the final Fmoc protecting group completed the peptide synthesis. Peptides were cleaved
from the resin via a 4 h reaction with a cleavage cocktail consisting of 0.4 mmol of 2,2′112

dithiobis(5-nitropyridine) (DTNP), in 10 mL of 96:2:2 TFA/TIS/H2O. Following cleavage
and side chain deprotection, the resin was washed with TFA and DCM and the volume of
the cleavage solution was reduced by evaporation with nitrogen gas. The peptide solution
was then transferred by pipette into cold, anhydrous diethyl ether, where the peptides were
observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge (International
Equipment Co., Boston, MA) for 10 min pelleted the peptide. To wash the peptides, peptide
pellets were dried, dissolved in minimal 96:2:2 TFA/TIS/H2O, then precipitated and
pelleted as described previously. This wash process was repeated 5 times for each peptide.
After washing, the final peptide pellet was dried, dissolved in a minimal amount of water,
lyophilized, and used without further purification.

3.2.3 Measurement of peroxidase activity via glutathione reductase coupled assay.
A coupled glutathione reductase (GR) assay was used to test the abilities of the
peptides to function as GPX mimics. A 0.5 mL solution containing 100 mM potassium
phosphate (KP) buffer, pH 8.0, 1 mM EDTA, 100 M glutathione, 200 M NADPH, 2
units of GR, and 10 M of ebselen, H-UGTTVRDYTQ-OH, or H-(Me)UGTTVRDYTQOH, were added to a quartz cuvette and mixed thoroughly. This was used to blank the
spectrophotometer at 340 nm. Assays were initiated by addition of 200 M H2O2. Activity
was followed by the decrease of absorption at 340 nm using an extinction coefficient of
6220 M-1 cm-1, at 25 °C, and each initial rate was measured at least three
times. Background NADPH consumption was corrected for by subtracting control
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experiment activities in which no peptide was present as well as an additional control in
which no H2O2 was present.

3.2.4 Stability test of Sec-containing peptides.
To test the stability of peptides in the presence of oxygenated buffer, HUGTTVRDYTQ-OH or H-(Me)UGTTVRDYTQ-OH were incubated in 100 mM KP
buffer, pH 8.0, at 25 °C. Aliquots were taken and centrifuged to pellet precipitated selenium
after 24, 48, and 96 h. GPX-like activity of the aliquots was monitored as described above.
To obtain mass spectra, aliquots were infused with a guard column at 10 L/min into a 100
L/min mobile phase flow consisting of 50/50 water/acetonitrile with 0.1% formic acid.
The mobile phase flow was introduced into an Applied Biosystems QTrap 4000 hybrid
triple-quadrupole/linear ion trap liquid chromatograph-mass spectrometer operating in
positive ESI mode. Mass spectra were collected in linear ion trap mode, scanning from m/z
200–1800
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3.3 Results
3.3.1 Synthesis of GPX-peptide mimics
Owing to the quaternary α-carbon, (αMe)Sec has proven challenging to synthesize.
Previously, a racemic pathway by Reich
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and a chiral pathway by Iwaoka

191, 192

have

been executed for the synthesis of (αMe)Sec, however each have their limitations. Our
previously reported synthetic method allows for quick synthesis, with moderate yields
while also obtaining high enantiomeric excess166. Briefly, this synthesis starts by alkylation
of an achiral methyl malonate through the use of a selenium-containing alkylating agent
synthesized in the presence of dichloromethane. The seleno-malonate was then subjected
to an enzymatic hydrolysis utilizing pig liver esterase followed by a Curtius rearrangement
producing a protected derivative of (αMe)Sec that could be used in solid phase peptide
synthesis166. By utilizing this methodology, access to both enantiomers, as well as other
relevant analogues, such as α-AAs, are possible.
With (αMe)Sec in hand, we synthesized the peptide of sequence: H-(αMe)Sec-GlyThr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH, and the control peptide of sequence: H-Sec-GlyThr-Thr-Val-Arg-Asp-Tyr-Thr-Gln-OH using standard solid phase Fmoc-based protocols.
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Both peptides correspond to AAs 49-58 of the human GPX active site. For the control

peptide, Fmoc-Sec(Mob)-OH was synthesized as reported previously. 58 Sec and (αMe)Sec
residues were coupled using HATU and DIC in DMF. 193 During cleavage of both peptides
from the 2-cholortrityl resin, DTNP was included in the cleavage cocktail (TFA/TIS/H2O)
to remove the Mob protecting groups, 89 and this deprotection afforded a mixture of three
different forms of the peptide: (i) peptide diselenide, (ii) peptide selenol, and (iii) Sec(5Npys) or (αMe)Sec(5-Npys) protected peptide. This crude peptide mixture containing these
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three redox states of the peptide were used without further purification for the enzyme
assay. The HPLC chromatograms of each unpurified peptide is shown in Figure 3.2.

3.3.2 GPX like peroxidase activity of peptide mimics
A coupled glutathione reductase (GR) assay was used to test the abilities of the
peptides to function as GPX mimics.
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Both peptides were able to reduce H2O2

significantly higher than the background rate. The rate for the (αMe)Sec-containing peptide
with 200 µM H2O2 was 23.50 ± 1.88 µM/min, while the rate for the Sec-containing peptide
was 17.96 ± 0.37 µM/min based on the slopes of the plot of A340 vs. time shown in Figure
3.3A. These values compare favorably to that of ebselen in our hands (38.84 ± 1.80
µM/min, data not shown). While the (αMe)Sec-containing peptide had only a slight kinetic
advantage, a much larger difference in stabilities of the two peptides was observed as
shown in Figure 3.3B, which shows the activity remaining after incubation in oxygenated
KP buffer, pH 8.0, as a function of time.

3.3.3 Mechanisms of loss in activity of GPX-peptide mimics
The loss in activity of the Sec-containing peptide in oxygenated buffer quantified
in Figure 3.3B is most likely due to oxidation of the Sec residue followed by
deselenization, which can occur by various mechanisms including β-syn elimination.
Deselenization results in the appearance of a red precipitate due to the insolubility of
elemental red selenium. Visual evidence for this phenomenon can be seen in Figure 3.4,
which shows a comparison of deselenization of peptides. As can be seen, a red precipitate
clearly forms after 96 hours in the tube with the Sec-containing peptide, but not in the
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(αMe)Sec-containing peptide. As is evident in Figure 3.4, no color change was observed
in the reaction containing our (αMe)Sec-peptide even after 96 hours of incubation. Fitting
with these observations, the (αMe)Sec-containing peptide maintained greater than 65%
activity (Figure 3.3B).
The (αMe)Sec-containing peptide cannot lose selenium through an oxidation/β-syn
elimination pathway and thus this cannot be the reason for the modest loss in activity after
96 h in oxygenated buffer. Some possible explanations for the observed decrease in activity
of the Sec-peptide are photo-degradation of the peptide due to the presence of selenium or
oxidation of other AAs.
To further investigate deselenization of both peptides, we submitted them for MS
analyses at the initial time point and after 96 hours of incubation in oxygenated buffer. The
results of these analyses are shown in Figure 3.5. Initially both peptides exist as a mixture
of three species: selenol (species A), diselenide (species B), and Sec(5-Npys) adduct
(species C). The MS analysis of the Sec-peptide provides clear evidence that β-syn
elimination occurred upon 96 h of incubation in oxygenated buffer due to the presence of
the dehydroalanine-containing peptide present in Figure 3.5D (species D). In contrast, the
dehydroalanine species is absent from our (αMe)Sec-peptide after incubation for the same
time period (Figure 3.5B). In addition, the MS data in Figure 3.5D show that
deselenization occurred by other mechanisms as evidenced by the presence of a truncated
peptide (species E) and a peptide in which the Sec residue was converted into alanine via
a radical mechanism (species F).195 Species D-F are absent in the mass spectrogram of the
(αMe)Sec-peptide after incubation for the same time period as is evidenced by a much less
complex mass spectrogram (compare Figures 3.5B and 3.5D).
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While the mechanism of β-syn elimination of a seleninate and selenoxides are well
understood,13, 188, 196 we are unaware of any report where oxidation of a Sec-containing
peptide results in cleavage of the peptide backbone. The cleavage product in which the Sec
residue eliminated from Sec-peptide completely (species E) is the most intense peak in the
mass spectrogram visible in Figure 3.5D. This truncation is possible through a mechanism
in which the seleninate oxygen attacks the carbonyl carbon of the peptide backbone,
resulting in a 5-membered, cyclic seleninate ester. Deselenization of Sec to alanine (species
F) has previously been reported and experimental evidence supported a radical
deselenization mechanism.195 Proposed mechanisms to explain the formation of species DF from the (αMe)Sec-peptide are shown in Figure 3.6.
As far as we are aware, the cleavage of the peptide backbone by a seleninate has
not been reported in the literature and potentially represents a mechanism by which Seccontaining enzymes can be inactivated. The cleavage reaction is undoubtedly accelerated
at basic pH as done here, and highlights the fact that Sec-containing enzymes may be better
suited to work at acidic pH.62 We do note however, that Adams and Macmillan report a
related phenomenon whereby a side chain selenolate attacks the backbone carbonyl to form
a selenoester, which can then be used for native chemical ligation.157

3.3.4 Enhanced stability of alpha-methyl Sec containing peptide.
We believe a likely explanation for the absence of truncated product in the
(αMe)Sec-peptide is due to steric hindrance caused by the methyl group on the α-carbon. .
It is well known that the  and  angles of -methyl AAs are restricted in comparison to
AAs lacking the methyl group at C.197 The resulting rigidity introduced by the methyl
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group on Cα most likely prevents nucleophilic attack, explaining the absence of species E
upon prolonged incubation in oxygenated buffer.
An additional mechanism in which the Sec-containing peptide can be oxidized in
buffer at basic pH is shown in Scheme 3.1.198 Initially a significant fraction of both peptides
are oxidized to the diselenide form. At basic pH, the diselenide can be oxidized to a
selenoseleninate. The selenoseleninate can then undergo hydrolysis to yield the seleninate
and a selenol. The selenol can reoxidize back to the diselenide to start the cycle over, or be
converted to an alanine-containing peptide via a radical mechanism (species F).195 The
seleninate can breakdown via β-syn elimination or truncation to yield species D and E.

Scheme 3.1: Oxidation of the diselenide forms of Sec- and (aMe)Sec-peptides. See
the text for a description of the pathways.
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In principle, the diselenide of the (αMe)Sec-containing peptide can undergo the
same cycle of oxidation shown in Scheme 3.1 to yield the seleninate. However, the MS
data in Figure 3.5B does not show evidence of the seleninate form being present. Either
our analysis has not detected this intermediate form, or the diselenide of the (αMe)Seccontaining peptide is resistant to oxidation. Of course the seleninate form of the (αMe)Seccontaining peptide cannot undergo β-syn elimination or truncation due to the presence of
the methyl group on Cα as discussed earlier. The selenol form of the (αMe)Sec-containing
peptide could also be converted into α-methyl-alanine-containing peptide by a radical
mechanism, but we also do not find evidence of this in our MS analysis.
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3.4 Summary and Future work
In conclusion, we have synthesized an (αMe)Sec-containing peptide that functions
as a GPX mimic to convert H2O2 into water. This peptide demonstrated peroxidase activity
that was 60% of that of ebselen, a known small molecule GPX mimic. We also found that
replacement of Sec with (αMe)Sec confers superior stability to the peptide as the oxidized
form of (αMe)Sec cannot undergo β-syn elimination or cleavage of the backbone. This AA
will undoubtedly find many chemical and biotechnological applications.
An obvious next step in this project is to test other substrates beyond H2O2. Since
GPX mostly reduces lipid hydroperoxides to their corresponding alcohols, work is needed
to test the ability of our (αMe)Sec-peptide to reduce lipid hydroperoxides. It is possible
that for larger substrates, the steric constrains imposed by (αMe)Sec may make this large
peptide mimic unsuitable for efficient catalysis.
Importantly, there is much work needed to increase the rates of peroxide reduction.
As stated, our peptide mimic was only 60% as active as ebselen. One way to improve rates
of our current GPX-mimic peptide is to change the AA sequence. The AA sequence of the
peptide might allow it to take on conformations that would speed up the rates of peroxide
reduction. For example, Yin and coworkers develevoped a GPX mimic peptide of
sequence: H-Arg-Gly-Sec-Arg-Asp-COOH (5P), and concluded: “In comparison with
other enzyme models, 5P provided a suitable substrate with proper catalytic site positions,
resulting in enhanced catalytic activity. In our mouse model, 5P showed excellent
inhibition of tumor growth and improved immunity.” We postulate that replacing Sec with
(αMe)Sec in their 5-mer sequence will provide enhanced stability to this already optimized
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peptide. Thus, the combination of peptide conformation with enhanced stability owning to
(αMe)Sec, should make a superior GPX-peptide mimic199.

3.4.1 Biotechnological applications of alpha-methyl Sec
Beyond it’s role as a GPX mimic, we envision there will be many other applications
for (αMe)Sec due to its unique stability. As described in Section 2.1.3, thioester formation
is a major limitation in commonly used native chemical ligation (NCL) reactions. One way
to overcome N→S acyl shift limitations for thioester formation is to modify the Cys residue
by targeting the amide bond to be alkylated to disrupt conjugation and increase the
electrophilicity of the carbonyl amide163, 200-202. Offer and coworkers used such an approach
to develop an Fmoc compatible method to generate thioesters that would permit direct use
in NCL203. Offer and coworkers found that trityl side-chain protected (αMe)Cys was stable
throughout peptide synthesis, and after deprotection, N→S acyl transfer and ligation could
occur efficiently resulting in a peptide thioester203. As discussed previously, Macmillian
and cowokers report that Se is a superior acyl transfer reagent over sulfur157. Thus, a
combination of the work done by Offer and Macmillian to generate C-terminal thioesters
via utilization of (αMe)Sec and an N→Se acyl shift should be highly effective; (αMe)Sec
should be a superior acyl-transfer reagent due to the increased nucleophilicity of Se to S
for carbonyl attack and its unique steric properties that will increase electrophilicity of the
carbonyl amide.
Additionally, (αMe)Sec can act as a reversible redox switch as it can readily cycle
between the -2 and +2 redox states (and others) due to its resistance to β elimination. One
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application of (αMe)Sec is that it could be used as a switchable surfactant. (αMe)Sec could
be esterified and N-acylated with a fatty acid and oxidized as depicted in Figure 3.7.

Figure 3.7: Switchable surfactant utilizing (αMe)Sec and its redox properties. (Left)
This molecule would be hydrophobic in the diselenide form. (Right) when oxidized to
the seleninic acid form, the molecule would have a charged, hydrophilic head group and
act as a detergent. Ascorbate reduction and oxidation back to the hydrophobic disulfide
form would be possible.

There are commercially available products available that function similarly,
including PPS Silent Surfactant™ from Expedeon and ProteaseMax™ from Promega204,
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. PPS Silent Surfactant™, which is commonly used as a Mass Spec detergent, can only

be cleaved using treatment with strong acids for 30 minutes, and is not reversible206. Using
(αMe)Sec as a redox-active switchable surfactant is advantageous in that it is recyclable
with little waste accumulation, would be time efficient, and uses ascorbate as an
inexpensive reductant.
These are only a few of the biotechnological applications we envision for
(αMe)Sec, and there is still much work to be done in exploring the chemical abilities of
this unique AA. We hope it will someday become commercially available as it is a powerful
tool in peptide and protein chemistry.
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3.5 Figures and Tables

A

B

Figure 3.2: HPLC chromatograms of unpurified (αMe)Sec- and Sec-containing
peptides. Each chromatogram is labeled with the relevant species of peptide.
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A

B

Figure 3.3: GPX-like activity and stability of Sec- and (αMe)Sec-containing
peptides. (A) GPX-like activity of (αMe)Sec-peptide (blue) and Sec-peptide (red)
assayed with H2O2. GSSG is formed as a by-product of the peptide catalytic cycle. GR
reduces GSSG back to GSH using NADPH, and the consumption of NADPH can be
measured via absorbance at 340 nm. (B) Percent activity remaining after incubation of
peptides in 50 mM potassium phosphate buffer, pH 8.0, after 24 h and 96 h, at rt.
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Initial (0 hr)

24 hr

96 hr

Figure 3.4. β-syn elimination in a Sec-containing peptide exposed to oxygenated
buffer, pH 8.0: Peptides (1 mM) were incubated in KP buffer, pH 8.0, for the indicated
times above. After 96 hours β-syn elimination is clearly visible in the Sec-peptide (tube
at right in each photo).
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A

B

C

D

Figure 3.5: Mass spectra of GPX-mimic peptides after 96 h of incubation in
oxygenated buffer. The arrow points to the observed m/z, given in the plot. The
(αMe)Sec-containing-peptide at time zero (A) and after 96 h incubation in KP buffer,
pH 8.0 (B). For (αMe)Sec-peptides; species A is the peptide in selenol form (theoretical
m/z = 1204.46), species A-NH3 is the ammonium adduct of A (theoretical m/z =
1220.46), species B is the peptide diselenide (theoretical m/z = 2406.91), and species C
is the 5-Npys adduct (theoretical m/z = 1359.45). The Sec-containing-peptide at time
zero (C) and after 96 h incubation in KP buffer, pH 8.0 (D). For Sec-peptides; species A
is the peptide in selenol form (theoretical m/z = 1190.45), species A-NH3 is the
ammonium adduct of A (theoretical m/z = 1207.45), species B is the peptide diselenide
(theoretical m/z = 2377.88), species C is the 5-Npys adduct (theoretical m/z = 1344.43),
species D is dehydroalanine in place of Sec (theoretical m/z = 1108.51), species D-NH3
(theoretical m/z = 1125.52), species E is truncated peptide where Sec is missing
(theoretical m/z = 1040.49), species E-potassium adduct (theoretical m/z = 1080.49), and
species F is alanine in place of Sec (theoretical m/z = 1111.53).
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Figure 3.6: Potential chemical mechanisms of deselenization of Sec-peptide. The
selenol in the sample can undergo oxidation to form the seleninate, which then undergoes
rapid β-syn elimination to produce the dehydroalanine-containing peptide (species D).
The truncated peptide (species E) is potentially explained by attack of the nucleophilic
seleninate oxygen onto the carbonyl of the amide backbone, resulting in a cyclic
seleninate ester and elimination of the Sec residue (lower pathway). Species F can be
produced through a radical mechanism. Initiation of the radical could be photo-induced
or alternatively, the selenolate can react with molecular oxygen to produce the selanyl
radical and superoxide. The selanyl radical could recombine with molecular oxygen
resulting in a seleninyl radical that can break down into selenium dioxide (SeO2) and an
alanine-containing peptide.
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CHAPTER 4: INCORPORATION OF ALPHA-METHYL SELENOCYSTEINE
INTO THIOREDOXIN REDUCTASE CONFERS RESISTANCE TO (I)
OXIDATIVE INACTIVATION AND (II) INACTIVATION BY REACTIVE
BIOLOGICAL ELECTROPHILES.

4.0 ABSTRACT
Selenocysteine (Sec) is the 21st proteogenic AA and it exists in the proteome of
mammals and other higher-level eukaryotes. The incorporation of Sec into proteins
involves the recoding of stop codon UGA into a sense codon and is energetically costly.
For this reason and others, the question of “why did nature chose selenium?” often arises
when selenoproteins are studied. It is now widely accepted that Sec-proteins evolved to
resist oxidative stress since Sec can be oxidized and rapidly reduced by biological reducing
agents. Herein, we provide biochemical evidence to expand this hypothesis: selenoproteins
can resist permanent inactivation by biological reactive electrophilic species (RES) such
as acrolein, 4-hydroxynonenal, and curcumin better than orthologous sulfur-containing
(cysteine (Cys)) enzymes. To test this hypothesis, we constructed a mutant thioredoxin
reductase (TrxR) where the penultimate Sec residue is replaced with alpha-methyl Sec
((αMe)Sec). Since this unique AA does not have a proton at its α-carbon, it can resist βsyn elimination when oxidized and is therefore forced to undergo a selenoxide elimination
with a formed Michael adduct. We show that our (αMe)Sec-TrxR is able to resist oxidative
inactivation even better than the WT Sec-TrxR when incubated with increasing amount of
H2O2 (0-100 mM). We then went on to inactivate TrxR enzymes with acrolein and showed
that we could restore up to ~30% Trx reductase activity for the (αMe)Sec-mutant using
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H2O2 and imidazole at 37 °C. We could also restore ~25% Trx reductase activity in acrolein
inhibited Sec-TrxR WT, but not in the orthologous Cys-TrxR.
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4.1 Introduction
Thioredoxin reductase (TrxR) is a NADPH dependent pyridine nucleotidedisulphide oxidoreductase whose canonical function is to reduce the small protein,
thioredoxin (Trx)29. TrxR and thioredoxin comprise the thioredoxin system which is a vital
antioxidant system responsible for maintaining redox homeostasis in the cell by providing
essential reducing equivalents to a number of important cellular targets35. Mammalian
thioredoxin reductase (mTrxR) has a selenocysteine (Sec) residue at the penultimate
position of its C-terminus that is involved in the catalytic function of the enzyme5.
However, cysteine (Cys) containing orthologs of TrxR exist in prokaryotes and lower level
eukaryotes that can catalyze the same reactions as their Sec-containing TrxR counterparts.
Due to the complicated and bioenergetically costly process of incorporating Sec into
mTrxR (which involves the recoding of stop codon UGA into a sense codon)48, 49, 58, the
question of “why did nature chose selenium?” frequently arises when mTrxR, and other
selenoproteins, are studied5.
It was previously thought that Sec replaced Cys in selenoenzymes as a chemical
necessity; that is, the reaction catalyzed by these enzymes would be much faster with
selenium at the C-terminus active site than sulfur11. However, this was found to be untrue
when Kanzok and coworkers found that the rate of E. coli Trx reduction by human (Seccontaining) TrxR was only about ~4 fold higher than the rate of E. coli Trx reduction by
Drosophila melanogaster (Cys-containing) TrxR12 (DmTrxR-CCS). The authors
determined that “these data speak against the proposition that selenocysteine in the COOHterminal Cys-X sequence of high Mr TrxRs is a chemical necessity.”12 Thus, it can be
concluded that the presence of Sec in mTrxR is not confined to a purely catalytic role.
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One hypothesis, first proposed by Chaudiere in 199213 and strongly revived by the
Hondal lab, is that Sec replaces Cys to resist oxidative stress14, 15. This hypothesis is
described in Section 1.2.1.
A new hypothesis that we explore in this work expands upon the idea that Sec has
evolved in enzymes to resist oxidative stress. We hypothesize that Sec evolved in enzymes
to not only resist oxidative stress, but electrophilic stress in general, better than Cys.
Ground-state oxygen atoms, which are diradicals, behave as distinctly electrophilic
reagents18. However, oxygen is not the only biological electrophile that Sec-enzymes
encounter in vivo. Indeed, there are many biological reactive electrophilic species (RES)
that have been shown to interact with selenoproteins, including Sec-TrxRs. Many RES
contain an α,β-unsaturated carbonyl moiety that makes them Michael acceptors for Michael
addition type reactions. Given its low pKa, Sec is an excellent biological nucleophile at
neutral pH making it a strong target for adduction by RES as demonstrated in Figure 4.1.
Figure 4.1: Sec RES
adduction. Due to the low
pKa of Sec, it acts as a
nucleophile at neutral pH
and can undergo Michael
addition reactions with RES
containing α,β-unsaturated
carbonyl functional groups.
Interactions between Sec-TrxRs and RES, and the biological consequences of such
reactions, have been well documented19-21, 207. Sec-TrxRs adducted by RES are sometimes
referred to as “SecTRAPs” (selenium compromised thioredoxin reductase-derived
apoptotic proteins). SecTRAPs are known to be devoid of thioredoxin reductase activity,
however, the N-terminus redox center of TrxRs (which contain two Cys residues) can
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donate one electron to molecular oxygen which then dismutates, producing H2O2208. Thus,
while Sec-TrxRs are typically considered antioxidant proteins, when adducted by RES,
SecTRAPs are pro-oxidants, increasing cellular oxidant levels (Figure 4.2).

Figure 4.2: Formation of a “SecTRAP” by electrophile alkylation of the C-terminal
Sec residue. (Left): First, NADPH donates two electrons to FAD, which in turn donates
two e- to the N-terminal redox center. This reduces the N-terminal S-S bond, and one of
the Cys-thiols goes on to reduce the C-terminal Se-S bond (shown at the bottom). Once
reduced, the Sec-selenol can reduce substrates, such as Trx. When Sec is adducted (as
displayed at the top), TrxR cannot reduce Trx and the N-terminal redox center is
accessible. (Right): One electron can be donated to molecular oxygen from the flavin
cofactor (pink, FAD), which then dismutates to H2O2.
We hypothesize that the accumulation of oxidant surrounding SecTRAPs may act
as a “molecular timer” and oxidize the Sec-selenide to a selenoxide, which will
subsequently undergo a selenoxide elimination reaction. The elimination of the RESadduct allows for restoration of activity by pathway 1, displayed in Figure 4.3.
A
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Figure 4.3: Selenoxide elimination mechanism for RES reversibility. (A) Once Sec
is alkylated by acrolein, mTrxR-CUG will produce oxidant, and Sec will be converted
to a selenoxide which can undergo β-syn elimination with a proton from acrolein
(pathway 1), or with the α-H from the enzyme backbone (pathway 2). Pathway 1 would
effectively remove the acrolein adduct, resulting in Sec-SeOH, which can be reduced by
the neighboring Cys residue back to the active form of the enzyme. Pathway 2 results in
Se leaving along with the acrolein adduct, and formation of DHA. Without Sec in the
active site, enzyme activity cannot be restored. (B) Our mutant mTrxR-C(αMe)UG
enzyme forces the removal of acrolein to take place through pathway 1. Thus, the mutant
should more easily be able to reverse the acrolein modification to restore Trx reductase
activity.
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One potential problem with testing this hypothesis is that β-syn elimination by
pathway 2 results in elimination of Se from the enzyme with concomitant dehydroalanine
(DHA) formation and inactivation of the enzyme. To circumvent this ambiguity, we
constructed a mutant mTrxR enzyme using protein semisynthesis that contains alphamethyl selenocysteine ((αMe)Sec) in place of the penultimate Sec residue in the C-terminus
of mTrxR. We previously reported the synthesis of this unique AA and demonstrated its
ability to resist β-syn elimination from overoxidation in a peptide that mimics the active
site of glutathione peroxidase (GPX)166. The benefit of using our mutant protein is
emphasized in Figure 4.3B.
First, we explored the ability of the (αMe)Sec-containing mTrxR mutant
((αMe)SecTrxR) to resist oxidative stress compared to the mTrxR-CUG wild type (WT).
We tested the abilities of WT mTrxR, (αMe)SecTrxR, and DmTrxR to resist inactivation
by H2O2 (0-100 mM) for several substrates including Trx, H2O2, and DTNB. In all cases,
but especially for peroxidase and DTNB reductase activity, our (αMe)SecTrxR showed a
superior ability to resist oxidative inactivation compared to the mTrxR WT and DmTrxR.
We next utilized the unique stability of (αMe)SecTrxR to explore a non-enzymatic
mechanism by which selenoproteins can reverse RES adduction. Acrolein is a potent
biological electrophile that is produced both endogenously and exogenously209. We found
that incubating (αMe)SecTrxR with ~1:1 acrolein for 10 min at 22 °C depleted ~76% Trx
reductase activity compared to an acrolein untreated control. We were able to subsequently
restore activity to 55% of the control, a gain of ~30% activity, when we treated the acroleinadducted αMeSecTrxR with 2 mM H2O2 and 5 mM imidazole at pH 7.15 and 37 °C for 15
min. Notably, WT mTrxR-CUG also can be reversed from acrolein inhibition using H2O2
135

and imidazole (albeit, to a lesser extent than our mutant), but inhibition of DmTrxR (which
lacks Sec) cannot be reversed under the same conditions.
The results of our in vitro acrolein reversibility experiments provide strong
evidence to support previous in vivo work by Randall and coworkers, who demonstrated
that acrolein rapidly inactivates Sec-TrxR in human bronchiolar epithelial cells, which
recovers over 4–8 h by a mechanism depending on the presence of cellular glutathione and
Trx. Their reported loss then subsequent recovery of Sec-TrxR activity corresponds with
reversal of the formed protein–acrolein adduct. Based on their results, the authors
concluded: “These findings indicate that acrolein-induced protein alkylation is not
necessarily a feature of irreversible protein damage, but may reflect a reversible signaling
mechanism that is regulated by GSH and Trx.”27
For the first time, we are providing mechanistic evidence that Sec-TrxRs can resist
electrophilic stress by breaking the selenium-carbon bond that forms when selenoproteins
are adducted by RES. Our findings have enormous implications in many areas of redox
biochemistry as they strongly suggest that protein alkylation by RES may be an important
reversible event. Sec-RES reversibility likely plays a role in adaptive responses to RES, or
may functions as an electrophile-specific signaling mechanism analogous to protein Smodifications27, 210. A more complete understanding of these reversal mechanisms provides
insight into the biological functions of electrophiles and will undoubtably contribute to
improved strategies for therapeutic intervention of RES affected proteins27.
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4.2 Materials and Methods
4.2.1 Materials.
Solvents such as dichloromethane, acetonitrile, dimethylformamide, methanol,
anhydrous diethyl ether, trifluoroacetic acid, and ethyl acetate were purchased from Fisher
Scientific (Waltham, MA). N-Fmoc amino acids and Boc-Cys(Mob)-OH were purchased
from RSsynthesis (Louisville, KY). 2-Chlorotrityl chloride resin SS (100-200 mesh), 1hydroxy-7-azabenzotriazole (HOAt) and 1-[bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) for SPPS were purchased
from Advanced ChemTech (Louisville, KY). Chitin resin for TrxR semisynthesis was
purchased from New England Biolabs (Ipswich, MA). Immobilized catalase beads was
obtained from BioVision Incorporated (San Francisco, CA). Corning™ Costar™ Spin-X™
Centrifuge Tube Filters utilized to remove catalase agarose were purchased through Fisher
Scientific (Waltham, MA). Hydrogen peroxide (30%, certified ACS), acrolein solution
(100μg/mL or 5000μg/mL in methanol, Ultra Scientific), were also purchased from Fischer
Scientific (Waltham, MA). NADPH for enzyme assays was purchased from AppliChem
(Darmstadt, Germany). Amicon® Ultra Centrifugal Filter Units were purchased from
Millipore Sigma (Darmstadt, Germany). RapiGest™ SF surfactant for MS analysis of TrxR
enzymes was purchased from Waters Corp. (Milford, MA). Sequencing grade modified
trypsin for digestion of TrxR enzymes was purchased from Promega (Madison, WI).
Imidazole (reagent grade), bovine serum albumin (lyophilized powder, BioReagent),
iodoacetamide, 2,2′-dithiobis(5-nitropyridine) (DTNP), 5,5′-dithiobis(2-nitrobenzoic acid)
(DTNB, 99%), selenocysteamine dichloride, pentafluorophenol (>99%), iodoacetaminde
(BioUltra), 4-hydroxynonenal (Calbiochem), curcumin (from Curcuma longa, powder),
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and silica gel for column chromatography were purchased from Millipore Sigma
(Milwaukee, WI). Sodium borohydride (98+%, powder), triisopropylsilane (98%),
piperidine, ninhydrin, formic acid (98+%), N-methylmorpholine (99%), and N,N'dicyclohexylcarbodiimide (99%), were purchased from ACROS Organics (Pittsburgh,
PA). All other chemicals were purchased from Sigma-Aldrich (Milwaukee, WI), Fisher
Scientific (Waltham, MA), or ACROS Organics (Pittsburgh, PA). Mass spectral analysis
was performed via positive ESI on a Thermo Q Exactive mass spectrometer where full MS
scans were performed at a resolution of 70,000 in positive ion mode. Collected data files
were analyzed using Xcalibur Qual Browser V3 (ThermoScientific, Waltham, MA).
Enzyme kinetic assays were performed on a Cary50 UV-Vis spectrophotometer (Walnut
Creek, CA).

4.2.2 Synthesis of Boc-Cys(Mob)-OPfp.
Boc-Cys(Mob)-OH (6.0 mmol, 2.05g) was dissolved in 10 mL of dry DCM and
cooled to 0 °C via ice bath, under nitrogen gas. To this, DCC (3.0 mmol, 619.0 mg)
dissolved in 10 mL of dry DCM was added. Reaction was allowed to proceed ~15 min with
constant stirring. A white precipitate was observed to form after ~5 min. Pentafluorophenol
(6.0 mmol, 1.1g) dissolved in 20 mL dry ethyl acetate was added under nitrogen gas, and
the reaction was immediately removed from ice and allowed to warm to rt (~22 °C), and
stirred an additional 1.5 hr. The white urea precipitate was removed from solution via
filtration, and the filtrate was placed on ice for 15 min to prompt formation of more
precipitate and filtered again. The final filtrate was reduced to a yellow oil via rotoevaporation, and column purified using ~25 g silica gel and ~300 mL of 80:20 hexanes:
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ethyl acetate as a solvent. 20 mL fractions were collected and the desired Boc-Cys(Mob)OPfp eluted with an Rf = 0.44. Impurities stick to the silica. The final eluant containing
Boc-Cys(Mob)-OPfp was dried using roto-evaporation and hi-vac producing a white,
crystalline solid in 89% yield (4.3 g).

4.2.3 Solid phase peptide synthesis of H-CUG-OH.
Fmoc-Sec(Mob)-OH, synthesized as described previously, was used make the
peptide of sequence H-Cys-Sec-Gly- OH (H-CUG-OH). We note that we followed the
recommendations of Jones189 for all of the abbreviations of amino acids and reagents for
peptide synthesis in this dissertation. The peptide was synthesized on a 0.1 mmol scale
using a glass vessel that was shaken with a model 75 Burrell wrist action shaker. First, 300
mg of 2-chlorotrityl chloride resin SS (100-200 mesh), was swelled in DCM for 30 min.
Fmoc-Gly-OH was then coupled directly to the resin using 8 mL of 2% Nmethylmorpholine (NMM) in DCM, shaking for 1 h at 22°C. The resin was then capped
using 10 mL of 10% methanol, 10% NMM in DCM. Next, Fmoc-Sec(Mob)-OH was
coupled to Gly using a solution of 0.2 mmol amino acid, 1% N,N′-Diisopropylcarbodiimide
(DIC), and 0.2 mmol 1-hydroxy-7-azabenzotriazole (HOAt) in DMF, shaking for 2 h, rt.
The last amino acid, Fmoc-Cys(Trt)-OH, was coupled using a solution of 0.2 mmol amino
acid, 1% DIC, and 0.2 mmol HOAt in DMF, shaking for 1 h, rt. Preactivation of any amino
acid was not performed prior to coupling. Between amino acid couplings, the Fmoc
protecting group was removed via two 10 min agitations with 10 mL of 20% piperidine in
DMF. Success of Fmoc removal steps and amino acid couplings were monitored
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qualitatively using a ninhydrin test142. Removal of the final Fmoc protecting group
completed the peptide synthesis.

4.2.4 Solid phase peptide synthesis of H-C(αMe)UG-OH.
The preparation of 2-chlorotrityl chloride resin, coupling and subsequent
deprotection of Fmoc-Gly-OH was completed a described above on a 0.1 mmol scale.
Next, Fmoc-(αMe)Sec(But)-OH, synthesized as described previously166, was coupled to Ndeprotected Gly using a solution of 0.2 mmol amino acid, 1% DIC, and 0.2 mmol HOAt
in DMF, shaking for 2 h, rt. The Fmoc group was then removed from (αMe)Sec via six, 45
min agitations with 10 mL of 20% piperidine in DMF. Note: ninhydrin test was not used
to monitor complete Fmoc removal as we found the (αMe)Sec-amine to be too hindered to
react with the ninhydrin dye. To couple Cys to (αMe)Sec, resin was washed extensively
with DCM to remove any DMF, then swelled in a minimal volume of DCM and shaken
with 2% NMM for 15 min. A solution of 0.22 mmol Boc-Cys(Mob)-Opfp (synthesized as
described above) in 5 mL DCM was then added to the resin, and the resin shaken for 1.5
hours at 22 °C. After 1.5 h shaking, 0.15 mmol HATU in 5mL of DMF was added and for
an additional 1 h. The resin was washed 4x with DMF, then 4x with DCM and the BocCys(Mob)-OPfp coupling step was repeated 12-15 times. Note: we were able to scale this
tripeptide synthesis up to a 0.3 mmol scale, but for best results typically made the tripeptide
on a 0.1 mmol scale.
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4.2.5 Cleavage of peptides from resin.
Peptides H-CUG-OH and H-C(αMe)UG-OH were cleaved from the resin via a 1.5
h reaction with a cleavage cocktail consisting of 4 fold excess of 2,2′-dithiobis(5nitropyridine) (DTNP), in 10 mL of cleavage cocktail (2% H2O, 2% TIS in TFA).
Following cleavage and side chain deprotection, the resin was washed with TFA and the
volume of the cleavage solution was reduced by evaporation with nitrogen gas. The peptide
solution was then transferred by pipette into cold, anhydrous diethyl ether, where peptide
was observed to precipitate. Centrifugation at 3000 rpm on a clinical centrifuge
(International Equipment Co., Boston, MA) for 10 min pelleted the peptide. To wash the
peptide, pellets were dried, dissolved in minimal volume of cleavage cocktail, then
precipitated and pelleted as described previously. This wash process was repeated 5 times
for each peptide to remove any unreacted DTNP. After washing, the final peptide pellet
was dried, dissolved in a minimal amount of water, lyophilized, and used without further
purification.

4.2.6 Semisynthesis of TrxR enzymes.
The production and purification of the recombinant DmTrxR-CCS and the semisynthetic mTrxR-CUG enzymes used in this study have been previously reported57, 61. In
order to replace the active site Sec of mTrxR (Sec489) with (αMe)Sec, we used a mTrxRintein fusion protein in which the final three amino acids (Cys-Sec-Gly) are missing. A
tripeptide of sequence H-Cys-(αMe)Sec-Gly-OH (synthesized as described above) was
then ligated to the enzyme using the technique of protein semisynthesis58. Procedures for
construction of this fusion protein and the conditions needed to carry out peptide ligation
141

in order to create mutants of mTrxR by semisynthesis have previously been reported57, and
we used analogous procedures in this work to obtain mTrxR-C(αMe)UG. The
concentrations of the final, purified mTrxR-CUG, mTrxR-C(αMe)UG, and DmTrxR-CCG
enzymes were determined based on the extinction coefficient of flavin at 460 nm (ε460 =
22.6 mM−1 cm−1 for the dimer)11.

4.2.7 Characterization of TrxR, general
After purification, TrxR enzymes were assayed for activity using Trx, DTNB,
selenocysteamine, and hydrogen peroxide substrates, as described previously211. All
activity assays were performed on a Cary 50 UV/VIS spectrophotometer from Varian
(Walnut Creek, CA) at 22 °C, in 100 mM KP, 1 mM EDTA, pH 7.0. Activity was
monitored over 2 min and Vo was determined from the linear slope. Plots of Vo/ET vs.
substrate concentration were fit by the Michaelis-Menten equation using KaleidaGraph
4.02 from Synergy Software (Reading, PA) and activities reported as moles of NADPH
consumed per min per mole of TrxR.

4.2.8 Activity Assays with Trx, H2O2, and selenocysteamine substrates
Activity assays for Trx, H2O2, and selenocysteamine substrates were performed by
monitoring NADPH consumption via decrease in absorbance at 340 nm (A340) using an
extinction coefficient of 6220 M−1cm−1. Stock solutions of H2O2 were freshly prepared in
ddI H2O before each experiment and the concentration of the solution was determined
spectrophotometrically using an extinction coefficient of 43.6 M−1cm−1 at 240 nm. Stock
solutions of selenocysteamine were freshly prepared in ddI H2O before each experiment.
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A stock solution of 20 mM NADPH in ddI H2O was prepared prior to experiments and
frozen in aliquots. Trx activity was measured via a 0.5 mL reaction containing 200 μM
NADPH and varying concentrations of E. coli Trx that ranged from 0-180 µM. All assays
were initiated by addition of the following concentrations of enzyme: 260 nM mTrxRC(αMe)UG, 2 nM mTrxR-CUG, and 200 nM DmTrxR-CCS. H2O2-peroxidase activity was
measured via a 0.5 mL reaction containing 200 μM NADPH and varying concentrations of
H2O2 that ranged from 0-400 mM. All assays were initiated by addition of the following
concentrations of enzyme: 260 nM mTrxR-C(αMe)UG and 6 nM mTrxR-CUG.
Selenocysteamine reductase activity was measured via a 0.5 mL reaction containing 200
μM NADPH and varying concentrations of selenocysteamine that ranged from 0-500 µM.
All assays were initiated by addition of the following concentrations of enzyme: 104 nM
mTrxR-C(αMe)UG and 2 nM mTrxR-CUG. Background NADPH consumption was
corrected for by subtracting the activity of control assays in which either TrxR enzymes or
substrates were omitted from the reaction. All assays were repeated in triplicate for each
enzyme.

4.2.9 Activity Assays with DTNB substrate.
DTNB activity assays were performed by monitoring formation of TNB ion via
increase in absorbance at 412 nm (A412) using an extinction coefficient of 13600 M−1cm−1.
Stock solutions of DTNB were freshly prepared in ethanol before each experiment. A stock
solution of 20 mM NADPH in ddI H2O was prepared prior to experiments and frozen in
aliquots. DTNB reductase activity was measured via a 0.5 mL reaction containing 200 μM
NADPH and varying concentrations of DTNB that ranged from 0-5 mM. All assays were
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initiated by addition of the following concentrations of enzyme: 6 nM mTrxRΔ3, 12 nM
mTrxR-C(αMe)UG, and 4 nM mTrxR-CUG. Background TNB- formation was corrected
for by subtracting the activity of control assays in which enzyme was omitted from the
reaction. All assays were repeated in triplicate for each enzyme.

4.2.10 Inactivation of TrxR enzyme activity by H2O2.
Resistance to oxidative stress of TrxR enzymes was completed by a two-part assay
in which TrxR enzymes were first exposed to increasing concentrations of H2O2 (0-100
mM), and second, enzyme activity remaining was assessed relative to a control reaction
where H2O2 was omitted. For all oxidative resistance reactions, 150 µL assays were
completed in 100 mM KP, 1 mM EDTA, pH 7 buffer at 22 °C. To monitor the Trxreductase activity remaining, mTrxR-CUG (25 nM), mTrxR-C(αMe)UG (1 µM), and
DmTrxR-CCS (225 nM) were pre-reduced by 5 min incubation with 200 µM NADPH.
Next, TrxR enzymes were incubated with increasing amounts of H2O2 for 25 min followed
by addition of 50 µL catalase agarose. Catalase agarose was then removed from the reaction
via centrifugation (3200 RPM, 2 min) in Corning™ Costar™ Spin-X™ Centrifuge Tube
Filters. Flow through was then combined with an additional 200 µM NADPH, and activity
assays were initiated by addition of 110 µM Trx. Trx-reductase activity was measured by
monitoring the consumption of NADPH as a decrease in A340 for three minutes. Treatment
of mTrxR enzymes with H2O2 and subsequent peroxidase activity was monitored exactly
as described for Trx reductase activity, except activity assays were initiated by addition of
250 mM H2O2. As before, peroxidase activity was measured by monitoring the
consumption of NADPH as a decrease in A340 for three minutes. To monitor the DTNB144

reductase activity remaining, mTrxR-CUG (8 nM), mTrxR-C(αMe)UG (13 nM), and
DmTrxR-CCS (75 nM) were pre-reduced by 5 min incubation with 200 µM NADPH. Next,
TrxR enzymes were incubated with increasing amounts of H2O2 for 25 min followed by
centrifugation in Amicon filters (30 kDa MWCO) at 13,000 RPM for 2 min. To ensure
complete removal of H2O2, a washing step was performed where 300 µL of 100 mM KP,
1 mM EDTA, pH 7 buffer was added, and reaction spun again (30 kDa MWCO amicon,
13,000 RPM). The washing step was repeated for a total of two washes. After spins, 45 µL
of retained enzyme solution was combined with 200 µM NADPH and buffer (final volume
150 µL assay), and DTNB-reductase activity was measured by monitoring the formation
of TNB- as an increase in A412 for three minutes. The assays were repeated in triplicate
for each enzyme and for each assay, a “no substrate” background was performed. In each
of these control experiments, no activity was detected ensuring complete removal of H2O2
by catalase agarose. For all substrates, the change in absorbance was converted to
percentage of activity remaining relative to the oxidant-untreated control.

4.2.10 The half maximal inhibitory concentration (IC50) of RES
Inhibition of TrxR enzymes by RES was completed by a two-part assay in which
TrxR enzymes were first exposed to increasing concentrations of either curcumin (0-100
µM), acrolein (0-18 nM), or 4-hydroxynonenal (0-800 µM), and second, enzyme activity
remaining was assessed relative to a control reaction where RES was omitted. Prior to
experimentation, fresh stock solutions of acrolein, 4-hydroxynonenal, or curcumin were
prepared in ethanol. For all RES inhibition reactions, assays were completed in 100 mM
KP, 1 mM EDTA, pH 7 buffer at 22 °C. To determine the IC50 of curcumin, mTrxR-CUG
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(12 nM) or mTrxR-C(αMe)UG (650 nM) were pre-reduced by 5 min incubation with 200
µM NADPH in a 0.5 mL assay. Next, TrxR enzymes were incubated with increasing
amounts of curcumin for 20 min followed by addition of 200 µM NADPH. To determine
the IC50 of 4-hydroxynonenal, mTrxR-CUG (12 nM) or mTrxR-C(αMe)UG (650 nM) were
pre-reduced by 5 min incubation with 200 µM NADPH in a 150 µL assay. Next, TrxR
enzymes were incubated with increasing amounts of 4-hydroxynonenal for 1 hr followed
by addition of 200 µM NADPH. To determine the IC50 of acrolein, mTrxR-CUG (10 nM),
mTrxR-C(αMe)UG (780 nM), or DmTrxR-CCS (150 nM) were pre-reduced by 5 min
incubation with 200 µM NADPH in a 150 µL assay. Next, TrxR enzymes were incubated
with increasing amounts of acrolein for 10 min followed by addition of 200 µM NADPH.
For all RES experiments, activity assays were initiated by addition of 150 µM Trx. Trxreductase activity was measured by monitoring the consumption of NADPH as a decrease
in A340 for three minutes. For each assay, a “no substrate” background was performed. In
each of these control experiments, no activity was detected. For all substrates, the change
in absorbance was converted to percentage of activity remaining relative to the RESuntreated (ethanol only) control.

4.2.11 Reversal of acrolein inhibition using imidazole and hydrogen peroxide.
Inhibition and subsequent reversal of TrxR enzymes by acrolein was completed by
a three-part assay in which TrxR enzymes were first inhibited by acrolein, then acrolein
inhibition was reversed via imidazole/H2O2 combinations, and third, enzyme activity
remaining was assessed relative to a control reaction where acrolein was omitted. Prior to
experimentation, fresh stock solutions of acrolein were prepared in ethanol and stock
146

solutions of H2O2 were prepared in ddI H2O and the concentration was determined
spectrophotometrically using an extinction coefficient of 43.6 M−1cm−1 at 240 nm.
Reversal assays utilized a combination of three buffers to facilitate pH changes. For all
enzymes, “Buffer A” was composed of 10 mM KP, 10 mM sodium acetate (NaOAc), 5
mM KCl, pH 7.0; “Buffer C + imidazole” was composed of 200 mM KP, 1 mM EDTA,
210 uM BSA, 21 mM imidazole, pH 7.25; and “Buffer C - imidazole” was composed of
200 mM KP, 1 mM EDTA, 210 uM BSA, pH 7.25. For reactions with mTrxR-CUG,
“Buffer B” was composed of 50 mM NaOAc, pH 4.5. For reactions with mTrxRC(αMe)UG, “Buffer B” was composed of 50 mM NaOAc, pH 5.3. For reactions with
DmTrxR-CCS, “Buffer B” was composed of 100 mM KP, pH 7.
To begin, either mTrxR-CUG (30 nM), mTrxR-C(αMe)UG (780 nM), or DmTrxRCCS (240 nM) were incubated with 400 µM NADPH in 55 µL of Buffer A for 5 min at 22
°C. To this, 35 µL of Buffer B was added (adjusting the reaction pH to 4.6 for mTrxRCUG; to pH 5.5 for mTrxR-C(αMe)UG; and to pH 7 for DmTrxR-CCS, followed
immediately by addition of either acrolein, or ethanol for control experiments. To achieve
75-85% inhibition: for mTrxR-CUG, 2.5 µM acrolein was used; for mTrxR-C(αMe)UG,
800 nM acrolein was used; and for DmTrxR-CCS, 7 µM acrolein was used. Enzymes could
react with acrolein or ethanol for 10 min at 22 °C.
Next, to reverse acrolein adduction, 40 µL of Buffer C (+/-) imidazole was added
to the reaction (i.e. for reversal conditions with imidazole, Buffer C + imidazole was used
and for reversal conditions with no imidazole, Buffer C – imidazole was used). For reversal
conditions involving H2O2, 2 mM H2O2 was added immediately after addition of Buffer C
(+/-) imidazole. Addition of Buffer C (+/-) imidazole adjusted reaction pH to ~7.1 for all
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enzymes. Reversal reactions were incubated for 10 min in a 37 °C water bath. After
incubation, to all reactions, 50 µL catalase agarose was added and incubated for 15 min at
22 °C. To remove catalase agarose, reactions were transferred to a Corning™ Costar™
Spin-X™ Centrifuge Tube Filter and centrifuged for 2 min at 3000 RPM. Flow through
was collected and an additional 200 µM NADPH was added, then enzymes were assayed
with Trx (150 µM Trx for assays with mTrxR-CUG and DmTrxR-CCS; and 220 µM Trx
for assays with mTrxR-C(αMe)UG). For all enzymes, final assays were 150 µL and Trx
reductase activity was measured by monitoring the consumption of NADPH as a decrease
in A340 for three minutes. For each assay, a “no substrate” background was performed. In
each of these control experiments, no activity was detected. For all substrates, the change
in absorbance was converted to percentage of activity remaining relative to the acroleinuntreated (ethanol only) control.

4.2.12 Mass Spec analysis of acrolein adducted mTrxR.
Reagents for acrolein adduction and reversal were prepared exactly as described
previously, with the exception that BSA was excluded from Buffer C (+/-) imidazole.
Briefly, to detect acrolein adduct via MS analysis, mTrxR-CUG (15 ug per sample, 30 nM
in solution) was incubated with 400 µM NADPH in Buffer A for 5 min at 22 °C, as
described previously. To this, Buffer B was added, adjusting the reaction pH to 4.6,
followed immediately by addition of 2.5 µM acrolein, and allowed to react for 10 min at
22 °C. Next, for reversal samples, Buffer C + imidazole followed by 2 mM H2O2 was
added, adjusting pH to ~7.1. For acrolein adducted samples, Buffer C – imidazole was
added, adjusting pH to ~7.1. All samples were incubated for 10 min in a 37 °C water bath.
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After incubation, 100 µL catalase agarose was added and incubated for 15 min then
removed via centrifugation, as described previously. Samples were then reduced with
sodium borohydride (NaBH4) to make the acrolein adduct more stable for MS experiments,
as described by Cassidy et al25. Briefly, to a solution of 15 µg mTrxR-CUG in Buffer C
(+/-) imidazole, 10 µL of 85 mM NaBH4 in 0.1 M sodium hydroxide was added and the
mixture was allowed to react overnight at 4 °C. After overnight reduction, excess NaBH4
was removed via centrifugation (2 min, 13,000 RPM) in 3kDa MWCO Amicon filters. 100
mM ammonium bicarbonate was added to the samples, and the reaction spun again in a
wash step. This wash step was repeated twice. After washing, mTrxR-CUG samples were
dried via speed vac prepared and analyzed via LCMS as described below.

4.2.13 Digestion of TrxR enzymes for liquid chromatography mass spectrometry
This work was completed in collaboration with Daniel Haupt. Samples of 15 µg
TrxR enzymes were isolated and dried down using a speed-vac. 75 µL of 0.1% RapiGest™
surfactant in 50 mM ammonium bicarbonate pH 7.8 was then added to each sample and
incubated at 37 ℃ for 1 h. Samples where then reduced with 5 µL of 100 mM DTT and
heated at 37 ℃ for 10 min. Next, samples were alkylated with 10.4 µL of 10 mM
iodoacetamide and incubated in the dark at rt for 30 min. To each sample, 25 µL of 0.1
µg/µL sequence-grade trypsin was added and then incubated at 37 ℃ overnight. The
following day, samples were dried down via speed-vac. Next, 100 µL of 7% formic acid
(FA) in 50 mM ammonium bicarbonate pH 7.8 was added to each sample prior to a 1 h
incubation at 37 ℃. Samples were dried down again prior to an addition of 100 µL of 0.1%
trifluoroacetic acid and incubated for 1 h at 37 ℃. Samples were dried down a third time
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using a speed-vac and then resuspended in 100 µL of 0.1% TFA. Each sample was then
centrifuged at 14,000 rpm at 4 ℃ for 5 min and the top 95 µL was collected for LCMS.

4.2.14 LCMS general method
Sample (20 µL of each) was injected onto a Waters X-select HSST3 (3.5 µm, 1.0 x
150 mm) liquid chromatography column at a flow rate of 0.1 mL/min. A 78-minute LC
method was used with mobile phase A containing 0.1% FA in H2O and mobile phase B
containing 0.1% FA in Acetonitrile (ACN). From 0.0 to 4.0 min, B was held at 3%. From
4.0 to 44.0 min, B was raised to 40%. From 44.0 to 48.0 min, B was raised to 60%. From
48.0 to 52.0 min, B was held at 60%. From 52.0 to 58.0 min B was dropped to 3%. Finally,
from 58.0 to 78.0 min, B was held at 3%. Samples were then ionized by ESI on a Thermo
Q Exactive mass spectrometer where full MS scans were performed at a resolution of
70,000 in positive ion mode. Collected data files were analyzed using Xcalibur Qual
Browser V3 (ThermoScientific, Waltham, MA).

4.2.15 MS analysis of full-length TrxR enzymes
This work was completed by Daniel Haupt. It is included herein for clarity.
Theoretical trypsin digests of wild type mitochondrial fruit fly thioredoxin reductase 1
(UniProtKB-P91938) and wild type mitochondrial mouse thioredoxin reductase 2
(UniProtKB- Q9JLT4) were performed manually based on available FASTA files taken
from the UniProt website and confirmed using the online ExPASy Peptide Mass feature.
A theoretical digest of mutated mouse thioredoxin reductase containing (αMe)Sec was also
performed by assuming an identical amino acid sequence as the mouse wild type with the
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exception of a single substitution of Sec489 to (αMe)Sec489. To determine the presence
of full-length enzyme, single charged [M+H]+ monoisotopic masses corresponding to the
elemental composition of each complete C-terminal peptide were calculated using NIST
mass values. However, for selenocysteine-containing peptides, the more abundant
isotope mass was used rather than the monoisotopic

80

Se

72

Se isotope mass. Total peptide

elemental composition also factored in the treatment of each cysteine and selenocysteine
residue

with

iodoacetamide

carbamidomethyl-selenocysteine

to

form

carbamidomethyl-cysteine

(CAM-Sec),

and

(CAM-Cys),

carbamidomethyl-

(αMethyl)selenocysteine (CAM-(αMe)Sec). The resulting mass/charge values for singlycharged

c-terminal

peptides

SGLDPTPACCS

(C48H79N14O21S2,

1251.50

m/z),

SGLEPTVTGCUG (C46H78N13O19SSe, 1285.46 m/z) and SGLEPTVTGC(αMe)UG
(C47H80N13O19SSe, 1299.48 m/z) were determined for wild type fruit fly, wild type mouse
and mutant mouse thioredoxin reductase enzymes, respectively. Next, data files were
opened with Thermo Xcalibur Qual Browser V3 to extract ion current peaks corresponding
to the mass/charge value designated for the sample-specific c-terminal peptide. Spectra
were visually evaluated and those containing singly charged isotopic envelopes differing
by no more than 0.05 m/z from the theoretical monoisotopic mass/charge values were used
to indicate successful detection of full-length protein.
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4.3 Results and Discussion
4.3.1 Synthesis of peptide containing (αMe)Sec
To the best of our knowledge, this is the first time that the incorporation of
(αMe)Sec into a peptide has been reported other than our earlier report where we
demonstrated that an (αMe)Sec-containing peptide was able to function as a GPX mimic166.
Importantly, in our previous study, (αMe)Sec was the N-terminal AA in the peptide
sequence (which was chosen to correspond to the active site of GPX), and we did not
attempt to couple another AA onto the amine of (αMe)Sec during solid phase peptide
synthesis (SPPS). For this study, we sought out to make the peptide of sequence H-Cys(αMe)Sec-Gly-OH for the semisynthesis of mutant mTrxR, and therefore had to couple
Fmoc-Cys-OH onto the amine of (αMe)Sec during SPPS, which proved to be a difficult
task.
Previous reports have highlighted the synthetic challenges of making peptides that
contain sterically hindered and bulky (αMe)AAs212-216. Specifically, it has been noted that
forming an amide bond between an (αMe)AA and the carboxylic acid of the next AA in
the peptide sequence is difficult due to the steric hinderance of the amine group, which is
adjacent to the disubstituted α-carbon, of an (αMe)AA212, 215. It has also been reported that
the incorporation of (αMe)AAs into peptides is exceptionally challenging since the
reactivities of both (i) the amino groups and (ii) the carboxyl groups of sterically hindered
α,α-disubstituted AAs are significantly lower than those of typical AAs213.
Traditional activation methods employed for amide bond formation, such as
carbodiimide protocol, are usually inefficient for (αMe)AA coupling, suffering from low
yields, slow reaction rates, and a necessity for large excess of reagents212-215. Other
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coupling reagents, such as HATU or HOAt, have also proven to be ineffective in the
synthesis of peptides containing (αMe)AAs. Albericio and coworkers previously reported
synthesis

of

peptides

that

consist

of

azobenzotriazolyoxytris(pyrrolidino)phosphonium

difficult

sequences

hexafluorophosphate

with

7-

(PyAOP)217.

PyAOP has been successfully applied for the preparation of a range of peptides containing
hindered AAs, such as Aib213, 218. PyAOP and the related PyBrOP were also used for the
synthesis of peptides containing the disubstituted Cα,α-dipropylglycine and Cα,αdiisobutylglycine215, and α-methyl cysteine219. However, in our hands, the best yield
achieved when attempting to couple Fmoc-Cys(Trt)-OH onto the deprotected
(αMe)Cys(Trt)-Gly on 2-chlorotrityl chloride resin using PyBOP was less than 30%
despite 5 or more coupling reactions (Trial 2, Table 4.1). We were not able to scale this
synthesis up to a 0.1 mmol scale (Trial 2, Table 4.1), and found the 0.05 mmol scale to
not always be reproducible. To speed up the coupling reaction, we applied heat via water
bath at 37 °C. However, heat resulted in undesired side products and very little peptide
produced (Trial 6 and 7, Table 4.1). It is possible that the peptide was cleaved from the
resin when heated and washed away after the coupling step. It is also possible that the Trt
protecting group was prematurely removed from either one of the Cys residues, and side
reactions with the reactive sulfur atom occurred. All trials using PyBrOP as a coupling
reagent are summarized in Table 4.1.
The symmetric anhydride method has been previously employed to facilitate the
acylation of Aib and other bulky α-disubstituted AA’s216. This method involves the
formation of the symmetric anhydride of the incoming amino, then coupling this directly
to the resin in the absence of other coupling reagents in polar solvents such as DCM216, 220.
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Again, when we employed this method for the acylation of N-deprotected (αMe)Sec(But)OH on 2-chlorotrityl chloride resin, we achieved low yields of our desired tripeptide (data
not shown).
Another method we explored was use of a proton sponge to increase the overall
basicity of the reaction. Carpino and coworkers previously showed that including a proton
sponge greatly improved the yield of an acylation reaction between resin-bound AIB and
an incoming 5-mer peptide without causing racemization221. After studying numerous
reaction conditions and bases to increase the nucleophilicity of the AIB-amine, they
conclude that a mixture of 2,6-di-tert-butyl-4-(dimethylamino)pyridine (DB(DMAP)) and
proton sponge is more effective than either one alone and much more effective than N,Ndiisopropylethylamine (DIEA) or 2,4,6-trimethylpyridine (TMP) bases221. While the use
of a strong base is important in boosting the coupling process toward completion, these
bases must be sterically hindered to avoid racemization221. Based on this, we included a
proton sponge in a number of attempted coupling reactions, using it in combination with
DB(DMAP) and other coupling reagents such as PyBrOP or HOAt. Unfortunately,
inclusion of a proton sponge did not improve the yield of our acylation reaction in any trial
(data not shown). Based on this, we abandoned the use of a proton sponge.
We also explored moving away from SPPS and attempting the synthesis in solution
since it is possible that the resin itself could contribute to steric hinderance. Additionally,
we reason it might be possible for a bound peptide to be constrained and less flexible than
a peptide in solution, which may prevent the peptide from adopting the necessary
conformation for successful acylation. Therefore, we attempted two synthetic pathways
exploring the use of various N-protecting groups including the base labile Fmoc protecting
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group, and the acid-labile p-methoxybenzyl carbonyl (Moz) protecting group. The
synthetic routes attempted for are displayed in Schemes 4.1 and 4.2.

Scheme 4.1: Synthetic pathway to obtain Cys-(αMe)Cys-Gly-OH in solution using
Fmoc-protection. N-Fmoc protected (αMe)Cys-OH is coupled to glycine ethyl ester
using PyBrOp coupling agent and diisopropylethylamine (DIPEA) base in
dichloromethane (DCM) solvent. The dipeptide is then column purified. Fmoc is then
removed using 1:3 diethylamine: acetonitrile (DEA: ACN), with subsequent DEA
extraction. Next, Fmoc-Cys(Trt)-OH is coupled to the deprotected dipeptide using
PyBrOp coupling agent. The final step of the synthesis, which was not completed, is the
removal of N-Fmoc and Gly COOH-ethyl ester using a LiOH saponification. MS for the
final product is given as Figure 4.4.
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For the Fmoc synthesis (Scheme 4.1), while we were able to obtain the Fmoc(αMe)Cys-Gly-ethyl ester dipeptide in 83% yield after silica purification, the subsequent
step resulted in very little desired tripeptide. After Fmoc-removal, almost none of the
incoming Cys(Trt) was coupled to the amine of (αMe)Cys. Instead, we observed selfcoupling of the (αMe)Cys-Gly dipeptide which resulted in H-(αMe)Cys-Gly-(αMe)CysGly-COOH dimer. This is shown by MS analysis in Figure 4.4. This is mostly likely due
to the premature removal of the ethyl ester from Gly during the Fmoc-deprotection step
using base. Thus, we wanted to move away from an Fmoc-protection strategy.

Scheme 4.2: Synthetic pathway to obtain Cys-(αMe)Cys-Gly-OH in solution using
Moz-protection. N-Moz protected (αMe)Cys(But)-OH is coupled to glycine ethyl ester
using PyBrOp coupling agent and diisopropylethylamine (DIPEA) base in
dichloromethane (DCM) solvent. The dipeptide is then column purified. Moz is then
removed using TFA with TIS scavenger, and subsequent TFA removal. Next, FmocCys(Trt)-OH is coupled to the deprotected dipeptide using PyBrOp coupling agent. The
final step of the synthesis is the removal of N-Fmoc and Gly COOH-ethyl ester using a
LiOH saponification. Corresponding MS is given as Figure 4.5.
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We next attempted the Moz-synthesis depicted in Scheme 4.2. This proved to be
more successful than the Fmoc-synthesis since we were able to obtain desired tripeptide.
However, the final product was found as a mixture of dipeptide and tripeptide where the
Cys-S-protecting groups were partially removed. Purifying these products is undesirable
since HPLC purification would be needed which typically results in a huge loss in yield
for small hydrophobic peptides. This problem is compounded by the fact that the final
crude product was only obtained in very small quantities. The MS analysis for the final
Moz- strategy product after saponification is given as Figure 4.5.
Though we were able to detect our desired tripeptide using the Moz-solution phase
synthesis strategy, we found solution phase synthesis to be challenging since the final
products were not entirely Cys-protected and were only obtained in very small yield.
Furthermore, preparative HPLC would be necessary, and this would cause a loss of yield
which is a problem considering the large amount of peptide needed for protein semisynthesis. Thus, we turned our attention back to SPPS, which typically results in pure
peptide and higher yields than solution synthesis.
Finally, we explored the use of activated esters to facilitate the synthesis of our
desired tripeptide as they have been well studied for the coupling of Cys residues during
SPPS222, 223. Like symmetric anhydrides, AA pentaflurophenol (PfP) esters are known to
be highly reactive and free from undesired side reactions220. Additionally, they are
advantageous over anhydrides because manual preparation of anhydrides must be
performed immediately before each coupling reaction, whereas PfP esters can be prepared
beforehand and stored as crystalline solids220, 224.
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We next turned our efforts to the synthesis of Fmoc-Cys(Mob)-OPfP to facilitate
the acylation between (αMe)Sec and Cys. Fmoc-Cys(Mob)-OPfP was synthesized
following literature procedures, stored as a solid, and used for SPPS of the tripeptide.
However, upon numerous couplings using Fmoc-Cys(Mob)-OPfP, we observed premature
removal of the Fmoc-protecting group on the incoming Cys(Mob)-OPfP, which resulted in
a mixture of double, triple, and even quadruple incorporated Cys residues, as observed via
MS analysis (Figure 4.6).
There are two possibilities when considering this undesired side reaction. First, it
is possible that the amino group of (αMe)Sec is basic enough to remove Fmoc. The ability
of the basic amino group to abstract a proton from the β-carbon of a negatively substituted
ethyl ester is not negligible, and it has previously been shown by Bodanszky and coworkers
that this can occur during SPPS225. Second, while Fmoc is stable to NMM for standard 12 hr acylation reactions, Fmoc may not be stable in the presence of NMM (or even weaker
bases) over prolonged coupling times. Indeed, it has previously been reported that up to
18% Fmoc-deprotection can occur using 10% morpholine in DCM after only 4 hours226.
To overcome multiple couplings, we utilized the base stable N-Boc protecting group on the
incoming Cys residue.
We began with the synthesis of Boc-Cys(Mob)-OPfP by first forming the
symmetric anhydride of Boc-Cys(Mob)-OH via a DCC coupling at 0 °C in dry DCM, then
opening up the anhydride by adding pentafluorophenol in dry EtOAc. After silica
purification, white, crystalline Boc-Cys(Mob)-OPfP was obtained in 84% yield (Figure
4.7 and 4.8). Next, Boc-Cys(Mob)-OPfP was utilized to facilitate the acylation reaction
between itself and the bound N-deprotected (αMe)Sec(But) in DCM, with no additional
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coupling reagent required. To ensure complete formation of the tripeptide, this coupling
step was repeated at least 10 times, as depicted in Scheme 4.3.

Scheme 4.3: Synthetic route to obtain Cys-(αMe)Sec-Gly tripeptide. (Top:) Starting
with Boc-Cys(Mob)-OH, N,N'-dicyclohexylcarbodiimide (DCC) is used to make a
symmetric anhydride intermediate in dichloromethane (DCM), which is then opened up
using pentafluorophenol in ethyl acetate (EtOAc). The resulting Boc-Cys(Mob)-OPfP is
added directly to the resin (grey sphere) with H-(αMe)Sec(But)-Gly-OH dipeptide
attached. SPPS procedures are used to perform ≥10 Boc-Cys(Mob)-OPfP couplings with
N-methylmorpholine and no coupling reagents.
The tripeptide was then cleaved from the resin in the presence of DTNP to remove
the Mob and But protecting groups from Cys and Sec respectively. This effectively
replaced each side chain protecting group with a 2-thio(5-nitropyridyl) (5-Npys) adduct, or
with the subsequent S-Se bond that forms spontaneously when adjacent Cys/Sec AAs are
treated with DTNP89, 90, 110. The deprotected tripeptide was washed via ether precipitations
to remove any remaining small organic compounds, including excess DTNP, which are
soluble in ether. The peptide was not purified before use in the semi-synthesis of TrxR
enzymes. MS analysis of peptides is given as Figures 4.9 and 4.10.
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4.3.2 Semisynthesis of mTrxR enzymes.
With tripeptides in hand, we went on to obtain mTrxR enzymes: mTrxR-CUG
(mouse WT), mTrxR-C(αMe)UG (mouse mutant), and mTrxRΔ3 (truncated mouse). To
circumvent the challenges of heterologous production of selenoproteins in E. coli48, 49, we
utilized intein-mediated peptide ligation to join residues 1-487 of mTrxRΔ3 with the
tripeptides H-Cys-Sec-Gly-OH or H-Cys-(αMe)Sec-Gly-OH, to produce full length
enzyme57, 58.
MS analysis of mTrxR enzymes confirmed the presence of the full-length WT and
mutant proteins, as shown in Tables 4.4 and 4.5. Mass spectra of the N- and C-terminal
redox centers are given as Figures 4.11-4.13. We classified our semi-synthetic enzymes
using kinetics for several known mTrxR substrates including Trx, H2O2, selenocysteamine,
and DTNB. The kcat and Km parameters for the WT, truncated, and mutant mTrxR enzymes
are summarized in Table 4.6, and the kinetics curves are given as Figures 4.14-4.17.
For each substrate, our (αMe)Sec mutant is ~100 fold less active than the WT
mTrxR. This is likely due to a combination of two factors: (i) the ligation of the tripeptide
to the C-terminus of the recombinantly expressed TrxR was not completed in 100% yield
(low Sec incorporation) and (ii) the added methyl group to Sec constrains the enzyme
backbone such that the C-terminus tail is not as flexible in the mutant than the WT, or
perhaps not in the correct conformation for catalysis. This is especially true for the larger
substrates tested, such as Trx which had the largest difference in catalytic efficacy between
the WT and (αMe)Sec-mutant mTrxRs. The mutant enzyme was more active (when
compared to the mTrxR WT) towards smaller substrates, H2O2 and DTNB, where steric
hinderance of the C-term was not a crucial factor.
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It is well known that (αMe)AA can induce secondary structures into enzymes they
are incorporated in. α-Aminoisobutyric acid (Aib) is the most commonly studied
(αMe)AA, and it has been well documented that Aib has dramatic influences on peptide
backbone conformation and often induces α-helical structures.197, 215, 227, 228 Additionally,
for Aib and other (αMe)AAs, the rotation about the N-Cα and Cα-C’ bond is restricted,
adding high rigidity to the peptides197, 229. Therefore, it is not unreasonable to conclude that
the lower enzyme activity observed for our mutant mTrxR compared to the WT could be
due to an unfavorable conformation induced into the C-terminus of the enzyme by the
incorporation of the (αMe)Sec residue.

4.3.3 Oxidative resistance of TrxR enzymes.
We previously showed that (αMe)Sec conferred resistance to oxidative inactivation
to a GPX-mimic peptide166. We hypothesized that (αMe)Sec would also confer resistance
to mTrxR if incorporated into the C-terminus redox center of the protein. A study by Snider
and coworkers showed that Sec-containing mTrxR was able to resist inactivation by 50
mM H2O2, maintaining ~70% Trx reductase activity14. However, we theorized that
replacing Sec with (αMe)Sec would give mTrxR enhanced protection against H2O2 at 50
mM or higher concentrations. One way in which the mTrxR wild type (WT) enzyme can
lose activity in the presence of H2O2 is through β-syn elimination which results in the
conversion of Sec to DHA, as described in Chapter 3. Without the catalytic Sec residue,
enzymes containing DHA would not be active. We have previously shown that (αMe)Sec
is not able to β-syn eliminate and chemically, cannot lose Sec166. Though (αMe)Sec can be
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oxidized to the selenenic acid or seleninic acid, these oxidation states can be reduced back
to the active selenol via the neighboring resolving Cys residue15, depicted in Scheme 4.4.

Scheme 4.4: Oxidation states of Cys and Sec-TrxR enzymes. When DmTrxR-CCS is
oxidized, it can only return to the original, active state from the Cys-SOH oxidation state,
as Cys-SO2– and Cys-SO3– forms are strongly resistant to reduction by glutathione, or
other biological reductants. In contrast, oxidation of mTrxR-CUG to either Sec-SeOH or
Sec-SeO2– does not result in permanent inactivation as these redox forms can be rapidly
reduced by non-enzymatic reduction by thiols or ascorbate back to the parent state.
However, when oxidized past the Sec-SeO2– form, mTrxR can undergo β-syn
elimination to DHA, or be oxidized to the irreversible Sec-SeO2– form, which would
result in loss of enzyme activity.
To test this, we exposed pre-reduced mTrxR-CUG, mTrxR-C(αMe)UG, and
DmTrxR-CCS enzymes to various concentrations of H2O2 for 25 min in 100 mM KP, 1
mM EDTA, pH 7 buffer at 22 °C. After incubation with H2O2, catalase agarose was added
to the reaction to quench any excess H2O2. Catalase agarose was then filtered away from
the reaction using Corning™ Costar™ Spin-X™ Centrifuge Tube Filters. Next, the
enzymes were assayed for peroxidase activity (H2O2 substrate), Trx reductase activity (Trx
substrate), and DTNB reductase activity (DTNB substrate). In all cases, the mTrxRC(αMe)UG mutant was able to resist oxidative inactivation better than both the WT mTrxR
and WT DmTrxR enzymes (Figure 4.18 A-C).
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The difference in oxidative resistance of Sec-TrxR enzymes was especially
apparent for the peroxide substrate (Figure 4.18 B). It is possible that for Trx and DTNB
substrates, both WT and mutant mTrxR enzymes are oxidized to higher oxidation states
such as the Sec-SeOH and Sec-SeO2- forms but can be reduced readily once excess H2O2
is removed, retaining activity (Figure 4.18A and C). However, when H2O2 is both the
oxidant and the substrate, the reduction of the selenenic and selenininc acid forms back to
the active selenol would be competing with the oxidation of Sec to the Sec-SeO3- form,
which cannot be reduced back to the active form of the enzyme (Scheme 4.4). It is also
possible in all cases, that the WT mTrxR is undergoing β-syn elimination with the
backbone, forming DHA.
In theory, our mutant mTrxR should retain nearly 100% enzyme activity since the
Sec residue should never be overoxidized to DHA. However, we do see some loss in
activity when the mTrxR-C(αMe)UG mutant is incubated with higher concentrations of
H2O2. It is possible that this loss of activity is due to oxidation of the C-terminus Cys
residue (adjacent to the (αMe)Sec), or either of the N-terminus redox active Cys residues.
The over oxidation of catalytic Cys residues would be especially detrimental to Trx
reductase activity. It is also possible that the (αMe)Sec residue itself is over oxidized to the
SeO3- form, which is not readily reversible. This would account for the loss of activity seen
for all substrates, but especially for loss of peroxidase activity which is dependent on the
catalytic Sec residue.
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4.3.4 Inactivation of TrxR by reactive biological electrophiles.
The adduction of TrxR enzymes by RES has been well documented19-21, 207. Many
RES that are found to inhibit TrxR are Micheal acceptors; that is, they contain an α,βunsaturated carbonyl functional group, as displayed in Figure 4.19.

Figure 4.19: Biological
RES.
The
α,βunsaturated
carbonyl
functional groups (in
red)
makes
these
compounds biological
Michael acceptors.
Acrolein is the simplest and most reactive of the α,β-unsaturated aldehydes, and it
rapidly binds to and depletes cellular nucleophiles such as glutathione209. It can also adduct
protein nucleophiles such as Cys, Lys, and His residues of proteins, and nucleophilic sites
in DNA. The high reactivity of acrolein is the basis for the cytotoxicity, genotoxicity, and
mutagenic activity observed in cells exposed to high concentrations of acrolein209. Acrolein
is universally present in the environment, cooked foods, and cigarette smoke. In foods,
acrolein is formed from the heating of carbohydrates, vegetable oils, animal fats, and AAs.
In the atmosphere, acrolein is produced by combustion of petroleum fuels and biodiesel230.
Acrolein can also be released in vivo via biochemical reactions such as heat-induced
dehydration of glycerol, retro-aldol cleavage of dehydrated carbohydrates, and lipid
peroxidation of polyunsaturated fatty acids. However, the main source of endogenous
acrolein is through the degradation of spermine and spermidine in situations of oxidative
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stress and inflammation230. Smoking of tobacco products equals or exceeds the total human
exposure to acrolein from all other sources231, 232.
Like acrolein, 4-hydroxynonenal (4-HNE) is an endogenous byproduct of lipid
peroxidation. Recent studies suggest that protein modification by 4-HNE can result in the
pathogenesis of several diseases, including liver disease and inflammation233. Curcumin is
a biologically active, polyphenolic natural product found in turmeric, which is derived from
the plant Curcuma longa19. It is a lipid-soluble, bright yellow compound that is used as a
spice to flavor curry and to dye textiles. Curcumin has been shown to exhibit antioxidant,
anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer activities and thus has
a potential against various malignant diseases, diabetes, Alzheimer’s disease, and other
chronic illnesses.234 The interaction of curcumin with TrxR accounts for most of
curcumin’s biological functions19, and both curcumin and 4-hydroxynoneal have been
demonstrated as potent inhibitors of mTrxRs25, 235.
We began by studying the effect of various RES on TrxRs. Pre-reduced TrxR
enzymes were incubated with various concentrations of RES including acrolein (Figure
4.20A and B), 4-hydroxynonenal (Figure 4.21A), and curcumin (Figure 4.21B), in 100
mM KP, 1 mM EDTA, pH 7 buffer, at 22 °C for various times depending on the RES.
The percent enzyme activity remaining was measured spectrophotometrically and
used to determine the IC50 value for each RES/enzyme combination. This data is
summarized in Table 4.5. Acrolein is the most potent RES for all TrxR enzymes tested, as
only nM concentrations of acrolein are needed to totally inhibit the enzymes.
Curcumin is the least potent RES and interestingly, there is a large difference
between the IC50 values of curcumin when comparing mTrxR-CUG and mTrxR165

C(αMe)UG. In fact, an IC50 value was never reached for the mutant mTrxR as curcumin is
only soluble in aqueous solutions up to 100 uM. At 100 uM, ~65% Trx reductase activity
remains for the mutant while an IC50 value of 34 uM curcumin was determined for the WT
mTrxR. This large difference can be attributed to the bulky methyl group at the Sec residue
of the mutant; curcumin is a relatively large RES and steric hindrance must prevent it from
binding to the hindered (αMe)Sec-residue at the active site of the mutant mTrxR.

4.3.5 Reversibility of Sec-acrolein adduct using imidazole and hydrogen peroxide.
The role of selenium in proteins has long been debated, but it is now generally
accepted that the ability of Sec to reverse oxidative modifications, which confers resistance
to oxidative stress to selenoproteins, is one reason that higher level eukaryotes undergo the
costly process of Sec incorporation15. A more recent hypothesis to explain the role of
selenium in proteins is that Sec-enzymes can reverse other electrophilic modifications,
such as Sec-adduction by RES like acrolein27 and 4-hydroxynonenal25 through nonenzymatic mechanisms. Notably, such reversibility would be very slow for orthologous
Cys-TrxR enzymes as sulfur carbon bonds are much less labile than selenium carbon
bonds.
The idea that Sec-adduction by a Michael acceptor could be reversible is not new
in the field of organic chemistry. It is well known that selenium-carbon bonds can be
broken through selenoxide eliminations. The selenoxide elimination is a common synthetic
tool used to install alkenes and convert ketones to enones236, 237. One form of selenoxide
elimination is β-syn elimination: where the selenoxide abstracts a proton that is attached to
a carbon beta to the selenoxide. We predict that a β-syn elimination mechanism could
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facilitate the removal of acrolein (or other RES) adduct, as shown in Figures 4.2 and
Scheme 4.5.
One limitation in testing the reversibility of RES adducts using mTrxR-CUG is that
there are two possible ways in which the selenoxide can β-eliminate (Figure 4.3A,
pathway 1 and 2). It can eliminate through the desired pathway 1 to remove the RES
adduct, but it could also abstract the α-proton of the enzyme backbone resulting in the
formation of DHA in place of the catalytic Sec residue, as shown in Figure 4.3A pathway
2. Without Sec, the enzyme would be inactive. Therefore, if we were unable to restore Trx
reductase activity during RES reversibility experiments, we would not be able to
distinguish if formation of DHA or the inability to reverse acrolein adduction was the
reason for our observed negative result. Our mutant mTrxR-C(αMe)UG enzyme negates
this ambiguity since it lacks the α-proton necessary for β-syn elimination with the protein
backbone. The formation of DHA is not possible, and therefore, it forces reversibility to
occur through the mechanism depicted in Scheme 4.5.
To test this, we inhibited pre-reduced mTrxR-CUG and mTrxR-C(αMe)UG with
acrolein at low pH of (pH 4.6 for WT and pH 5.5 for mutant) for 10 min at 22 °C. The
greater acidity of Sec (pKa ~ 5.3) versus Cys (pKa ~ 8.3) or His (pKa ~ 9.2) causes it to be
deprotonated at lower pH, and this property allowed us to selectively adduct Sec instead of
other AA residues. We attempted to adduct the (αMe)Sec-mutant at pH 4.6 (as we did the
WT), however the enzyme precipitated so we chose pH 5.5, which we found to be the
lowest pH the mutant enzyme could tolerate for the 10 min acrolein incubation step. The
precipitation of mTrxR-C(αMe)UG at pH 4.6 could be due to conformational changes of
the C-term induced by the addition of the methyl group. As a negative control (i.e. we are
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confident reversal would not be obtained), we also adducted DmTrxR-CCS with acrolein
under similar conditions. To ensure the Cys residues were primarily in the reactive thiol
form, we conducted the adduction reaction at pH 7 instead of pH 4.5 or 5.5. Our full
reversibility pathway is displayed in Scheme 4.5.

Scheme 4.5: Alkylation of mTrxR-CUG with acrolein and subsequent reversibility
of the acrolein adduct through a selenoxide elimination pathway. Here, H2O2
converts the acrolein adducted Sec-enzyme to a selenoxide, which can undergo βelimination with a proton from the acrolein adduct. Imidazole is included to scavenge
acrolein once eliminated from the enzyme.
For all acrolein adduction experiments, we chose an acrolein concentration that
provided 70-80% inhibition of Trx reductase activity (see Figure 4.22, condition 1). At
this level of reduced activity, we are confident that only enough acrolein was used to adduct
the most reactive residue, which should be the penultimate Sec at low pH. Using a larger
excess of acrolein would undoubtably inhibit all enzyme activity, but we aimed to use
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minimal concentrations of acrolein to avoid the unwanted adduction of other AAs. Further
chemoselectivity comes from the fact that RES are considered “soft” electrophiles and have
been shown to preferentially target “soft” nucleophiles, such as Cys27. Since Sec is even
larger, and hence, “softer” than Cys, acrolein should react preferably with the Sec residue
over other nucleophilic AAs.
We next explored conditions by which we could restore Trx reductase activity in
the acrolein adducted enzymes. One important feature of SecTRAPs is that they produce
their own biological oxidants by providing one electron from the N-terminus redox center
to O2208. Additionally, when TrxR is alkylated with an electrophile, the antioxidant function
of TrxR is turned off, increasing the amount of cellular oxidative stress. We predict that
this accumulation of surrounding oxidant acts as a “molecular timer” to oxidize the selenide
to a selenoxide (Figure 4.3). We also anticipate needing a scavenger to bind to acrolein
and prevent acrolein from reattaching to the Sec (or other nucleophilic AAs) once removed.
Initially, we envisioned that GSH would be a good candidate for a scavenger as it
is omnipresent in the cell and was previously shown by Randall and coworkers to be an
essential part of acrolein reversal in vivo27. Thus, we began by incubating acrolein-inhibited
mTrxR-CUG with GSH in buffer pH 6.5 and monitored Tr-reductase activity. We tested
many conditions; we varied pH, GSH incubation time and temperature, concentration of
GSH, etc., but we did not observe any significant increases in activity for any condition
tested. A sample of this data is given in Figure 4.23. One potential problem is that GSH
might not be in the thiol form at neutral pH since the pKa of Cys is ~8.3. We hope to find
conditions where GSH can be used for acrolein reversibility in the future.
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Imidazole is another good candidate for an acrolein scavenger as it should react
readily with acrolein yet have no side reactions with TrxR or Trx in the subsequent enzyme
assay. Like hydralazine, which has previously been used as a protective reagent for
acrolein, imidazole contains amidine functionality that reacts strongly with acrolein238. The
imidazole functionality is found in His residues which would undoubtably be present to
scavenge acrolein in biological systems.
Using the above rational, we incubated acrolein adducted enzymes with 2 mM H2O2
and 5 mM imidazole in 200 mM KP buffer, pH 7.15, at 37 °C for 10 min (Figure 4.22,
condition 4) and were able to restore Trx-reductase activity to 55% of the control (a gain
of 30%) for the mTrxR-C(αMe)UG mutant, and 45% of the control for the mTrxR-CUG
WT (a gain of 25%). The ability for our mutant mTrxR to restore more activity than the
WT is likely due to the inability for (αMe)Sec-TrxR to undergo β-elimination with the
peptide backbone. In other words, it is possible that when acrolein-adducted mTrxR-CUG
was oxidized, it underwent β-syn elimination with both the α-H of the protein backbone
(forming inactive DHA), and the α-H of the acrolein adduct, restoring partial Trx reductase
activity.
Despite efforts to optimize the reversal reactions (data not shown), we were not
able to achieve 100% reversal of Trx-reductase activity for any TrxR tested. This is likely
due to unwanted acrolein adduction of Cys or His residues (which would not be reversible),
despite our rigorous efforts to avoid such occurrence.
To further explore the mechanism of the reversal reaction, we attempted to reverse
acrolein inhibition using either imidazole alone (Figure 4.22, condition 2) or H2O2 alone
(Figure 4.22, condition 3). Notably, some Trx reductase activity is restored for both the
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mTrxR WT and mutant with H2O2 alone, indicating the importance of oxidants in the repair
mechanism. A small percentage of Trx reductase activity is recovered using imidazole
alone for the mTrxR-C(αMe)UG mutant, but the Trx reductase activity for the WT is within
error of the acrolein inhibited enzyme (i.e. the WT did not appear to recover activity with
imidazole alone). The ability of mTrxR-C(αMe)UG to restore Trx reductase activity with
imidazole alone could be the result of two mechanisms. First, it is possible that TrxR
produces enough H2O2 on its own that the selenoxide elimination can still occur as depicted
in Figures 4.2 and Scheme 4.5. It is also possible for reversal to occur through a basemediated mechanism, as depicted in Scheme 4.6.

Scheme 4.6: Removal of acrolein from Sec
through a base mediated mechanism.
Once adducted, the ketone/enol forms of
acrolein are in equilibrium. When in the enol
form, imidazole acts as a base to abstract the
proton from the acrolein alcohol, which
causes removal of the acrolein adduct.
We were not able to restore any activity under the above discussed conditions for
our DmTrxR-CCS negative control, and conditions for which H2O2 was included,
DmTrxR-CCS lost more Trx reductase activity than the non-reversed condition. This is
seemingly due to oxidative inactivation as Cys-TrxR enzymes lose activity readily in the
presence of oxidants, especially when heated, as was done in this experiment.
It is not surprising that both Sec-TrxR enzymes were able to reverse acrolein
inhibition while Cys-TrxR was not. Chemically, we would expect the S-C bond formed
between Cys and acrolein to be much more stable than the corresponding Se-C bond
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formed between Sec and acrolein. Because Se is much larger than S, the formed Se-C bond
would be considerably longer, and therefore weaker, than the formed S-C bond. Hence, the
Sec-acrolein adduct of mutant and WT mTrxR should break more readily than the Cysacrolein adduct of DmTrxR. Indeed, it is known that selenoxide elimination reactions occur
at ~100 °C milder temperatures, and are 1x105 times as fast as related sulfoxide elimination
reactions5, 239, 240.
Additionally, it has been previously reported that peptide Cys-acrolein adducts can
be reversed through a Schiff base mechanism, if the formed Cys-acrolein adduct is in close
proximity to the peptide amine.22 Notably, Lys side chain amines cannot catalyze this
reversibility, and this chemistry was never tested in proteins. The authors also state ≤ 3%
acrolein is reversed from Cys residues in the absence of a peptide amine, highlighting the
inherent stability of a Cys-acrolein adduct.22 Combined with these previous reports, our
findings strongly suggest that Cys-RES adducts are not chemically reversible and would
require enzymatic mechanisms of reversal. As recently reviewed by Aye, RES-alkylation
of Cys is generally irreversible.241 One notable exception to this is alkylation of Cys by
nitro olefin fatty acids. This is due to the much lower pKa of the proton that is beta to the
sulfur atom of the adduct (pKa ~17) in comparison to enals and enones that lack such an
electron withdrawing group (pKa ~30).241, 242
Our observation that TrxR activity can be recovered after alkylation with an enal
like acrolein or other “Michael acceptor” can be explained in terms of the lability of certain
types of C–Se bonds that are in close proximity to a carbonyl carbon. As depicted in Figure
4.24, especially labile C–Se bonds that can be easily cleaved are ones in which the selenium
atom is bonded: (i) directly to the carbonyl carbon, (ii) to the carbon alpha to the carbonyl
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carbon or, (iii) to the carbon beta to the carbonyl carbon. It is well known that selenoesters,
like thioesters, are highly labile due to the lack of π-bonding between the chalcogen and
the carbonyl carbon.243 It is much less recognized that both α-thio and α-selenocarbonyl
compounds can be reduced to the corresponding ketone by soft nucleophiles (middle panel
of Figure 4.24)244, 245. As shown here, and is widely known in the literature, oxidation of
a β-selenocarbonyl (β-syn selenoxide elimination - last panel of Figure 4.24) results in
formation of the alkene with cleavage of the Cβ–Se bond.236, 237 This last type of bond
cleavage is the one needed to impart resistance to RES to a selenoenzyme.

Figure 4.24: Lability of carbon-selenium bonds in relationship to a carbonyl
carbon. (left panel) Cleavage of a selenoester by a thiolate. (middle panel) reduction of
an α-selenoketone by a thiolate. (right panel) β-syn selenoxide elimination or reverse
Michael reaction results in cleavage of the Cβ–Se bond.
Though previous publications have found connections between a “protective
function of selenoproteins” in the presence of RES26, none have explicitly showed that this
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protective function is due to the reversibility of the RES adduct on Sec. In fact, many
studies state that the adduction of Sec in proteins by RES is an irreversible modification19,
235, 246-248

. Others have observed the reversibility of RES inhibition but have not attributed

this to Sec. One example comes from and Park and coworkers who show that low
concentrations of acrolein rapidly inactivate TrxR both in vitro and in vivo which leads to
a significant increase in intracellular peroxide levels after 1 hr24. They went on to determine
that loss in TrxR activity is due to acrolein modification of the C-terminal Sec residue, and
state that TrxR inactivation is irreversible in vitro, but do not provide data or methods
detailing these reversibility experiments24. However, they also state: “interestingly, TrxR
activity was restored without any treatment within 24 h in human endothelial cells
(HUVEC). The restoration of TrxR activity in HUVEC is associated with increases in the
levels of TrxR mRNA.” They go on to conclude that acrolein inhibition of TrxR is
reversible by compensative TrxR gene induction24. While this may be partially correct, the
authors did not discuss the possibility that the formed acrolein adduct on Sec could be
reversible in vivo through a selenoxide elimination mechanism. A selenoxide elimination
mechanism (as we propose herein) would undoubtably be feasible in their system since the
authors show a significant increase in intracellular peroxide levels, and state that GSH (or
other cellular acrolein scavengers) are present in HUVEC.
Another example comes from Cassidy and coworkers who studied the interactions
of electrophilic lipids with purified TrxR and used site directed Sec mutagenesis to
characterize how RES affect tumor suppressor protein p5325. They observed that when
TrxR was treated with 4-HNE, both Cys and Sec adducts were formed. The authors state:
“This observation can be rationalized if one considers that the kinetically favored product
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(the Sec adduct formed by reaction with the highly nucleophilic Sec anion) might give rise
to the thermodynamically more stable Cys adduct if this system were to approach
equilibrium.” Further evidence for 4-HNE-Sec adduct reversibility in this study comes
from the fact that detection of tryptic peptides containing lipid adducts by MS analysis
required reduction of the complex with sodium borohydride prior to digestion25.
Ultimately, the authors conclude that selenium sufficiency both increases TrxR activity and
spares p53 function in cells treated with electrophilic lipids, which provides a mechanism
for how dietary selenium confers protection against cancer25. Though the authors elude to
both the reversibility of protein-Michael adducts and a protective mechanism of selenium,
they never connect these two concepts; the authors never explicitly pronounce that the
ability of Sec to reverse the formed adduct confers a gain of function to selenoproteins.
Further support for our idea that electrophilic adduction on the Sec residue of TrxR
can be reversed may possibly come from a misinterpreted result from the study of the
inhibition of the selenoenzyme GPX with 4-hydroxynonenal by Romero and coworkers.249
This study found that GPX could not be completely inhibited with a great excess of 4hydroxynonenal (1 mM), and GPX could regain 41% of its activity after inhibition with
0.12 mM 4-hydroxynonenal by addition of 1 mM glutathione.249 The authors attribute the
restoration in activity to reversing the alkylation of Lys92 catalyzed by glutathione. This
conclusion was reached because it is known that a Schiff base that forms between a Lys
side chain and an α,β-unsaturated carbonyl can be reversed by hydrolysis and they
considered the alkylation of Sec to be irreversible.249 The authors did not consider the
possibility of a β-syn selenoxide elimination despite the fact that H2O2 was used as the
substrate in their assays. An alternative explanation is that the additional glutathione added
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in their rescue experiment was needed to scavenge the 4-hydroxynonenal that was ejected
from the β-syn selenoxide elimination.
In this report we have extended the original concept that selenoenzymes resist
inactivation by ROS to a broader idea that selenoenzymes can resist electrophilic stress by
RES as well. As we previously noted, oxygen and related ROS are just a specific subset of
RES, though the mechanism through which the selenoenzyme recovers from each type of
stress is different. In the case of recovery from ROS, a selenoenzyme can undergo fast
reductive mediated repair by intracellular reducing agents such as glutathione or ascorbate.

Figure 4.25: Repair pathways for a selenoenzyme after exposure to RES or ROS.
Active enzyme is represented by the color green. Enzyme that is inactivated by repairable
by a non-enzymatic reaction is represented by the color orange, red represents
irreversible inactivation to the enzyme. The enzyme colored in magenta represents an
enzyme that is repairable by an enzyme-mediated repair pathway. In this case,
sulfiredoxin is capable of repairing Cys-enzymes that have been overoxidized to sulfinic
acid in an ATP-dependent manner.250 The corresponding seleninic acid form of a
selenoenzyme can be chemically reduced by GSH or ascorbate and does not need an
enzyme catalyzed reaction for repair, highlighting a large advantage for Sec-enzymes
compared to the Cys-ortholog. Likewise, Sec-enzymes that are alkylated by an enal or
enone can undergo a non-enzymatic repair pathway, but this pathway involves oxidation
instead of reduction.
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In the case of recovery of recovery from RES, a selenoenzyme can undergo fast oxidative
mediated repair via a β-syn selenoxide elimination. These concepts are illustrated in Figure
4.25 and highlight the gain of function that selenium adds to an enzyme relative to sulfur.
As mentioned in the introduction, the mechanistic work we present here strongly
corresponds with a previous study from Randall and coworkers who provided in vivo
evidence for the reversibility of mTrxR-acrolein adducts. In this study, the authors
demonstrate that acrolein rapidly inactivates Sec-TrxR in human bronchiolar epithelial
HBE1 cells, which recovered over 4–8 h by a mechanism depending on the presence of
cellular GSH and Trx and corresponding with reversal of protein–acrolein adduction27.
However, they do not provide mechanistic details of this reversal, and propose that their
observed GSH-dependent restoration of mTrxR activity depends on glutathione Stransferase (GST) activity27. While GST could be involved in the reversal at a cellular level,
we have provided evidence supporting non-enzymatic reversal mechanisms.
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4.4 Conclusion and future work
Herein, we reported the construction and characterization of a mutant enzyme:
mTrxR-C(αMe)UG. Our mutant protein cannot undergo β-syn elimination with the peptide
backbone (which would result in inactive DHA), due to the presence of an α-methyl group
in place of the standard α-proton166. This unique property confers enhanced oxidative
resistance to mTrxR-C(αMe)UG compared to the mTrxR-CUG WT enzyme. We utilized
the ability of mTrxR-C(αMe)UG to resist oxidative stress to explore a new hypothesis:
selenoproteins have evolved to resist electrophilic stress. To do this, we first inactivated
mTrxR-C(αMe)UG with acrolein, then restored its Trx reductase activity using H2O2 and
imidazole through a selenoxide elimination pathway. These conditions are consistent with
the biological environment that is known to surround SecTRAPs208. Notably, we were also
able to restore activity in the mTrxR-CUG WT, but not the Cys-TrxR ortholog, providing
strong evidence that Sec-enzymes may have evolved to resist electrophilic stress.
Importantly, our work ties up loose ends from previous studies on these topics.
Randall and coworkers state: “rather than representing irreversible protein damage, protein
alkylation by acrolein and other electrophiles may be an important reversible event in
adaptive responses to electrophilic stress or function as electrophile-specific signaling
mechanism analogous to protein S-nitrosylation or S-glutathionylation. A more complete
understanding of such reversal mechanisms would not only offer better insight into the
biological functions of electrophiles but may also contribute to improved strategies to
manage chronic pulmonary diseases associated with environmental acrolein exposure or
cigarette smoking.”27
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Herein, we provide the mechanistic evidence that other studies are missing24-27, and
we provide evidence to support a new hypothesis for why nature chose selenium. We
anticipate that our work will provide a mechanistic foundation for numerous in vivo
findings in the future.
Going forward, we hope to find conditions for which more Sec-enzyme activity can
be recovered upon reversing a Sec-RES adduct. This will likely require the finetuning of
reaction conditions for both alkylation and reversal steps. Furthermore, reversal of other
RES adducts, beyond acrolein, should be explored. It is possible that less reactive RES,
such as curcumin or 4-HNE, would afford more recovered activity than acrolein due to
fewer side-reactions where other residues besides Sec are alkylated.
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4.5 Figures and tables

Figure 4.4: Mass spectra of product from Fmoc-strategy solution phase synthesis
of H-Cys-(αMe)Cys-Gly-OH. The spectra at the top shows the MS results from peptide
submitted after the coupling step shown in Scheme 4.1. Notably, none of the desired
tripeptide is observed (theoretical m/z = 1031.32). Instead, a mixture of (αMe)Cys-Gly
dipeptide and (αMe)Cys-Gly-(αMe)Cys-Gly is observed. The larger peptide is the result
of dipeptide self-coupling. The theoretical m/z for both of these observed products is
given below the structures provided below the spectrum.
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Figure 4.5: Mass spectra of product from Moz-strategy solution phase synthesis of
N-Cys-(αMe)Cys-Gly-OH. The spectra shows the MS results from peptide submitted
after the final saponification step shown in Scheme 4.2. Notably, some of the desired
tripeptide is observed! However, the desired tripeptide is observed as a mixture of
products and HPLC purification results in very low final yield. The theoretical m/z for
both of these observed products is given below the structures provided in the spectrum.
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Figure 4.6: Mass spectra of tripeptide: H-Cys-(αMe)Cys-Gly-OH after cleavage
from the resin. When synthesizing this peptide, we observed “over coupling” of Cys to
the deprotected (αMe)Cys-amine when using Fmoc-Cys(Mob)-OPfP (discussed in the
main text). Here, there are 5 major species present (from left to right): (i.) truncated
dipeptide H-(αMe)Cys-Gly-OH (theoretical m/z = 193.06), (ii.) desired tripeptide HCys-(αMe)Cys-Gly-OH (theoretical m/z = 296.07), (iii.) double Cys coupled peptide HCys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 399.08), (iv.) triple Cys coupled peptide
H-Cys-Cys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 502.08), (v.) quadruple Cys
coupled peptide H-Cys-Cys-Cys-Cys-(αMe)Cys-Gly-OH (theoretical m/z = 605.09).
Note: the text eludes to this “over coupling” problem in the context of the H-Cys(αMe)Sec-Gly-OH peptide. We observed the same over coupling regardless of the
penultimate αMeAA; we chose to show this spectrum as an example for its clarity.
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Figure 4.7: 1H-NMR spectra for Boc-Cys(Mob)-OPfP. The crystalline solid after
column purification was dissolved in deuterated chloroform, and spectrum taken with a
Bruker 500 mHz NMR spectrometer.
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Figure 4.8: 13C-NMR spectra for Boc-Cys(Mob)-OPfP. The crystalline solid after
column purification was dissolved in deuterated chloroform, and spectrum taken with a
Bruker 500 mHz NMR spectrometer.
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Figure 4.9: Mass spectrum of tripeptide: H-Cys-(αMe)Sec-Gly-OH after cleavage
from the resin with contaminant DTNP deprotection. For all, the peaks are labeled
with the observed value above the highest point. (A) The m/z spectra, showing that two
major species of the peptide are present: (i.) S-Se “bridge” (theoretical m/z = 342.00,
displayed in chemical structure), and (ii.) the doubly (5-Npys) protected species
(theoretical m/z = 651.99, displayed in chemical structure). (B and C) The Se isotope
patterns for the major peaks are expanded.
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Figure 4.10: Mass spectrum of tripeptide: H-Cys-Sec-Gly-OH, after cleavage from
the resin with contaminant DTNP deprotection. (A) The m/z spectra, showing three
major species are present: (i.) S-Se “bridge” (theoretical m/z = 327.98), (ii.) peptide
disulfide or diselenide with single (5-Npys) adduct (theoretical m/z+2 = 482.98), and (iii.)
the doubly (5-Npys) protected species (theoretical m/z = 637.96). (B and C) High
resolution Se isotope patterns for the major species are expanded. The structures
corresponding with the major peaks, with theoretical m/z, are displayed in part A.
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Figure 4.11: Mass spectrum of mTrxR-CUG C-terminus redox center peptide.
Sample was not reduced and alkylated prior to MS analysis, so Cys/Sec residues are in
the selenosulfide bridge, as displayed in the structure provided. The theoretical m/z is
given as the exact mass in the structure.
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Figure 4.12: Mass spectrum of mTrxR-C(αMe)UG C-terminus redox center
peptide. Sample was not reduced and alkylated prior to MS analysis, so Cys/Sec residues
are in the selenosulfide bridge, as displayed in the structure provided. The theoretical
m/z is given as the exact mass in the structure.
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Figure 4.13: Mass spectrum of mTrxR N-terminus redox center peptide. Sample
was not reduced and alkylated prior to MS analysis, so Cys residues are in the disulfide
bridge, as displayed in the structure provided. The theoretical m/z is given as the exact
mass in the structure.
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Figure 4.14: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with Trx
substrate. (A). mTrxR-CUG (wild type), and (B). mTrxR-C(αMe)UG (mutant).
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Figure 4.15: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with
H2O2 substrate. (A). mTrxR-CUG (wild type), and (B). mTrxR-C(αMe)UG (mutant).
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Figure 4.16: Michaelis–Menten kinetics of semi-synthetic mTrxR enzymes with
selenocysteamine (SeCya) substrate. (A). mTrxR-CUG (wild type), and (B). mTrxRC(αMe)UG (mutant).
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Figure 4.17: Michaelis–Menten kinetics
of semi-synthetic mTrxR enzymes with
DTNB substrate. (A). mTrxR-CUG (wild
type), (B). mTrxR-C(αMe)UG (mutant),
and (C). mTrxRΔ3 (truncated, missing last
three AAs).
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Figure 4.18: Resistance to oxidative
inactivation of mTrxR-CUG (red),
mTrxR-C(αMe)UG
(green),
and
DmTrxR-CCS (blue). Enzymes were
incubated with varying [H2O2] for 25 min
at 22 °C, in KP buffer pH 7. Enzyme
activity
was
monitored
spectrophotometrically for substrates: (A) Trx
substrate (130 µM Trx), (B) H2O2 substrate
(250 mM), and (C) DTNB substrate (2mM
DTNB). The activities represent the
amount of activity remaining relative to the
oxidant-untreated control. For (B),
DmTrxR-CCS is not included as it lacks
the selenium atom necessary to reduce
peroxides. For plots (A-C), the error bars
represent the standard deviation from three
or more trials and are normalized to the
percentage of remaining activity.

194

A

B

Figure 4.20: Inhibition of TrxR enzymes by acrolein. (A) inhibition of mTrxR-CUG
(WT) and mTrxR-C(αMe)UG (mutant) by acrolein after 10 min incubation in 100 mM
potassium phosphate, 1 mM EDTA, pH 7 buffer at 22 °C. (B) Inhibition of DmTrxRCCS (WT) by acrolein using the same conditions as mTrxR inhibition described in (A).
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Figure 4.21: Inhibition of mTrxR enzymes by 4-HNE and curcumin. (A) inhibition
of mTrxR-CUG (WT) and mTrxR-C(αMe)UG (mutant) by 4-hydroxynonenal after 20
min incubation in 100 mM potassium phosphate, 1 mM EDTA, pH 7 buffer at 22 °C.
(B) inhibition of mTrxR-CUG (WT) and mTrxR-C(αMe)UG (mutant) by curcumin after
60 min incubation in 100 mM potassium phosphate, 1 mM EDTA, pH 7 buffer at 22 °C.
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Figure 4.22: Inhibition of TrxR by acrolein and subsequent reversal of acrolein
inhibition using H2O2 and imidazole. For all, Trx reductase activity was monitored by
depletion of NADPH spectrophotometrically at A340. mTrxR-CUG (red), mTrxRC(αMe)UG (green), and DmTrxR-CCS (blue) were inhibited by acrolein (condition
1), and no reversal reaction was attempted for this condition. Next, acrolein adduction
was reversed via one of the following: (condition 2) 5 mM imidazole; (condition 3)
2 mM H2O2; or (condition 4) 2 mM H2O2 and 5 mM imidazole. All “reversal” reactions
were conducted in 200 mM KP, 1 mM EDTA, pH 7, at 37 °C for 10 min. Condition 0
(control) represents the normalized Trx reductase activity of all enzymes before acrolein
inhibition or reversal, and all other bars represent the amount of activity remaining
relative to the acrolein-untreated control.
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Figure 4.23: Adduction and
reversal of mTrxR-CUG by
acrolein and GSH. (Top):
Experimental design for acrolein
adduction of mTrxR-CUG at pH
4.5, then reversal by addition of
GSH at pH 6.4. Here, we did not
add H2O2 and rely on the enzyme
to produce its own oxidants.
(Left): Absorbance at 340 nm
over 5 min time with Trx
substrate. A decrease of A340
indicates
consumption
of
NADPH. Each line is an average
of 6 trials. The black line is the
acrolein
untreated
(ethanol)
control,
representing
100%
activity. Blue and green have been
treated with acrolein and blue was
subsequently subjected to reversal
conditions with GSH at pH 6.4.
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Table 4.1: Synthesis of H-Cys-(αMe)Cys-Gly-OH using SPPS and PyBrOP coupling
agent. Each trial highlights a different synthesis where H2N-(αMe)Cys-Gly-resin was
formed, and Fmoc-Cys(Trt)-OH is to be coupled to the dipeptide using 4-fold excess
PyBrOP coupling reagent in DMF solvent.

Trial

1

2

3

4

5

6

7

Scale
(mmol)

#Coupling
reactions
(Temp,
time)

Desired
peptide
detected
by MS?

0.05

2x
(22 °C, 3 h)

Yes - not
as major
product

0.05

4x
(22 °C, 2 h)
1x
(22 °C, 12 h)

Yes - as
major
product

0.1

4x
(22 °C, 2 h)
1x
(22 °C, 12 h)

Purity
(estimated
by MS)

0.05

Yes - not
as major
product

0.05

5x
(22 °C, 2 h)
1x
(22 °C, 12 h)

Yes - not
as major
product

0.1

7x
(37 °C, 2 h)
2x
(22 °C, 12 h)

0.1

6x
(37 °C, 2 h)
2x
(37 °C, 12 h)

Comments

~10%

N/A

Primarily
(αMe)CysGly dimer
present

~70%

4mg total,
~30% yield

First
“successful”
synthesis

N/A (no desired peptide
detected).

No

4x
(22 °C, 2 h)
1x
(22 °C, 12 h)

Crude yield

Could not
scale up Trial
2.

~40%

Not able to
estimate due
to presence of
insoluble
contaminate.

Highly
contaminated
by white
solid.

~30%

5mg total,
~35% yield

Low yield of
desired
product.

No

N/A (no desired peptide
detected).

Only brown
residue
resulted. No
peptide at all.

No

N/A (no desired peptide
detected).

Some (~3
mg) peptide
present, not
correct m/z.
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Table 4.2: Full MS digest of mTrxR-CUG enzyme.
Peptide Sequence (H-XXX-COOH)

Position

Theoretical
mass (Da)

Detected
mass (Da)

Notes and modifications
detected

GGQQSFDLLVIGGGSGGLACAK

35-56

2092

N/A

Cys54(CAM)

EAAQLGK

57-63

716.39

716.39

(K)VAVADYVEPSPR

65-76

1302.7

1430.8

WGLGGTCVNVGCIPK

80-94

1617.8

1617.8

(K)LMHQAALLGGMIR

96-108

1410.8

1538.9

DAHHYGWEVAQPVQHNWK

109-126

2202

2202

TMAEAVQNHVK

127-137

1227.6

1227.6

SLNWGHR

138-144

869.44

869.44

VQLQDR

145-150

758.42

758.42

YFNIK

154-158

684.37

911.53

ASFVDEHTVR

159-168

1160.6

1160.6

ATLLSAEHIVIATGGRPR

176-193

1862.1

1862.1

YPTQVK

194-199

735.4

735.4

GALEYGITSDDIFWLK

200-215

1827.9

1827.9

ESPGK

216-220

517.26

517.26

TLVVGASYVALECAGFLTGIGLDTTVMMR-(SIPLR)

221-249

3045.5

3714.8

SIPLR

250-254

585.37

585.37

GFDQQMSSLVTEHMESHGTQFLK

255-277

2637.2

N/A

GCVPSHIK

278-285

897.46

897.46

LPTNQLQVTWEDHASGK

287-303

1924

1924

EDTGTFDTVLWAIGR

304-318

1680.8

1680.8

Only detected with N-term
Lys missed cleave
N-term redox center,
Cys86,91(CAM)
Only detected with N-term
Lys missed cleave

Missed cleave fused with
adjacent SIPLR; no CAM,
2 phosph. detected

Cys279(CAM)

VPETR

319-323

601.33

601.33

TLNLEK

324-329

717.41

717.41

AGISTNPK

330-337

787.43

787.43

IIVDAQEATSVPHIYAIGDVAEGRPELTPTAIK

341-373

3474.8

3474.8

LLAQR
SSTLMDYSNVPTTVFTPLEYGCVGLSEEEA-VALHGQEHVEVYHAYYKPLEFTVADR
DASQCYIK

377-381

600.38

600.38

386-441

6349

N/A

442-449

984.45

984.45

Cys446(CAM)

MVCMR

450-454

696.3

696.3

Cys452(CAM)

EPPQLVLGLHFLGPNAGEVTQGFALGIK

455-482

2902.6

2902.6

CGASYAQVMQTVGIHPTCSE EVVK

483-506

2651.2

2651.2

LHISK

507-511

597.37

597.37

SGLEPTVTGCUG

513-524

1285.5

1285.5

Color key:

Peptide not found

Missed Cleavage
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Cys407(CAM)

Cys483,500(CAM)

C-term redox center,
Cys522(CAM) Sec523(CAM)
Peptide found as expected

Table 4.3: Full MS digest of mTrxR-C(αMe)UG enzyme.
Peptide Sequence (H-XXX-COOH)

Position

Theoretical
mass (Da)

Detected
mass (Da)

Notes and modifications
detected

GGQQSFDLLVIGGGSGGLACAK

35-56

2,092.05

N/A

Cys54(CAM)

EAAQLGK

57-63

716.39

716.39373

VAVADYVEPSPR

65-76

1,302.67

1302.668

WGLGGTCVNVGCIPK

80-94

1,617.79

1617.787

LMHQAALLGGMIR

96-108

1,410.77

1538.866

DAHHYGWEVAQPVQHNWK

109-126

2,202.03

2202.026

TMAEAVQNHVK

127-137

1,227.62

1227.615

SLNWGHR

138-144

869.44

869.4377

VQLQDR

145-150

758.42

758.4155

YFNIK

154-158

684.37

684.3715

ASFVDEHTVR

159-168

1,160.57

1160.5694

ATLLSAEHIVIATGGRPR

176-193

1,862.06

1862.0606

YPTQVK

194-199

735.40

735.40357

GALEYGITSDDIFWLK

200-215

1,827.92

1827.9163

ESPGK

216-220

517.26

517.26165

TLVVGASYVALECAGFLTGIGLDTTVMMR

221-249

3,045.55

3614.7191

SIPLR

250-254

585.37

585.37187

GFDQQMSSLVTEHMESHGTQFLK

255-277

2,637.21

2637.2072

GCVPSHIK

278-285

897.46

897.4611

LPTNQLQVTWEDHASGK

287-303

1,923.96

1923.9559

EDTGTFDTVLWAIGR

304-318

1,680.82

N/A

N-term redox center,
Cys86,91(CAM)
Missed Cleavage

Missed Cleavage,
Cys233(CAM)

Cys279(CAM)

VPETR

319-323

601.33

601.3304

TLNLEK

324-329

717.41

717.41413

AGISTNPK

330-337

787.43

787.43084

IIVDAQEATSVPHIYAIGDVAEGRPELTPTAIK

341-373

3,474.85

3474.8478

LLAQR
SSTLMDYSNVPTTVFTPLEYGCVGLSEEEA-VALHGQEHVEVYHAYYKPLEFTVADR
DASQCYIK

377-381

600.38

600.38277

386-441

6,349.01

N/A

Cys407(CAM)

442-449

984.45

984.44551

Cys446(CAM)

MVCMR

450-454

696.30

696.29898

Cys452(CAM)

EPPQLVLGLHFLGPNAGEVTQGFALGIK

455-482

2,902.58

2902.5825

CGASYAQVMQTVGIHPTCSE EVVK

483-506

2,651.23

2651.2262

LHISK

507-511

597.37

597.37187

SGLEPTVTGC(αMe)UG

513-524

1,299.48

1299.4788

Color key:

Peptide not found

Missed Cleavage
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Cys483,500(CAM)

C-term redox center,
Cys522(CAM),
(αMe)Sec523(CAM)
Peptide found as expected

Table 4.4, (A): Kinetic parameters of mTrxR enzymes with E. coli Trx.
Enzyme

kcat (min-1)

KM (M)

kcat/KM (min-1 M-1)

kcat/KM(mutant)
/kcat/KM(WT)

mTrxR-CUG

1770  60

42  4.4

4.2 x107

mTrxRC(Me)UG

15  0.76

26  4.8

5.8 x10

5

mTrxR a

NA

NA

NA

–
0.0138
–

a

The truncated enzyme ends at glycine 487 and is missing the C-terminal tripeptide.

b

Taken from (Eckenroth, et al. 200761).
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Table 4.4, (B): Kinetic parameters of mTrxR enzymes with H2O2.
Enzyme

kcat (min-1)

KM (mM)

kcat/KM (min-1 M-1)

kcat/KM(mutant)
/kcat/KM(WT)

mTrxR-CUG

1110  62

134  16

8.2 x103

mTrxRC(Me)UG

10.5  0.5

35  8.0

3.0 x10

2

mTrxR a

NA

NA

NA

–
0.037
NA

a

The truncated enzyme ends at glycine 487 and is missing the C-terminal tripeptide.

b

Taken from (Eckenroth, et al. 200761).

203

Table 4.4, (C): Kinetic parameters of mTrxR enzymes with DTNB.
Enzyme

kcat (min-1)

KM (M)

kcat/KM (min-1 M-1)

kcat/KM(mutant)
/kcat/KM(WT)

a

mTrxR-CUG

3170  450

3  0.7

1.1 x109

mTrxRC(Me)UG

1125  145

5  0.9

2.3 x10

8

0.209

mTrxR a

2900  500

12  2.7

2.4 x108

0.218

–

The truncated enzyme ends at glycine 487 and is missing the C-terminal tripeptide.
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Table 4.4, (D): Kinetic parameters of mTrxR enzymes with selenocysteamine.
Enzyme

kcat (min-1)

KM (M)

kcat/KM (min-1 M-1)

kcat/KM(mutant)
/kcat/KM(WT)

mTrxR-CUG
mTrxRC(Me)UG
mTrxR a

3740  450

79  0.7

4.7 x107

50  145

92  0.9

5.4 x10

5

NA

NA

NA
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–
0.011
–

Table 4.5: Half maximal inhibitory concentration (IC50) of RES for TrxR enzymes.
Enzyme

RES

IC50

mTrxR-CUG

Acrolein

231 nM

mTrxR-CUG

4-HNE

235 µM

mTrxR-CUG

Curcumin

34 µM

mTrxR-CUG

Cinnamaldehyde

225 µM

mTrxR-CUG

Dimethylfumarate

>1 mM

mTrxR-C(αMe)UG

Acrolein

57 nM

mTrxR-C(αMe)UG

4-HNE

118 µM

mTrxR-C(αMe)UG

Curcumin

>100 µM

mTrxR-C(αMe)UG

Cinnamaldehyde

230 µM

mTrxR-C(αMe)UG

Dimethylfumarate

>1 mM

Acrolein

7 µM

DmTrxR-CCS
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